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ABSTRACT 
Escherichia coli Proteomics and Bioinformatics. 
(May 2007) 
Lili Niu, B.Sc., Beijing University 
Chair of Advisory Committee: Dr. James C. Hu 
 
A lot of things happen to proteins when Escherichia coli cells enter stationary phase, 
such as protein amount, post-translational modifications, conformation changes, and 
component of protein complex. Proteomics, which study the whole component of 
proteins, can be used to study the products of the genome and the physiology of 
Escherichia coli cells at different conditions. By comparing proteome from different 
growth phases, such as exponential and stationary phase, a lot of proteins with changes 
can be identified at the same time, which provides a pilot for further studies of 
mechanism. 
Current global proteomic studies have identified about 27% of the annotated 
proteins of E. coli, most of which are predicted to be abundance proteins. Subproteomics, 
the study of specific subsets of the proteome, can be used to study specific functional 
classes of proteins and low abundance proteins. In this dissertation, using non-denatured 
anion exchange column with 2D SDS-PAGE and tandem mass spectrometry, difference 
of E. coli cells between exponential and stationary phase were studied for whole soluble 
proteome. Also, using heparin column and mass spectrometry with tandem mass 
spectrometry, heparin-binding proteins were identified and analyzed for exponential 
  
iv 
growth and stationary phases. To manage and display the data generated by proteomics, 
a web-based database has been constructed for experiments in E. coli proteomics (EEP), 
which includes NonDeLC, Heparome, AIX/2D PAGE and other proteomic studies.  
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CHAPTER I 
INTRODUCTION 
Overview                             
In chapter I, the stationary phase of E. coli, importance of proteomic and 
subproteomic studies, current status of proteomics studies, methods to study proteomics 
and methods to manage and display proteomic data will be discussed. Then the 
objectives of this dissertation and the content of each chapter will be described. 
Stationary phase of E. coli  
E. coli is one of the most commonly used model organisms for molecular biology. In 
nature, E. coli can be found in the intestinal tract of warm-blooded animals, groundwater, 
and spring. E. coli can grow in a variety of conditions, such as low nutrient (Death and 
Ferenci, 1994), abundant nutrient, high pH (Avetisyan et al., 1991), low pH (Hsin-Yi and 
Chou, 2001; Leyer et al., 1995), aerobic (Iuchi and Weiner, 1996), anaerobic (Partridge 
et al., 2006; Weber et al., 2006), and wide temperature range (Cullum et al., 2001; 
Riehle et al., 2005), many of which are unlike the growth conditions commonly used in 
the laboratory.  
 
 
_________________         
This dissertation follows the style of Molecular Microbiology. 
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In the laboratory, the first growth phase of cells is lag phase when the growth rate is 
slow because cells are trying to adapt to the new growth condition. Once cells adapt to 
the new condition, cells enter exponential phase when they multiply exponentially. 
Stationary phase is the growth phase when the growth rate slows due to depletion of 
nutrients and accumulation of toxic products (Ramirez Santos et al., 2005). When E. coli 
cells enter stationary phase in the laboratory, many conditions are similar to the natural 
growth conditions, which makes stationary phase a good example to study how E. coli 
cells adapt to changes and stresses in nature. 
During the transition from exponential growth to stationary phase, E. coli cells have 
many changes in both morphology and physiology and become more resistant to stresses 
such as starvation, oxidative stress, osmotic stress, and low pH (Ishihama, 1997). In 
stationary phase, cells become more spherical and smaller, which is due to induction of 
the bolA gene (Loewen and Hengge-Aronis, 1994). BolA is very likely affecting cell 
morphology by controlling transcription of dacA, dacC, and ampC (Hengge-Aronis, 
2002). The cell membrane becomes more rigid (Ramirez Santos et al., 2005). Stationary 
phase cells do not divide their genetic material until all cells reach one single 
chromosome. 
Changes also occur in the genetic material. The nucleoid is more condensed 
(Ishihama, 1997). Many defects arise on DNA such as fragmentation of chromosome, 
deletions and point mutation. mRNAs for stationary phase-specific genes, such as rpoS, 
bo1A, and dps, are polyadenylated (Cao and Sarkar, 1997).  Synthesis of ribosomal RNA 
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is shut off, which is not regulated by Fis, H-NS and RpoS (Aviv et al., 1996). 
In stationary phase, changes also happen to proteins. While expression of many 
proteins is decreased (Ishihama, 1997), others are up-regulated (Groat et al., 1986; 
Ishihama, 1997). RpoS, (p) ppGpp, cyclic AMP (cAMP)-CRP and Lrp regulate 
expression of many proteins during stationary phase (Eisenstark et al., 1996; Gentry et 
al., 1993; Hengge-Aronis, 1993, 1996, 2002; Ishihama, 1997; Lange et al., 1995; Tani et 
al., 2002). In stationary phase, RpoS (σS) accumulates, bind and directs the RNA 
polymerase to over 50 genes to response to starvation and stresses (Hengge-Aronis, 
2002).  During transition from exponential to stationary phase, E. coli cells start to 
produce (p)ppGpp (Kramer et al., 1981), which serves as an alarm responding low 
nutrient in growth media. (p)ppGpp affects different cellular processes, such as DNA 
replication and cell division (Schreiber et al., 1995), cyclopropane fatty acid synthesis 
(Eichel et al., 1999) and gene expression.  (p)ppGpp regulate expression of different 
genes, such as DNA replication inhibitor gene (cspD) (Yamanaka and Inouye, 1997), 
thioredoxin gene (Lim et al., 2000), ribosome modulation factor (RMF) gene (Izutsu et 
al., 2001a), ribosome-associated protein  (Izutsu et al., 2001b) and glutaredoxin 2 (Grx2, 
encoded by grxB) (Potamitou et al., 2002). In stationary phase, expression of many 
genes is up-regulated by cAMP, such as glycogen biosynthesis genes (Romeo and Preiss, 
1989), and galactose ABC transporter gene (mal) (Death and Ferenci, 1994).  
When cells transit from exponential growth to stationary phase, proteins also have 
changes in post-translational modifications (Desnues et al., 2003; Dukan and Nystrom, 
1998; Fredriksson et al., 2005) or conformation. The composition of some protein 
  
4 
complexes might also change. Specific E. coli proteins are oxidative modified during 
stationary phase. These proteins are Hsp70 chaperone DnaK, histone-like protein H-NS, 
elongation factor EF-Tu and EF-G, the universal protein UspA, glutamate synthase, 
glutamine synthetase, aconitase, malate dehydrogenase, and pyruvate kinase (Dukan and 
Nystrom, 1998; Tamarit et al., 1998).  
Importance of proteomic and subproteomic studies 
Methods that have been used to study the physiology of E. coli cells can be grouped 
into two major categories: study of a single gene or gene product or study of many genes 
or gene products at the same time. The later approach includes genomics (Borodovsky, 
1998; Dobrindt, 2005; Martin and Rosner, 2002; Mori, 2004; Riley and Serres, 2000; 
Tao et al., 1999), transcriptomics, proteomics (Hatzimanikatis et al., 1999), 
metabolomics (Verhoeckx et al., 2004) and fluxomics (Wiback et al., 2004).  
Transcriptomics have been applied to study transcription E. coli genes under 
different conditions, such as nitrogen starvation (Kabir et al., 2004) , leucine-responsive 
regulatory protein (Lrp) regulation (Tani et al., 2002), RpoS regulation (Patten et al., 
2004). To study expression of the final product of most genes, proteins, proteomics is a 
more direct way than transcriptomics since mRNA level does not always correlated with 
the amount and properties of proteins. Translational control, protein degradation, post-
translational modifications and protein-protein interactions (Anderson and Seilhamer, 
1997; Anderson and Anderson, 1998; Lottspeich, 1999) cannot be detected directly by 
transcriptomics. 
The term “proteome” first appeared in the literature in 1995 (Kahn, 1995), although 
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studies of proteomes have been done since the development of two-dimensional gel 
electrophoresis (O'Farrell, 1975). The proteome shows different expression patterns for 
the same organism under different conditions or in different tissues. In E. coli, gene 
expression is tightly related to physiology. In response to various conditions, such as low 
pH, nutrient starvation, phage infection, and antibiotics, E. coli regulates gene 
expression in order to adapt to the changes (Hua et al., 2004; Schembri et al., 2003). 
Proteomics is a way to understand how protein expression patterns are related to the 
physiology of E. coli at the protein level. 
Proteomics can be used to study many subjects, such as protein expression profiles 
(Baglioni et al., 2003; Champion et al., 2003; Ihling and Sinz, 2005; Kerner et al., 2005; 
Kim et al., 2005; Lopez-Campistrous et al., 2005; Raman et al., 2005; Silva et al., 2006; 
Tonella et al., 2001; Xu et al., 2006), protein localization (Lopez-Campistrous et al., 
2005), protein topology (Daley et al., 2005), protein-protein interaction (Arifuzzaman et 
al., 2006; Butland et al., 2005) and protein post-translational modification (Aebersold 
and Mann, 2003; Larsen and Roepstorff, 2000; Simpson and Pepperkok, 2003).  
Subproteomics is a term applied to the analysis of specific sets of proteins, such as 
proteins with a particular post-translational modification (Demirev et al., 2001), proteins 
at different subcellular locations (Berven et al., 2006; Nouwens et al., 2000; Rey et al., 
2005; Schaumburg et al., 2004; Trost et al., 2005), and even insoluble proteins (Graham 
et al., 2006). Moreover, because global proteomics are biased towards abundant proteins 
(Champion et al., 2003; Corbin et al., 2003; Tonella et al., 2001), subproteomics also has 
the benefit of enriching and identifying low abundance proteins (Cordwell et al., 2000).  
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Methods to study proteomics and subproteomics 
To study the proteome, efficient separation of the complex protein mixture is 
essential. Two traditional ways to separate protein samples for proteomic studies are 
one-dimensional and two-dimensional gel electrophoresis (2D PAGE) (O'Farrell, 1975). 
One-dimensional gel electrophoresis (Schagger and von Jagow, 1987; Wolf et al., 1970) 
is sufficient to separate protein mixtures containing less than 100 components, while 
two-dimensional gel electrophoresis can separate complex protein mixtures containing 
thousands of components (Henzel et al., 1993; Langen et al., 2000; Loo et al., 2001; 
Tonella et al., 2001). 2D PAGE has advantage to study protein abundance (Rosen and 
Ron, 2002) and post-translational modifications (Yan et al., 2002). However, 2D PAGE 
has some limitations. For example, detecting low abundance proteins, proteins with 
extreme pIs, proteins with extreme molecular weights (MW) or membrane proteins is 
difficult (Bunai and Yamane, 2005). Further, 2-D electrophoresis and its analysis is 
extremely labor intensive. Recently an advanced technique, fluorescence difference 2-D 
gel electrophoresis technology (2D-DIGE), has been developed to improve separation 
and relative quantitation of complex protein mixtures (Yan et al., 2002) from proteome 
samples with different treatments. This method is more accurate quantitative analysis 
than conventional 2D PAGE. 
Liquid chromatography, such as two-dimensional LC separation coupled with MS, 
has been applied as a new tool to separate mixtures of protein (Badock et al., 2001; 
Champion et al., 2003; Ferguson and Smith, 2003) or peptides (Ihling and Sinz, 2005; 
Vollmer et al., 2003; Yates et al., 1993). Multidimensional protein identification 
  
7 
technology (MudPIT) is one of the popular methods which analyze large-scale proteome 
by multidimensional liquid chromatography and tandem mass spectrometry (Washburn 
et al., 2001). Using MudPIT, proteome is digested into peptides first proceeding LC 
separation.  Protein with extreme pI, MW or low abundance can be identified by LC. LC 
analysis of proteomes not only can overcome some of the limitations of 2-D gels, but 
can also keep the proteins or protein complexes in their native state (Champion et al., 
2003).  
After separating lysates into less complex protein mixtures, individual proteins must 
be identified. Mass spectrometry is a sensitive and accurate way to identify proteins. 
Matrix assisted laser desorption/ionization (MALDI) (Karas and Hillenkamp, 1988; 
Yates, 2000) and electro-spray ionization (ESI) (Duan et al., 2006; Hauer et al., 1992; Le 
Bihan et al., 2001; Le Bihan et al., 2003) are two commonly used mass spectrometry 
methods to ionize peptide to obtain precise peptide masses by coupling with different 
kind of mass analyzers. The majority of mass spectrometry (MS) processes utilize 
electrospray ionization (ESI) as a means for introducing a LC separated peptide mixture 
into a mass spectrometer (Wolters et al., 2001).  However, there are advantages for using 
MALDI rather than ESI for high throughput samples, specifically the ability to do the 
separations offline with the analysis.  By having static spots “frozen in time” (Graber et 
al., 2004) on the MALDI plate it is possible to go back and sequence specific peptides 
that are of interest and perform data dependent data-mining.  Additionally it is often 
difficult with LC-ESI to determine the optimal time to sequence peptides as they elute 
from the LC column. Several studies have shown the tendency of MALDI to 
  
8 
preferentially ionize basic residues (Cohen and Chait, 1996; Krause et al., 1999) but 
other factors such as size, secondary structure (Wenschuh et al., 1998), hydrophobicity 
(Cohen and Chait, 1996), and charged side chains (Baumgart et al., 2004) can also 
influence MALDI ion yields.  Higher signal intensities generally produce better ion 
scores; however, other factors also affect the peptide fragmentation and the resultant ion 
score (Zhen et al., 2004). 
The peptide masses can be used to do MS fingerprinting by matching their peptide 
masses to the theoretical peptide masses generated from a protein or DNA database 
(Cottrell, 1994; Pappin et al., 1993; Thiede et al., 2005). Furthermore, by using tandem 
mass spectrometry (MS/MS) (Aebersold and Goodlett, 2001; Aebersold and Mann, 2003; 
Ferguson and Smith, 2003; Griffin et al., 2001; Larsen and Roepstorff, 2000; Wu and 
Yates, 2003; Yates, 2000) you can get partial peptide sequences, which provide more 
information to increase the number and accuracy of protein identifications. 
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Current status of proteomics studies in E. coli 
Current global proteomic studies have identified about 27% of the annotated 
proteins of E. coli, most of which are predicted to be abundant proteins. In the E. coli 
Swiss-2D PAGE database (Tonella et al., 2001), thousands of proteins were separated by 
2D PAGE gels and about 273 proteins were identified. In our lab, non-denaturing 2D 
LC/MS (NonDeLC) separated and identified 310 proteins (Champion et al., 2003) from 
exponential phase of E. coli cells grown in M9 minimal glucose medium. By using the 
same gel-independent methods, Champion et. al. (2003), studied the proteomes of 
exponential and stationary phase E. coli grown in MOPS minimal glucose medium. In 
total for both growth phases, 520 different proteins were identified (Champion et al. in 
preparation). Using 2D LC-MS/MS, 404 high quality proteins, which have more than 
one peptide identified, were identified by Corbin et. al. (2003). Using 2D PAGE/MS, 
570 exponential phase proteins were identified by Project CyberCell (Sundararaj et al., 
2004). Overall 1047 proteins have been identified of the more than 4000 proteins that are 
predicted from the E. coli genome.  
About 75% predicted proteins haven‟t been identified by current proteomic studies. 
One reason is that not all gene products are expressed under the same conditions. 
Expression is regulated to adapt to different growth conditions, such as different growth 
media and different growth phases. Aanother reason is that global proteomics are biased 
towards high abundance proteins (Champion et al., 2003; Corbin et al., 2003; Tonella et 
al., 2001). The codon adaptation index (CAI) is a parameter used to predict the 
expression level of genes (Eyre-Walker, 1996; Sharp and Li, 1987). Proteins with higher 
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CAI values (≥0.5) are predicted to be high abundance proteins, while proteins with low 
CAI values (<0.5) are predicted to be low abundance proteins. For proteins with a CAI 
greater than or equal to 0.5 of the whole proteome, 70% have been identified in the 
global proteomic studies just cited. For proteins with a CAI less than 0.5, only 20% have 
been identified. One way to solve this problem is to apply methods with higher 
sensitivity. Another way is to apply sub-proteomics, which can enrich and identify low 
abundance proteins by focusing on specific groups of proteins. 
Different physical properties have been studied using proteomic approach. Using 
tandem affinity purification (TAP) (Butland et al., 2005) or his-tag purification 
(Arifuzzaman et al., 2006), thousands of protein pair candidates were identified for E. 
coli. Protein carbonylation has been studies for cells under different stresses (Ballesteros 
et al., 2001; Dukan and Nystrom, 1998). During stationary phase, several TCA cycle 
enzymes, glutamine synthetase, glutamate synthase, pyruvate kinase, DnaK, and H-NS 
are carbonylated (Dukan and Nystrom, 1998).  
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Methods to manage and display proteomic data 
Studies of proteomics, genomics, transcriptomics, metabolomics, and other „OMICS‟ 
create large amounts of data, which are difficult to organize either manually or using a 
computer spreadsheet such as Excel. Relational Database Management Systems 
(RDBMS), which can be supported by MySQL® or Oracle®, are easier and more 
efficient tools to store, organize and analyze data (Baclawski et al., 1993). Using a 
database, not only the final results, but also details of every step of experiments, such as 
materials and methods, can be stored. To analyze and mine the proteomic data, scripts 
can be written to query such databases. Moreover, these databases can be connected to 
website interfaces using Perl-CGI, PHP and HTML and the data can be displayed to 
multiple users.  
There are many web-based databases for E. coli proteomic and genomic studies, 
some of them are listed in Table 1.1. Among these databases, only a few of them are for 
E. coli proteomic studies, such as Project CyberCell (Sundararaj et al., 2004). Right now, no 
E. coli proteomic database contains proteomics data from other groups. Since more and more 
proteomic data obtained from different studies, it is important and useful to have a database 
containing E. coli proteomic data from different group. This summary of data in database will 
facilitate the comparison of different studies. 
As the amount of proteomic data increases, database and computational techniques 
become more important for analyzing data of proteomics. Proteomic studies in this 
dissertation will use these tools to analyze data. Moreover, web-based databases will be 
constructed to facilitate the management and displaying the data.  
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Studies of this dissertation and content of each chapter 
This dissertation studied differences between exponential growth and stationary 
phase of E. coli cells at the protein level, and applied bioinformatics tools to manage, 
display the data generated by proteomics, and to display the genome annotation of 
different E. coli strains. 
Chapter II describes the study of E. coli heparin-binding proteins from both 
exponential growth and stationary phase cells. Chapter III describes the study of the 
whole proteome for E. coli cells from both exponential growth and stationary phase 
using anion-exchange columns (AIX), 2D PAGE and MS/MS. Chapter IV describes a 
web-based database, Experiments in E. coli Proteomics (EEP), which manages data 
generated by proteomic studies. Chapter V describes studies of E. coli bioinformatics, 
which applies different bioinformatic tools on studies of genomics and proteomics. 
Chapter VI describes conclusions of this dissertation. 
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Table 1.1. E. coli web-based databases. 
 
 
 
Name URL References 
ASAP https://asap.ahabs.wisc.edu/asap/home.php (Glasner et al., 2003) 
AlignACE http://arep.med.harvard.edu/ecoli_matrices/ (Robison et al., 1998) 
ColiBASE http://colibase.bham.ac.uk/ (Chaudhuri et al., 2004) 
Colibri http://genolist.pasteur.fr/Colibri/ (Medigue et al., 1993) 
E. coli 
genome 
project 
http://www.genome.wisc.edu/  
EcoCyc http://ecocyc.org/ (Karp et al., 1996; Karp et al., 
1997, 1998; Karp et al., 2000; 
Karp et al., 2002; Keseler et 
al., 2005; Paley and Karp, 
1996) 
EcoGene http://bmb.med.miami.edu/EcoGene/EcoWeb/ (Rudd, 2000) 
EchoBase http://ecoli-york.org/ (Misra et al., 2005) 
GenProtEC http://genprotec.mbl.edu/ (Riley and Space, 1996; 
Riley, 1997; Serres et al., 
2004) 
GenoBase http://ecoli.naist.jp/  
PEC http://www.shigen.nig.ac.jp/ecoli/pec/index.jsp  
Project 
CyberCell 
http://www.projectcybercell.ca/ (Sundararaj et al., 2004) 
RegulonDB http://www.cifn.unam.mx/Computational_Gen
omics/regulondb/ 
(Huerta et al., 1998; Salgado 
et al., 1999; Salgado et al., 
2000; Salgado et al., 2001; 
Salgado et al., 2004; Salgado 
et al., 2006) 
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CHAPTER II 
HEPAROME 
Background 
There are more than 4300 predicted protein-coding genes for E. coli (Riley et al., 
2006). No method can identify all the proteins at one time. One reason is that not all of 
the proteins are expressed in all growth conditions. Expression is regulated to adapt to 
different growth conditions, such as different growth media or different growth phases. 
Another reason is that studies of the whole proteome by current methods are not 
sensitive enough to detect low abundance proteins. However multiple methods can be 
applied to study different sub-proteomes, which are specific groups of proteins that share 
some physical property, such as phosphorylation, glycosylation or ubiquitination 
(Ferguson and Smith, 2003; Larsen and Roepstorff, 2000; Zhang et al., 2004). 
In this chapter, we describe the use of heparin chromatography to enrich for heparin-
binding proteins of E. coli cells from both exponential growth and stationary phase cells1. 
Heparin is a negatively charged sulfated glycosaminoglycan (Fig. 2.1), which can bind 
to proteins such as certain receptors, growth hormones and enzymes involved in nucleic 
acid metabolism (Imai et al., 2002). Heparin columns have been applied to proteomics 
of Haemophilus influenzae (Fountoulakis and Takacs, 1998; Langen et al., 2000) and  
_________________ 
1In this chapter, protein samples and SDS-PAGE were prepared by me. Mass 
spectrometry was run by Dr. Sam Perkins from Dr. David Russell‟s laboratory.  
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Mycoplasma pneumoniae (Ueberle et al., 2002).  
Because heparin is negatively charged, polyanion-binding proteins, such as nucleic 
acid-binding proteins are expected to be identified in the heparin binding sub-proteome, 
also called the “Heparome”. By comparing the differences of the E. coli Heparome 
between exponential growth and stationary phase, proteins that are important during 
stationary phase for regulation, information transfer, transportation, and metabolism 
were expected to be identified. 
 
 
 
 
 
 
Figure 2.1. The structure of heparin, a sulfated poly-glycosaminoglycan. 
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Results 
Identification of E. coli heparin-binding proteins 
Exponential growth and stationary phase cells of E. coli K-12 strain MG1655 were 
grown and harvested as described in Materials and Methods. The strategy to identify 
heparin-binding proteins is shown in Figure 2.2. Clarified lysates were loaded onto 
heparin affinity columns as described in Materials and Methods. The majority of 
proteins were in the flow-through and about 10% of the total proteins (by Bradford assay) 
bound to the heparin column. Bound proteins were eluted with a salt gradient and 
collected in 16 fractions (Fig. 2.3). Proteins in each fraction were identified by MALDI-
MS analysis of tryptic peptides combined with Applied Biosystems GPS Explorer 
Software. Two methods were used to generate the tryptic peptides. An aliquot of each 
fraction was digested with trypsin followed by separation of peptides by liquid 
chromatography (LC). In addition, each fraction was separated by SDS-PAGE (Fig. 2.4) 
followed by in-gel digestion of protein bands excised from the gel.  
Many protein bands existed in adjacent fractions, and the patterns of protein bands 
in adjacent fractions were changing continuously. Observed molecular weights of protein 
bands ranged from 15 kD to 230 kD. Later fractions contained more protein bands with 
lower observed molecular weights.  
  
  
17 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Flowchart of the strategy to identify heparin-binding proteins of E. coli cells. 
Clarified cell lysates were loaded on heparin-HPLC columns. Heparin-binding proteins 
were collected in 16 fractions. An aliquot of each fraction was separated on SDS-PAGE. 
Proteins on gels were excised, in-gel digested with trypsin, and identified by MS or/and 
MS/MS. Another aliquot of each fraction was dialyzed, digested by trypsin, separated by 
LC and identified by MS/MS. Proteins identified multiple times were counted only once. 
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Figure 2.3. UV280 traces from the AKTA HPLC heparin column for samples from 
exponential growth (A) and stationary phase (B) of E. coli cells. The dark line is the 
UV280 plot in absorbance units and the grey line is the salt gradient as a percent.  
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Figure 2.4. SDS-PAGE separation for heparin columns fractions from exponential 
growth (A) and stationary phase (B) lysate of E. coli cells.  
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The number of non-redundant proteins identified in each fraction ranged from 21 to 
124 (Fig. 2.5). In total 1,358 redundant proteins were identified by either in-gel/MS/MS 
or LC/MS/MS from these 32 elution fractions (see table in APPENDEX A). Most of the 
proteins were identified in multiple fractions and/or in both exponential growth and 
stationary phase samples. For example, the product of rpoA was found in fractions 3-14 
and 2-11 from the exponential growth and stationary phase samples, respectively. 
318 non-redundant proteins were identified as heparin-binding proteins (Table 2.1A). 
240 non-redundant proteins were identified from the exponential growth sample (Table 
2.1B), 234 non-redundant proteins were identified from the stationary phase sample 
(Table 2.1C), and 156 non-redundant proteins were found in both growth phases (Table 
2.1A and Table 2.1B) (Fig. 2.6).   
The theoretical molecular weights of the 318 heparin-binding proteins ranged from 
6 kD to 170 kD, and the molecular weight distribution of heparin-binding proteins was 
similar to that of the whole proteome (Fig. 2.7A). Since heparin is a highly sulfated 
glycosaminoglycan, we expected mostly basic proteins to bind to the heparin column. 
However theoretical pIs of the heparin binding proteins ranged from 4.5 to 11.5, and the 
pI distribution of heparin-binding proteins was similar to that of predicted proteins from 
the whole genome of E. coli (Fig. 2.7B). Based on this fact, we concluded that protein 
binding to heparin might be due to the charges on patches of proteins (Sendak and 
Bensadoun, 1998) instead of the overall pI.  
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Figure 2.5. Distribution of protein identification on heparin columns. The number of 
non-redundant proteins identified in each fraction was plotted for the exponential growth 
sample (gray) and the stationary phase sample (white).  
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Table 2.1A. Heparin-binding proteins identified from exponential growth and 
stationary phase E. coli cells. 
 
 
 
 
 
a) Non-redundant proteins are the number of specific gene products.  
b) Each protein is counted only once in combined and total numbers. 
 
 
 
 
 
 In-gel/MS LC/MS Combined 
Exponential phase    
Redundant proteins 
Non-redundant proteins 
471 
151 
489 
178 
960 
240 
    
St tionary phase   
Redundant proteins 
Non-redundant proteins 
358 
117 
604 
196 
962 
234 
    
Totals    
Redundant proteins 
Non-redundant proteins 
829 
195 
1093 
241 
1922 
318 
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accA/P30867, accC/P24182, accD/P08193, aceE/P06958, adhE/P17547, alaS/P00957, 
arcA/P03026, argA/P08205, aroC/P12008, aroH/P00887, atpA/P00822, atpD/P00824, 
bglX/P33363, ccmH/P33925, creA/P08367, crl/P24251, crp/P03020, cysH/P17854, 
dapE/P24176, deaD/P23304, def/P27251, dinG/P27296, dksA/P18274, dnaK/P04475, 
era/P06616, erfK/P39176, fabA/P18391, fabB/P14926, fabF/P39435, fabG/P25716, 
fabH/P24249, fabI/P29132, fabR/P27307, fadR/P09371, ftnA/P23887, fur/P06975, 
gapA/P06977, ghrA/P75913, gidB/P17113, glf/P37747, glgB/P07762, glgC/P00584, 
glmU/P17114, glnE/P30870, glnS/P00962, gltB/P09831, gltX/P04805, glyA/P00477, 
gnd/P00350, guaB/P06981, gyrA/P09097, gyrB/P06982, hflX /P25519, hisG/P10366, 
hisS/P04804, hns/P08936, hscC/P77319, hupA/P02342, hupB/P02341, hycE/P16431, 
ihfA/P06984, ihfB/P08756, infA/P02998, infB/P02995, infC/P02999, iscS/P39171, 
kdgR/P76268, lexA/P03033, ligA/P15042, lon/P08177, lpd/P00391, lpxB/P10441, 
lrp/P19494, malP/P00490, map/P07906, mdoG/P33136, metE/P25665, metF/P00394, 
metG/P00959, metJ/P08338, mfd/P30958, miaA/P16384, minE/P18198, mnmG/P17112, 
moaB/P30746, moaC/P30747, mprA/P24201, mraW/P18595, mug/P43342, nuoG/P33602, 
nusB/P04381, ompA/P02934, ompC/P06996, ompF/P02931, ompR/P03025, 
ompT/P09169, oppA/P23843, oxyR/P11721, panC/P31663, parC/P20082, parE/P20083, 
pbpC/P76577, pcnB/P13685, pdxH/P28225, pepA/P11648, pgk/P11665, pheS/P08312, 
pheT/P07395, pnp/P05055, pntA/P07001, ppc/P00864, ppk/P28688, prc/P23865, 
proC/P00373, purU/P37051, rbfA/P09170, rcsB/P14374, relA/P11585, rhlB/P24229, 
rhlE/P25888, rho/P03002, rlpB/P10101, rluC/P23851, rluE/P75966, rne/P21513, 
rnr/P21499, rob/P27292, rplA/P02384, rplB/P02387, rplC/P02386, rplD/P02388, 
rplE/P02389, rplF/P02390, rplI/P02418, rplJ/P02408, rplK/P02409, rplL/P02392, 
rplM/P02410, rplN/P02411, rplO/P02413, rplP/P02414, rplQ/P02416, rplR/P02419, 
rplS/P02420, rplT/P02421, rplU/P02422, rplV/P02423, rplW/P02424, rplX/P02425, 
rplY/P02426, rpmA/P02427, rpmB/P02428, rpmC/P02429, rpoA/P00574, rpoB/P00575, 
rpoC/P00577, rpoD/P00579, rpsA/P02349, rpsB/P02351, rpsC/P02352, rpsD/P02354, 
rpsE/P02356, rpsF/P02358, rpsG/P02359, rpsH/P02361, rpsI/P02363, rpsJ/P02364, 
rpsK/P02366, rpsM/P02369, rpsN/P02370, rpsO/P02371, rpsP/P02372, rpsQ/P02373, 
rpsR/P02374, rpsS/P02375, rpsT/P02378, rpsU/P02379, rsd/P31690, rsmC/P39406, 
rsuA/P33918, secA/P10408, selB/P14081, skp/P11457, slyA/P55740, spoT/P17580, 
stpA/P30017, sucA/P07015, sucB/P07016, suhB/P22783, talB/P30148, tgt/P19675, 
thrS/P00955, tktA/P27302, trpR/P03032, trpS/P00954, ttk/P06969, tufA/tufB/P02990, 
tyrR/P07604, tyrS/P00951, ugpQ/P10908, uidR/Q59431, ung/P12295, uvrB/P07025, 
uvrY/P07027, xthA/P09030, yaaA/P11288, yaeH/P37048, yafC/P30864, yafJ/Q47147, 
yafL/Q47151, ybaK/P37175, ybeZ/P77349, ybgK/P75745, ybiB/P30177, ycbB/P22525, 
ycgK/P76002, yciK/P31808, ycjX/P76046, ydcC/P28917, ydfH/P77577, ydgH/P76177, 
ydjA/P24250, yegQ/P76403, yejK/P33920, yfaA/P17994, yfhD/P30135, yfiF/P33635, 
yfjH/P52123, yggH/P32049, yggS/P52054, yhaJ/P42623, yhhX/P46853, yibK/P33899, 
yibQ/P37691, yihA/P24253, yjeQ/P39286, yjgA/P26650, ykgM/P71302, ynhG/P76193, 
zwf/P22992 
 
Table 2.1B. Heparin-binding proteins found in exponential growth of E. coli cells. Gene 
name and SwissProt ID are displayed for every protein. Entries bolded are proteins 
identified only in the exponential growth phase. 
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Table 2.1C. Heparin-binding proteins found in stationary phase of E. coli cells. Gene 
name and SwissProt ID are displayed for every protein. Entries bolded are proteins 
identified only in the stationary phase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
accA/P30867, accC/P24182, accD/P08193, aceA/P05313, aceE/P06958, aceF/P06959, 
adhE/P17547, ahpC/P26427, aidB/P33224, allR/P77734, arcA/P03026, aroC/P12008, 
atpA/P00822, atpD/P00824, atpF/P00859, bfr/P11056, carB/P00968, cbpA/P36659, 
clpA/P15716, cpsB/P24174, crp/P03020, dacB/P24228, def/P27251, dinB/Q47155, 
dksA/P18274, dnaK/P04475, dnaX/P06710, dps/P27430, eda/P10177, envC/P37690, 
erfK/P39176, fabA/P18391, fabB/P14926, fabG/P25716, fabH/P24249, fabI/P29132, 
fmt/P23882, ftnA/P23887, gadB/P28302, ghrA/P75913, glgB/P07762, glnK/P38504, 
glnS/P00962, gltB/P09831, gltX/P04805, gnd/P00350, gpmA/P31217, groL/P06139, 
grxB/P39811, guaB/P06981, gutQ/P17115, gyrA/P09097, hflX/P25519, hisB/P06987, 
hisS/P04804, hns/P08936, htpG/P10413, hupA/P02342, hupB/P02341, icd/P08200, 
ihfA/P06984, ihfB/P08756, ilvE/P00510, infA/P02998, infB/P02995, infC/P02999, 
iscS/P39171, ivy/P45502, kdgR/P76268, lacZ/P00722, ligA/P15042, lon/P08177, 
lpd/P00391, lpxD/P21645, lrp/P19494, malP/P00490, malQ/P15977, manX/P08186, 
map/P07906, mdh/P06994, mdoG/P33136, metE/P25665, metJ/P08338, metQ/P28635, 
mfd/P30958, mglA/P23199, moaB/P30746, mprA/P24201, mraW/P18595, mukB/P22523, 
nadR/P27278, nagA/P15300, nikE/P33594, nusG/P16921, ompC/P06996, ompR/P03025, 
oppA/P23843, oxyR/P11721, parC/P20082, pcnB/P13685, pdxH/P28225, pepA/P11648, 
pgk/P11665, phoB/P08402, polA/P00582, ppc/P00864, ppk/P28688, ppx/P29014, 
prc/P23865, purC/P21155, purR/P15039, purU/P37051, rbfA/P09170, rbsA/P04983, 
relA/P11585, relE/P07008, rhlE/P25888, rho/P03002, rlmB/P39290, rluC/P23851, 
rmf/P22986, rnc/P05797, rnr/P21499, rob/P27292, rplA/P02384, rplB/P02387, 
rplC/P02386, rplD/P02388, rplE/P02389, rplF/P02390, rplI/P02418, rplJ/P02408, 
rplK/P02409, rplL/P02392, rplM/P02410, rplN/P02411, rplO/P02413, rplP/P02414, 
rplQ/P02416, rplR/P02419, rplS/P02420, rplT/P02421, rplU/P02422, rplV/P02423, 
rplW/P02424, rplX/P02425, rplY/P02426, rpmA/P02427, rpmB/P02428, rpmC/P02429, 
rpmD/P02430, rpoA/P00574, rpoB/P00575, rpoC/P00577, rpsA/P02349, rpsB/P02351, 
rpsC/P02352, rpsD/P02354, rpsE/P02356, rpsF/P02358, rpsG/P02359, rpsH/P02361, 
rpsI/P02363, rpsJ/P02364, rpsK/P02366, rpsM/P02369, rpsN/P02370, rpsO/P02371, 
rpsP/P02372, rpsQ/P02373, rpsR/P02374, rpsS/P02375, rpsT/P02378, rpsU/P02379, 
rsmC/P39406, secA/P10408, selA/P23328, serA/P08328, skp/P11457, slyA/P55740, 
sodB/P09157, speG/P37354, spy/P77754, sthA/P27306, stpA/P30017, sucA/P07015, 
sucB/P07016, suhB/P22783, talB/P30148, thrS/P00955, tig/P22257, tpx/P37901, 
trpS/P00954, truA/P07649, truD/Q57261, tsf/P02997, tufA/tufB/P02990, tyrS/P00951, 
uvrB/P07025, wcaI/P32057, wrbA/P30849, xthA/P09030, yaaA/P11288, yaeB/P28634, 
yaeH/P37048, yaiN/P55756, ybaK/P37175, ybeX/P77392, ybeZ/P77349, ybiB/P30177, 
ycgK/P76002, yciH/P08245, yciK/P31808, ydcP/P76104, ydgH/P76177, ydjA/P24250, 
yeaO/P76243, yegQ/P76403, yffB/P24178, ygeA/P03813, yggH/P32049, yggS/P52054, 
yhaJ/P42623, yhbJ/P33995, yhhK/P37613, yhhX/P46853, yicC/P23839, yihA/P24253, 
yihI/P32130, yjgA/P26650, ykgM/P71302, ynhG/P76193, yraL/P45528, zwf/P22992 
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Figure 2.6. Comparison of heparin-binding proteins between exponential growth and 
stationary phase. 240 proteins were found in exponential growth, 234 were found for 
stationary phase, and 156 were found in both. In total, 318 proteins were identified as 
heparin-binding proteins.  
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A) 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
Figure 2.7. Comparisons of the distributions of molecular weight (A) and pI (B) 
between heparin-binding proteins and predicted proteins of the whole genome. 
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Heparin-binding proteins were found in all functional classifications (Fig. 2.8), as 
defined by the cluster of orthologus groups (COG) (Tatusov et al., 2003). 19 heparin-
binding proteins were in the category of „replication, recombination and repair‟. 84 
heparin-binding proteins were in the „translation‟ category, including 47 ribosomal 
proteins, 9 tRNA synthetases, 3 protein chain elongation factors, and 3 protein chain 
initiation factors. 27 heparin-binding proteins were in the „transcription‟ category, 
including 14 transcription regulators, 4 subunits of RNA polymerases, and RNase III. 
Overall 40.8% (130) of the heparin-binding proteins were in categories related to DNA- 
or RNA-binding proteins. The rest of them were distributed among other categories.  
Comparing with other E. coli proteomic studies and proteins predicted from the 
whole E. coli genome, Heparome has high percentage in „translation‟, „transcription‟, 
„replication, recombination and repair‟ categories (Fig. 2.8).  
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Comparison between exponential growth and stationary phase 
After the initial identification, comparisons were made of presence, predicted 
abundance, and chromatographic behavior between exponential growth and stationary 
phase. 
Presence 
For the 318 heparin-binding proteins, 84 of them were only found in exponential 
phase, and 78 of them were only found in stationary phase. By comparing proteins 
unique to exponential and stationary phase, two functional groups, transcription and cell 
wall/membrane biogenesis have more proteins for exponential phase (Fig. 2.9). For 
stationary phase unique Heparome, proteins were found more in three functional groups. 
They are carbohydrate transport and metabolism, post-translational modification, protein 
turnover, chaperones, and inorganic ion transport and metabolism (Fig. 2.9).  
Abundance 
To find heparin-binding proteins whose abundance changed between exponential 
growth and stationary phase, we used CyDye DIGE 2D PAGE and DeCyder™ v6.5 
differential analysis software. Aliquots of every exponential or stationary phase elution 
fraction were pooled, labeled with fluorescent dyes, and separated by 2D-PAGE. Five 
heparin-binding  were more abundant in stationary phase and 9 were more abundant in 
exponential growth phase (Table 2.2).The 5 more abundant heparin-binding proteins in 
stationary phase are the products of the dps, elaB, ivy, manX and metJ genes. The 9 more 
abundant heparin-binding proteins in exponential growth are the products of the cysH, 
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engB, mdoG, metE, rplD, rplI, rpsB, rpsF, and rsuA genes. 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. COG functional classification of heparin-binding proteins found only in 
exponential or stationary phase. G:  Carbohydrate transport and metabolism. O:  Post-
translational modification, protein turnover, chaperones. P:   Inorganic ion transport and 
metabolism. K:  Transcription. M:  Cell Wall/membrane biogenesis. 
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More abundant in stationary phase 
sp_id
a
 gn
b
 b_number
c
 product 
P27430 dps b0812 Stress response DNA-binding protein 
P52084 elaB b2266 Hypothetical protein 
P45502 ivy b0220 Inhibitor of vertebrate C-lysozyme 
P08186 manX b1817 Mannose phosphotransferase system, EIIAB component 
P08338 metJ b3938 Met regulon regulatory protein 
    
More abundant in exponential phase 
sp_id gn b_number product 
P17854 cysH b2762 Phosphoadenylyl sulfate (PAPS) reductase 
P24253 engB b3865 GTPase essential for cell cycle 
P33136 mdoG b1048 Periplasmic oligosaccharide synthesis 
P25665 metE b3829 Methionine synthase, cobalamin-independent; 5-
methyltetrahydropteroyltriglutamate-homocysteine methyltransferase; 
binds Zn(II) 
P02388 rplD b3319 50S ribosomal subunit protein L4 
P02418 rplI b4203 50S ribosomal subunit protein L9 
P02351 rpsB b0169 30S ribosomal subunit protein S2 
P02358 rpsF b4200 30S ribosomal subunit protein S6 
P33918 rsuA b2183 16S RNA pseudouridine 516 synthase 
 
a: sp_id: SwissProt gene ID 
b: gn: Gene Name 
c: b_number: Blattner Number 
Table 2.2. Heparin-binding proteins with abundance changes between exponential 
growth and stationary phase 
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Chromatography behavior---elution shifts 
The elution profiles were compared for heparin-binding proteins present in both 
exponential growth and stationary phase. An elution shift was defined as a change in the 
peak elution position of ≥3 fractions. Among the 156 heparin-binding proteins found in 
both growth phases, 7 had an elution shift between these two growth phases (Table 2.3). 
These proteins are the products of the def, dnaK, ftnA, ppc, ppk, relA and yaeH genes. 
The elution positions of FtnA were verified by enhanced chemiluminescence (ECL) 
western (Fig. 2.10).  
Validation of protein identification 
Validation of proteins from in-gel/MS/MS--difference between Obs. MW and theoretical MW 
To validate the protein identifications from in-gel/MS/MS, we compared the 
observed molecular weight (Obs. MW) on the gel with the theoretical molecular weight 
(MW). Among the 829 redundant proteins found by in-gel/MS/MS, 77% had observed 
molecular weights that were of the theoretical molecular weight (MW) (Fig. 2.11). The 
other proteins could be processed, degraded, or run aberrantly on SDS-PAGE. 
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sp_id
a gnb b_numberc Product Fractions 
Exp.
d
 Stat.
e
 
P27251 def b3287 peptide deformylase 5, 6 2 
P04475 dnaK b0014 chaperone Hsp70; DNA biosynthesis; 
autoregulated heat shock proteins 
1 6, 7 
P23887 ftnA b1905 cytoplasmic ferritin (an iron storage protein) 1 6 
P00864 ppc b3956 phosphoenolpyruvate carboxylase 1 6 
P28688 ppk b2501 polyphosphate kinase 1 10 
P11585 relA b2784 (p)ppGpp synthetase I (GTP 
pyrophosphokinase); regulation of RNA 
synthesis; stringent factor 
6 12, 14 
P37048 yaeH b0163 putative structural protein 10 6 
 
a: sp_id: SwissProt gene ID 
b: gn: Gene Name 
c: b_number: Blattner Number 
d: Exp.: Exponential phase 
e: Stat.: Stationary phase 
 
Table 2.3. Proteins with elution shift on the heparin column between exponential growth 
and stationary phase  
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CL        FT        1         2          3         4         5         6       7
Exp
Stat
 
 
 
 
 
 
 
Figure 2.10. Identification of FtnA in heparin-column elution fractions by Western 
blotting with anti-FtnA antibody. Exp: exponential growth. Stat: stationary phase. CL: 
cell lysate. FT: flow through. 1 to 7 are elution fraction numbers. 
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Figure 2.11. Distribution of difference between Obs. MW and theoretical MW for heparin-
binding proteins identified by in-gel digestion combined with MS or/and MS/MS. Among 
829 redundant proteins, 538 (77%) of them have the difference in ±30% between Obs. MW 
and theoretical MW.
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Validation of protein identification from both in-gel/MS/MS and LC/MS/MS methods– pI 
distribution in every fraction 
We predicted that proteins eluting in early fractions, which bind to heparin relatively 
loosely, would have a lower pI than proteins eluting in late fractions, which bind to the 
heparin tightly. To validate the identifications from both in-gel/MS/MS and LC/MS/MS, 
the pI distribution of proteins in every fraction was plotted (Fig. 2.12 and Fig. 2.13). The 
peak of the pI distributions shifted from 5 or 6 for proteins in early fractions to 10 or 11 
for proteins eluting in later fractions. This result fit the property of heparin column, 
which bind basic protein more tightly.   
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Figure 2.12. pI distribution of heparin-binding proteins in elution fractions of the 
exponential growth sample.  
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Figure 2.13. pI distribution of heparin-binding proteins in elution fractions of the 
stationary phase sample. 
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Discussion 
In-gel/MS/MS and LC/MS/MS 
In this study we used in-gel/MS/MS and LC/MS/MS to identify 195 and 241 
heparin-binding proteins respectively, with 118 proteins identified by both methods.  
Properties of heparin-binding proteins 
The distribution of theoretical pI‟s of the heparin-binding proteins was similar to 
that of the predicted whole proteome of E. coli. We conclude that factor affecting 
proteins binding to the heparin column may include the charges on patches of proteins 
instead of the overall pI. Moreover, molecular weight distribution of heparin-binding 
proteins is also similar to that of whole genome. 
Changes in stationary phase Heparome 
Protein presence 
For stationary phase Heparome, there are more proteins in carbohydrate transport 
and metabolism, post-translational modification, protein turnover, chaperones, and 
inorganic ion transport and metabolism. It is not surprised that E. coli cells need more 
chaperon proteins since more misfolding proteins are generated when cells enter 
stationary phase (Mujacic and Baneyx, 2007). Also due to depletion of nutrient, cells in 
stationary phase might also increase the expression of carbohydrate transport proteins to 
obtain different carbon sources.  
Protein abundance  
Among the 5 more abundant heparin-binding proteins in stationary phase, the 
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product of dps is a stress response DNA-binding protein that is known being up-
regulated in stationary phase. The product of ivy/ykfE is the inhibitor of C-lysozyme 
(Deckers et al., 2004). With increasing amount of C-lysozme, E. coli cells might 
increase the resistance of antibacterial lysozyme in stationary phase. The product of 
manX is one of the components of the major transporter for the mannose (Erni and 
Zanolari, 1985; Erni et al., 1987) and the product of metJ is repressor of the methionine 
biosynthetic genes (Usuda and Kurahashi, 2005). These data suggest that in stationary 
phase of glucose starvation, E. coli cells increase the ability to transfer other sugar, such 
as mannose, and decrease the biosynthesis of methionine.  
Chromatography behavior on heparin columns 
Before behavior of proteins on heparin columns was examined, we asked if the 
amount will affect the behavior of proteins. By loading different amount of proteins onto 
same heparin column separately, elution profiles of heparin-binding proteins do not 
change (Fig. 2.14). Based on the properties of heparin column, we also predicted that 
most of the proteins that eluted early would be more acidic, while proteins eluted late 
would be more basic. The peaks of the protein‟s pI in early fractions are 5-6, while those 
of late fractions are 10-11, which agrees with our prediction. Most of the heparin-
binding proteins with pIs lower than 5 were found in early fractions (1 to 8), such as the 
products of the ahpC, bfr, dksA, dnaK, ftnA, gnd, groL, hscC, metQ, purC, rpoD, tpx and 
tig genes. Most of the heparin-binding proteins with pIs higher than 10 were found in 
late fractions (9 to16th), such as products of rhlE, rluE, rmf and ribosomal proteins. The 
presence of proteins with high pIs in early fractions or proteins with low pIs in late 
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fractions might be caused by protein-protein interactions, protein and small molecule 
binding, changes of protein conformations, or post-translational modifications. 
Proteins found with elution shift on heparin column belong to different biological 
processes, which indicate specific changes when cells enter stationary phase. The 
changes of behavior on the heparin column might be due to protein stability, changes in 
protein conformations, post-translational modifications (Dukan and Nystrom, 1998; 
Fredriksson et al., 2005; Tamarit et al., 1998), or protein-protein interactions.  
For example, the product of ftnA is a cytoplasmic ferritin, which stores free iron 
during stationary phase (Andrews, 1998). In stationary phase, more ferritin is expressed 
to form a spherical protein which is composed of 24 identical subunits. This spherical 
protein contains a large hollow centre that acts as an iron-storage cavity to accommodate 
at least 2000 iron. Since FtnA is negatively charged, most of them flew through the 
heparin column. FtnA from exponential phase elutes out early, but FtnA from stationary 
phase binds to heparin column more tightly. Since heparin column is negatively charged, 
surface of ferritin from stationary phase could have more positively charges caused by 
post-translational modification or conformation changes. To test if the conformation 
changes, size exclusion column combined with ECL western could be applied to analyze 
the size of the ferritin in these two growth phases. Ferritin in monomer will be 19 kD 
and 24mer will be around 456 kD. Also oligomers between monomer and 24mer could  
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Figure 2.14. Elution profiles of different amount protein loaded on heparin columns. 10 
mg (black), 20 mg (blue), 40 mg (pink), and 60 mg (yellow) proteins from stationary 
phase E. coli cells were loaded onto 5ml heparin HiTrap columns. Heparin-binding 
proteins were eluted with increasing NaCl concentration. Ratio for heights of four 
elution curves is about 1:2:4:4.8. Capacity of this column is about 50 mg proteins in cell 
lysate. 
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be detected.  To test if it is due to the post-translational modification changes, 2D PAGE 
combined with ECL western or followed with MS and tandem MS could be applied. If 
the post-translational modification changes, different spots of FtnA protein could show 
up on 2D PAGE which could be detected by ECL Western. Also MS and tandem MS 
could differentiate same peptides with different modifications.   
Another example is RelA, (p)ppGpp synthetase I and stringent factor. RelA from 
exponential phase eluted out in fraction 6th from heparin column, while RelA from 
stationary phase eluted out later in fraction 12th to 14th (Fig. 2.15A).  RelA binds to 
blocked ribosomes in stationary phase (Ramagopal and Davis, 1974; Wendrich et al., 
2002) and its activity is regulated by N-terminal of L11 (Yang and Ishiguro, 2001). 
Elution patterns of ribosomal proteins were different between exponential and stationary 
phases (Fig. 2.15B). We proposed that property changes of ribosomal protein affect the 
chromatography behavior of RelA from these two growth phase samples. 
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A) 
 
 
 
B) 
 
 
 
 
Figure 2.15. A) Elution positions of RelA on heparin columns. B) Distribution of ribosomal 
proteins on heparin columns. Exp. exponential phase. Stat. stationary phase. 
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Heparin-binding proteins and other proteomic studies 
The Heparome includes proteins in all functional classifications. Compared with 
other proteomic studies (Champion et al., 2003; Corbin et al., 2003; Tonella et al., 2001) 
(Project CyberCell; Champion, et al., 2005 submitted) and the whole genome, the 
Heparome enriched proteins in 3 categories: „translation‟, „transcription‟ and „replication, 
recombination and repair‟. The codon adaptivity index (CAI) (Eyre-Walker, 1996; Sharp 
and Li, 1987) values were applied to predict protein abundance. Proteins with high CAI 
values are predicted high abundance proteins, while proteins with low CAI values are 
predicted low abundance proteins. Most of the heparin-binding proteins in the 
„translation‟ category are predicted high abundance proteins, while most of heparin-
binding proteins in „transcription‟ category are predicted low abundance proteins. There 
are 19 heparin-binding proteins that are in category of „replication, recombination and 
repair‟. 
Among the 84 heparin-binding proteins in the „translation‟ category, there are 47 
ribosomal proteins, 9 tRNA synthetase, 3 protein chain elongation factors, 3 protein 
chain initiation factors and other proteins related to metabolism of tRNA, rRNA and 
mRNA. CAI values of 70 heparin-binding proteins in this category are higher than 0.4. 
47 out of these 70 proteins are high abundance ribosomal proteins. Among the 27 
heparin-binding proteins in „transcription‟ category, there are 14 transcription regulators, 
4 subunits of RNA polymerases, and RNase III. CAI values of 16 heparin-binding 
proteins in this category are lower than 0.4. 10 of these 16 proteins are low abundance 
transcriptional regulator. In total 130 heparin-binding proteins (40.8%) are in these 3 
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categories that are DNA-binding or RNA-binding proteins. The rest of them distribute in 
other categories. 
Comparing our data with other known proteomic studies (Champion et al., 2003; 
Corbin et al., 2003; Tonella et al., 2001) (Project CyberCell; Champion et al., 2006 
submitted) the Heparome found 116 novel proteins (Fig. 2.16A). In summary, current 
proteomic studies identified 1163 gene products of E. coli K-12 (Fig. 2.16A), which 
cover 27% of all coded proteins on genome. Most of the predicted high abundant 
proteins, which have CAI values higher than 0.6, were already identified (Fig. 2.16B), 
while most of the predicted low abundant proteins, which have CAI values lower than 
0.4, have not been previously found. The Heparome makes a contribution to identify low 
abundance proteins that cover many categories of functional classifications. For example, 
E. coli K-12 has 177 transcription regulators (Table 2.4), 165 of which are predicted low 
abundant proteins (CAI value lower than 0.4), previous studies identified 24 
transcription regulators in total. The Heparome identified 17 transcription regulators, 13 
of which are unique to the Heparome (Table 2.4). 
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A) 
 
 
 
 
B) 
 
 
 
 
 
Figure 2.16. A) Venn diagram of summary for Heparome and other proteomic studies. (318 
proteins were identified as heparin binding proteins and 1047 proteins were identified by 5 
other proteomic studies (Tonella L, 2001; Corbin RW., 2003; Project CyberCell; Champion 
MM., 2003; and Champion MM., 2005 in press). 116 proteins were unique to Heparome. In 
total 1163 proteins have been identified for E. coli K12). B) Distribution of the CAI range of 
proteins identified by current proteomic studies. (116 newly identified heparin-binding 
proteins are presented in black, all other studies are presented in gray and dashed boxes are 
protein numbers of whole E. coli proteome in certain CAI range.) 
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Table 2.4. Genes of transcription regulators in E. coli K-12.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transcriptional regulators  
abgR/ydaK fabR/yijC lacI  nlp yafC ydcI ygaV yjhU 
acrR fadR leuO  oxyR yafY ydcN ygbI yjiE 
agaR farR lldR pdhR yagI ydcR ygeV yjiR 
allR/ybbU fhlA lrhA perR yagP ydeW ygfI  yjjM  
alpA fruR lrp phnF yahB ydfH yggD ynaK 
alsK fucR lysR prpR yajF ydhB ygiP yncC 
argR galR malI pspC ybaD ydhM ygiT yneJ 
arsR galS malT pspF ybaO ydjF yhaJ ynfL 
ascG gatR  marR  purR ybbS yeaT  yhcS yphH 
asnC gcvA metJ rbsR ybdM yebK yhfR yqfE 
betI  glcC metR rpiR  ybdO yeeY  yhjC yqgE 
cbl glpR mhpR sgcR ybeF  yegW yiaG yqjI 
cueR gntR  mlc slyA ybhD  yehV yiaJ ytfA 
cynR hcaR mntR/ybiQ soxR ybiH yeiE yiaU ytfH 
cysB hdfR/yifD/yifA mprA/emrR srlR ycaN yfaH yidP ytfJ 
cytR hipB mtlR tdcA ycdC yfaX yidZ zntR 
deoR hyfR  nac treR ycfQ  yfeR yieP   
dgoR/yidW iciA nadR ttk  ycfX yfeT yihL   
dicA iclR nagC tyrR ycgE yfhH yihW   
dsdC idnR nanK  uidR yciT yfiE  yjdC   
ebgR ilvY nanR  uxuR ycjC yfjR yjeB   
envR iscR nhaR xapR ycjW ygaA yjfQ   
exuR kdgR nikR xylR_1  ycjZ ygaE  yjhI   
 
There are 177 transcription regulators. 24 of them (bold) were identified in previous 
proteomic studies (Tonella et al., 2001; Corbin et al., 2003; Project CyberCell; Champion 
et al., 2003; and Champion et al., 2006 submitted), 17 of them (underlined) were identified 
by Heparome. 
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Materials and methods 
Sample preparation 
E. coli K-12 strain MG1655 was inoculated from a single colony grown on minimal 
agar (0.2% glucose) into 5 ml of MOPS minimal glucose medium (0.4% glucose, 19 
mM NH4Cl, 1.32 mM K2HPO4, 2 g/ml thiamine, 10 g/ml uridine, 0.52 mM MgCl2, 
0.25 M CaCl2, 8.37 g/l MOPS, 0.72 g/l tricine, 48 mg/l K2SO4, 2.92 g/l NaCl, 3 mg/l 
FeSO47H2O, and micronutrients) and grown overnight with aeration at 37°C for 16 to 
18 hours. 5 ml of overnight culture was used to inoculate 2 liters of MOPS media, which 
was evenly divided into 2 separate 1-liter non-baffled flasks. Cultures were grown with 
aeration (250 RPM) in a 37°C water bath. 1 liter of the culture was harvested at mid-
exponential growth (OD600  0.5) and the other at late-stationary phase (OD600  2.0, 
about 17 hours after OD600 reached 0.5). Cells were pelleted in a JA10 rotor (Beckman) 
at 4500 x g for 20 minutes, washed twice in chilled lysis buffer (50 mM NaPO4, 50 mM 
NaCl, pH 7.2) , and resuspended in lysis buffer containing 5 mM PMSF, 5 mM DTT and 
5 mM p-aminobenzamidine. 
Resuspended cells were lysed by two passes through a chilled large French press 
cell at 16,000 psi. The lysate was centrifuged at 17,000 x g for 30 minutes in a JA-20 
rotor to remove the debris and intact cells. The supernatant was passed through a 0.45 
µm polyethersulfone syringe filter (Whatman PuradiscTM) prior to heparin-HPLC. 
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Heparin-HPLC 
5 to 7 ml of the clarified cell lysate, containing ~50 mg of protein as estimated by 
Bradford assay, was loaded onto a 5 ml HiTrap Heparin HP column (Amersham 
Biosciences) on an AKTA Purifier system (Amersham Biosciences). The column was 
washed with 40 ml (8 column volumes) of 50 mM sodium phosphate buffer with 50 mM 
NaCl, pH 7.2, at which point the OD280 had returned to the baseline level. Heparin-
bound proteins were eluted with a 60 ml (12 column volumes) 50 mM to 1M NaCl 
gradient in the same buffer and collected as twenty 3 ml fractions. Significant protein 
was only observed in the first 16 of these fractions by Bradford assay. 
One-dimensional SDS polyacrylamide gel electrophoresis 
One-third of every 3 ml elution fraction, which contained on average 80 µg of 
protein, was precipitated by addition of 500 µl of 50% TCA (final concentration of TCA 
is about 14%), washed twice by cold acetone, and resuspended in 20 µl SDS-PAGE 
sample loading buffer. Proteins in each sample were separated on 5 cm x 8 cm 10% 
Laemmli SDS polyacrylamide gels (37.5:1 acrylamide: bis-acrylamide) run at 20V/cm. 
The gels were stained with coomassie blue R-250 to visualize protein bands. 
CyDye DIGE two-dimensional SDS polyacrylamide gel electrophoresis 
 CyDye DIGE two-dimensional PAGE was performed by the Protein Chemistry 
Laboratory at Texas A & M University. Heparin-binding proteins from either the 
exponential growth or stationary phase sample were pooled by mixing 200 µl from 16 
protein-containing fractions. The pooled proteins were precipitated by 14% TCA, 
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washed twice with cold acetone and dried. Same amount of protein from exponential 
growth and stationary phase were combined as internal standard. Around 50 ng protein 
samples from exponential growth and stationary phase and the internal standard are each 
labeled with a different CyDye DIGE Fluor minimal dye. These labeled samples were 
then focused on Igphor immobilized gradient gels (14 cm pH 3–10 Nonlinear, Pharmacia) 
for 60–80,000 Volt hours, and separated by 12% SDS gels (14 x 14 cm) in the second 
dimension. This CyDye DIGE two-dimensional PAGE was repeated three times for 
statistic analysis. DeCyder™ v6.5 differential analysis software was used to visualize 
and analyze CyDye DIGE two-dimensional PAGE. 
Montage in-gel digestion 
459 coomassie-stained bands of approximately 2mm thick slices were excised from 
the Laemmli PAGE, 232 bands for the exponential growth sample, 227 bands for the 
stationary phase sample. In-gel digestions were carried out using the Montage In-Gel 
Digest Kit (Millipore). 
In-solution sample digestion 
200 µl aliquots of each heparin fraction were dialyzed three times for 4 hours each 
against 25 mM ammonium bicarbonate and subsequently dried on a speed vacuum at 
medium temperature. These were then reconstituted in 30 µl 50 mM ammonium 
bicarbonate, mixed with 2 µl of 20 µg/ml trypsin, and incubated overnight at 37°C. The 
samples were then frozen at -20°C prior to analysis.  
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Liquid chromatography 
In-solution digested samples were analyzed using LC peptide separation and 
MALDI. 
Mass spectrometry 
Data was acquired in batch mode on the Applied Biosystems 4700. MS spectra were 
collected at 50 shots/spectrum, 40 sub-spectra per spot for a total of 2000 shots per spot 
using a random laser search pattern. The mass range was 800-5000 m/z with a focus 
mass of 2000 m/z. 15 MS/MS spectra per spot were collected at 70 shots/spectrum, 80 
sub-spectra for a total of 5600 shots per spot. The mass window for MS/MS spectra was 
150 relative resolution of the parent peak. The metastable ion suppressor and the 
collision cell were on with atmospheric gas present. LC spots were internally calibrated 
using the angiotensin I Mr 1296.6853 (Sigma) and glu-fibrinogen peptide B Mr 
1570.6774 (Sigma). In-gel spots were externally calibrated with a mixture of Sigma 
angiotensin I Mr 1296.6853, ACTH 1-17 Mr 2093.0867, ACTH 18-39 Mr 2465.1989, 
and ACTH 7-38 Mr 3657.9294.  
Analysis of spectral data was performed using the Applied Biosystems GPS 
Explorer Software Version 2.0. The parameters were as follows: taxonomy, Escherichia 
coli; database, Swiss Prot; enzyme, trypsin; maximum missed cleavages, 1; variable 
modifications, oxidation (Met), propionamide (Cys); peptide tolerance, 100 ppm; and a 
significance threshold of 90%. If systematic error is taken into account the ppm error for 
these externally calibrated spots is less than 40 ppm, however this was not feasible for 
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such a large sample set. Peak filtering for MS was from 800-5000 Da with a S/N limit of 
15. Peak filtering for MS/MS was from 60 Da to 20 Da below each precursor mass with 
a minimum S/N filter of 8 and a mass tolerance of 0.3 Da. In-gel digestion spectra were 
searched using both MS and MS/MS data in “Combo mode” by Mascot 
(http://www.matrixscience.com from Matrix Science Ltd.). LC separation spectra were 
searched based on MS/MS data only by Mascot.  
Positive in-gel identifications had a confidence interval ≥ 99.50 %, had a linear 
systematic error in the PMF assignments, and a lack of redundant PMF identifications 
(peptide masses matched to more than one identification). Positive LC MS/MS 
identifications had a protein confidence interval of ≥ 99.50 % and linear systematic error. 
Identifications based on single peptides were thrown out unless the protein was also 
found in other fractions of the same sample with more than 1 peptide. 
Enhanced chemiluminescence (ECL) western blot 
 Proteins run on 10% Tris-Tricine gel were transfer to 0.2 µm nitrocellulose 
membrane using wire electrodes Trans-Blot cell (Bio-Rad) at 100 V for 3 to 4 hours. 
ECL Western blotting was performed according to manufacturer‟s protocol (SuperSignal 
West Pico, PIERCE). FtnA-specific polyclonal antisera were offered by Dr. Simon C. 
Andrews.  
Validation of the results  
Most of the proteins (70%) identified by in-gel/MS/MS have difference between ± 
30% between the observed molecular weight (MW) and the theoretical molecular weight 
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(MW). All proteins identified by LC/MS/MS have 2 or more peptides. pI distribution of 
each fraction was also plotted to validate the chromatography behaviors of heparin-
binding proteins on heparin columns. The peaks of the protein‟s pI in early fractions are 
5-6, while those of late fractions are 10-11. 
Bioinformatics 
Data was organized and analyzed in a MySQL database, using Perl and PHP to 
provide a web-based user interface. This database is searchable and viewable at 
http://eep.tamu.edu/heparome. Identified proteins can be searched by gene name, 
SwissProt ID, b number, growth phases, or elution fraction number. 
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 CHAPTER III 
PROTEOMIC STUDIES BY AIX COLUMN AND 2D PAGE 
Background 
In E. coli, gene expression is tightly related to physiology. In response to various 
conditions, such as low pH, nutrient starvation, phage infection, antibiotics, etc., E. coli 
regulates gene expression in order to adapt to the changes (Arnold et al., 2001; Hua et al., 
2004; Schembri et al., 2003). Proteomics has been used in many areas to understand how 
protein expression patterns are related to the physiology of E. coli at the protein level, 
such as when cells enter stationary phase. 
To increase the accuracy of protein identification, sample complexity should be 
reduced first. To separate complex protein mixtures and identify the proteins that present, 
non-denaturing liquid chromatography (NonDeLC) has been used (Badock et al., 2001; 
Champion et al., 2003; Ferguson and Smith, 2003). Under different conditions, a 
protein‟s chromatographic behavior will change if there are any covalent or non-covalent 
modifications, such as changes in binding partners. Coupled with mass spectrometry, 
NonDeLC can study proteins‟ chromatographic behavior and protein complex without 
denaturing the proteins. However, to study abundance and post-translational 
modifications, 2D PAGE (Henzel et al., 1993; Langen et al., 2000; Loo et al., 2001; 
Tonella et al., 2001) is an easier and more direct way to use. Two-dimensional gel 
electrophoresis (O'Farrell, 1975) is an traditional ways to separate complex protein 
mixtures containing thousands of components (Henzel et al., 1993; Langen et al., 2000; 
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Loo et al., 2001; Tonella et al., 2001).  
In this study, these two methods were combined to study the soluble E. coli 
proteome from both exponential and stationary phase samples1. To study the differences 
in the soluble proteome from these two growth phases, many characters were 
investigated, such as protein patterns on 2D PAGE for fractions from anion exchange 
(AIX) chromatography, the elution profile for every protein from AIX column, 
abundance of proteins and proteins‟ chromatographic behavior.  
Results 
The strategy to study the E. coli proteome by combining NonDeLC, 2D PAGE, and 
mass spectrometry is shown in Fig. 3.1. The soluble E. coli proteins from both 
exponential growth and stationary phase were fractionated by AIX chromatography. An 
aliquot of each protein-containing fraction was separated by 2D PAGE. In total there 
were 19 2D gels run for each growth phase. Gel images were acquired and analyzed 
using the Z3 2D gel analysis system as described in Materials and Methods (Fig. 3.2). 
The amount of protein present in each spot was determined by comparison with horse 
myoglobin, which was added to each fraction as an internal marker of protein abundance. 
 
 
________________ 
1: In this chapter, protein samples were prepared by me, two-dimensional PAGE was 
performed by the Protein Chemistry Laboratory at Texas A & M University, and proteins 
on 2D PAGE were excised by me and identified by Dr. Sam Perkins from Dr. David 
Russell‟s laboratory using mass spectrometry.  
  
  
58 
 Spots detected on only one gel and containing ≤ 100 ng of protein were filtered out. The 
observed molecular weight (Obs. MW) and observed pI (Obs. pI) of every spot were 
calculated using markers for molecular weight and standard curves from Pharmacia for 
pI. The numbers of spots visualized on individual 2D gels varied from 31 to 335 (Table 
3.1). The 2D gels of early fractions had more protein spots than the gels of later fractions. 
Later fractions contained more acidic proteins (lower pI) (Fig. 3.3). These trends were 
the same for both growth phases. 
To study abundance and elution pattern of proteins across a series of gels from one 
growth phase and then to compare different growth phases, protein spots on the 38 2D 
gels need to be connected, and spots on different gels corresponding to the same protein 
need to be inferred. This was done as described in Materials and Methods.   
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Figure 3.1. Flowchart of the strategy used to identify the soluble proteome of E. coli by 
LC and 2D PAGE. Clarified cell lysates were loaded onto mono Q HPLC columns. 
Bound proteins were eluted into 25 5 ml fractions. An aliquot of each fraction was 
separated on 2D PAGE. Spots on gels were analyzed using Z3 2D gel analysis systems 
combing with computer program. The identities of protein spots were determined by 
excising spots, in-gel digestion with trypsin, and MS/MS analysis. 
  
 
E. coli clarified lysate
Presence of proteins on 2D gels
Obs. pI and Obs. MW of proteins on 2D gels
Protein abundance on individual 2D gels
AIX
Elution profiles and abundance of proteins 
from AIX column
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Figure 3.2. Analysis of 2D gels using Z3 2D gel analysis system. To each visualized 
spot, Z3 software assigns an ID number, locates the coordinates (X and Y), and 
calculates the spot intensity (Q). 
 
61506727071014
128566027641010
413278398861008
QYXID
ID: Spot ID
X, Y: the coordinates of the spot in         
the gel image (in pixels)
Q: spot quantity
1008
1010
1004
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Table 3.1. Number of spots visualized on every 2D PAGE 
  Exp.a 
Fraction 
# 
Number of visualized 
spots 
Stat.
b
 
Fraction 
# 
Number of visualized 
spots 
E5 249 S5 212 
E6 243 S6 335 
E7 205 S7 190 
E8 216 S8 236 
E9 227 S9 167 
E10 145 S10 183 
E11 204 S11 232 
E12 213 S12 200 
E13 231 S13 172 
E14 261 S14 223 
E15 149 S15 155 
E16 97 S16 101 
E17 107 S17 127 
E18 111 S18 124 
E19 61 S19 56 
E20 64 S20 62 
E21 47 S21 64 
E22 94 S22 31 
E23 125 S23 121 
a: exponential phase 
b: stationary phase 
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Figure 3.3. 2D PAGE of fractions from AIX HPLC for both exponential growth and 
stationary phase. Numbers labeled below gels are pI range and arrows are the pI of the 
majority of spots on gels. 
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Q5 Q6 Q7 Q22 Q23
Exp.
Stat.
Link information (X, Y, Q) of every spots
Normalize spots quantity using internal marker-Myoglobin
Calculate Obs.PI and Obs.MW using markers
Filter out spots with amount lower than 100 ng
Z3
Perl 
Script
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Strategy to analyze a series of 2D PAGE. 2D gels from both exponential and 
stationary phases were connected using the Z3 software, which assigns an ID number, 
locates the coordinates (X and Y), and calculates the spot intensity (Q). Perl scripts were 
applied to calculate spots quantity, observed molecular weight and observed pI.  
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In total, elution profiles for 1949 nonredundant spots were identified. 734 of these 
were more abundant in exponential growth, 920 were more abundant in stationary phase 
and 295 were present in equivalent amount in both growth phases. Details of visualized 
spots, such as elution profile, Obs. MW, Obs. pI and amount, can be found in EEP 
(http://eep.tamu.edu/2DPage/index.php?page=results2.html) (Fig. 3.5 and Fig. 3.6). 
After comparing the abundance of spots between these two growth phases, spots with 
big difference of amount (ratio >10 or only in one growth phase with amount > 2 µg) 
were chose to be analyzed further. In total 193 selected spots were cut and identified by 
MS/MS. Some spots did not have protein identified, while some spots were identified as 
same proteins. Overall, 102 cut spots have proteins identified (Table 3.2A), and 91 cut 
spots have no protein identified (Table 3.2B). In total 61 proteins were identified (Table 
3.3). Some proteins were found only in one protein spot, such as DnaK (Fig. 3.7), other 
proteins were found in multiple protein spots, such as AceA (Fig. 3.8).  AceA were found 
in two protein spots with similar elution positions (Fig. 3.8A) but different abundance 
trends between exponential growth and stationary phase (Fig. 3.8B). In total, 34 of the 
protein identified were more abundant in exponential growth, 25 were more abundant in 
stationary phase, and 2 have equivalent amount in both growth phases (Table 3.4).  
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Figure 3.5. Example of elution profiles for spots visualize on a series of 2D PAGE. Spot 
ID, Obs. pI, Obs. MW, amount ratio between exponential growth and stationary phase, 
growth phase, total amount, and spots amount (µg) in every fractions from AIX column 
were displayed. 
  
 
  
66 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Elution profiles of proteins with pI from 7 to 8 and with MW from 20 to 200 
kD. Proteins from eight spots on 2D PAGE were found. Blue line refers sample from 
exponential growth and red line refer stationary phase. Obs. MW and Obs. pI were on 
the right side of elution profile for every spot.  
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Spot_ID Gene b 
number 
 Spot_ID Gene b 
number 
 Spot_ID Gene b 
number 
2_2295 aceA b4015  2_1658 fusA b3340  1585 purC b2476 
2_1911 aceA b4015  2_1501 fusA b3340  1754 pykF b1676 
1499 aceE b0114  2458 galM b0756  1689 ribB b3041 
1413 acnB b0118  3_1686 gdhA b1761  2_1770 rpsA b0911 
1416 a acnB b0118  2651 ghrB b3553  2_1148 a rpsA b0911 
1392 acnB b0118  1678 glnS b0680  2_1450 rpsA b0911 
1470 acnB b0118  1686 glnS b0680  2_1148 
b 
rpsA b0911 
1976 adhE b1241  2177 gltD b3213  1052 a serA b2913 
3079 ahpC b0605  2341 glyA b2551  2256 serA b2913 
3053 ahpC b0605  2254 gnd b2029  2296 serA b2913 
2398 aspC b0928  2307 gnd b2029  1172 e serC b0907 
1743 aspS b1866  4_1183 groL b4143  1479 sucA b0726 
1363 a atpA b3734  2_2165 groS b4142  2_1814 tig b0436 
2_1823 atpA b3734  2034 guaB b2508  2_2166 a tig b0436 
2_1327 a atpA b3734  2028 leuA b0074  2_1399 tig b0436 
1426 atpA b3734  1299 leuD b0071  2_1341 tig b0436 
1648 atpG b3733  3086 luxS b2687  1218 tktA b2935 
3150 bcp b2480  3083 mdaB b3028  1434 tpx b1324 
2792 cbpA b1000  1843 mdoG b1048  2779 tsf b0170 
3115 crr b2417  1567 metE b3829  1545 tsf b0170 
1089 cysK b2414  2900 metF b3941  1142 tsf b0170 
2758 cysK b2414  2974 mtn b0159  1096 tsf b0170 
2859 dapD b0166  1048 nadE b1740  4_2227 tufA b3339 
2_1735 dnaK b0014  3165 ndk b2518  2_1272 tufA b3339 
2_1948 dnaK b0014  1609 pflB b0903  2_1940 tufA b3339 
1185 dnaK b0014  2613 pflB b0903  2471 tufA b3339 
3133 dps b0812  1222 pgk b2926  2_1232 tufA b3339 
3146 efp b4147  3_1827 pnp b3164  2_1959 tufA b3339 
2516 eno b2779  2720 potD b1123  2_1963 tufA b3339 
2_1593 fusA b3340  3066 ppa b4226  2_2177 a uspA b3495 
2_1474 fusA b3340  1151 proS b0194  1339 yhgF b3407 
1574 fusA b3340  1117 proS b0194  1772 ynjA b1753 
2_1566 fusA b3340  3117 proS b0194  2_1139 ynjA b1753 
2_1589 fusA b3340  1650 purC b2476  3009 yodA b1973 
 
Table 3.2A. Cut spots with protein identified.  
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Table 3.2B. Cut spots without protein identified.  
Spot_ID Spot_ID Spot_ID Spot_ID Spot_ID Spot_ID 
1066 1430 2124 2743 2_1161 2_1842 
1070 1441 2164 2769 2_1220 2_1868 
1078 1550 2246 2805 2_1224 2_1989 
1085 1553 2269 2810 2_1266 2_1995 
1103 1558 2305 2819 2_1325 2_2104 
1170 1628 2323 2863 2_1405 2_2471 a 
1171 1673 2338 2866 2_1419 3_1621 
1186 1706 2425 2873 2_1541 3_1763 
1263 1749 2436 2890 2_1562 3_1765 
1289 1826 2456 2892 2_1573 3_1776 
1298 1955 2484 3082 2_1701 4_1339 
1300 1998 2507 3170 2_1751 4_1717 
1326 2047 2535 1628 b 2_1774 4_2181 
1346 2103 2554 2_1075 2_1792 a 4_2321 
1364 2104 2732 2_1137 2_1792 b 4_2329 
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Table 3.3. Proteins identified from 2D PAGE.  
         
Gene 
Name 
b 
Number 
SwissProt Cal. 
pI
a
 
Obs. pI
b
 Cal. 
MW 
(kD)
c
 
Obs. 
MW 
(kD)
d
 
Total 
Amount 
in Exp. 
e
 
(µg) 
Total 
Amount 
in Stat. 
f
 
(µg) 
aceA b4015 P05313 5.16 4.90; 
5.10 
47.52 49.55; 
45.60 
3.64 1.49 
aceE b0114 P06958 5.46 5.4 99.54 256.05 13.91 1.22 
acnB b0118 P36683 5.24 5.20; 
5.30; 
5.45; 
5.50 
93.5 103.90;1
03.65; 
110.75; 
107.30 
0.46 7.08 
adhE b1241 P17547 6.33 6.1 96 101.8 2.24 0.12 
ahpC b0605 P26427 5.03 4.9 20.63 24.6 2.29 24.82 
aspC b0928 P00509 5.54 5.6 43.57 42.6 0.1 1.04 
aspS b1866 P21889 5.47 5.6 65.91 69.4 0.03 0.54 
atpA b3734 P00822 5.8 5.80; 
5.90; 
6.00 
55.22 79.90; 
79.10; 
50.95; 
40.00 
20.05 5.39 
atpG b3733 P00837 8.84 8.35 31.58 29.05 1.14 0.06 
bcp b2480 P23480 5.03 4.95 17.63 16.6 0.57 0.03 
cbpA b1000 P36659 6.33 6.4 34.46 33.9 0.02 0.75 
crr b2417 P08837 4.73 4.5 18.12 20.7 0 16.43 
cysK b2414 P11096 5.83 5.70; 
5.95 
34.36 35.40; 
34.50 
22.36 0.2 
dapD b0166 P03948 5.56 5.45 29.89 32.75 4.76 0.26 
dnaK b0014 P04475 4.83 4.70; 
4.75; 
5.90 
68.98 78.00; 
76.90; 
43.80 
0.22 12.2 
dps b0812 P27430 5.72 5.6 18.56 17.45 0.17 2.04 
efp b4147 P33398 4.9 4.3 20.46 16.9 2.64 0 
eno b2779 P08324 5.32 5.1 45.52 43.5 2.58 0 
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Table 3.3. Continued 
 
Gene 
Name 
b 
Number 
SwissProt Cal. 
pI
a
 
Obs. pI
b
 Cal. 
MW 
(kD)
c
 
Obs. 
MW 
(kD)
d
 
Total 
Amount in 
Exp. 
e   
 
(µg) 
Total 
Amount 
in Stat. 
f 
(µg) 
fusA b3340 P02996 5.24 5.00; 
5.05; 
5.10; 
5.40 
77.45 101.75; 
93.95; 
89.30 
16.59 23.64 
galM b0756 P40681 4.84 4.8 38.19 40.35 0.09 2.69 
gdhA b1761 P00370 5.98 6.05 48.58 44.3 0.06 2.79 
ghrB b3553 P37666 5.5 5.45 35.4 38.3 0.97 0.03 
glnS b0680 P00962 5.89 5.80; 
5.90 
63.35 68.85; 
67.95 
3.74 0.21 
gltD b3213 P09832 5.54 5.6 51.88 52.3 0 4.41 
glyA b2551 P00477 6.03 6.1 45.32 43.4 2.04 0 
gnd b2029 P00350 5.05 5.1 51.48 45.6 0.92 15.7 
groL b4143 P06139 4.85 4.9 57.2 48.3 2.77 29.34 
groS b4142 P05380 5.15 4.85 10.39 15.3 0.03 2.05 
guaB b2508 P06981 6.02 5.8 52.02 55.15 2.39 0.69 
leuA b0074 P09151 5.47 5.4 57.17 55.75 0.77 0.04 
leuD b0071 P30126 5.16 5.3 22.36 24.3 2.48 0 
luxS b2687 P45578 5.18 5.25 19.29 23.05 0.54 6.53 
mdaB b3028 P40717 5.85 5.9 21.89 24.3 0 4.54 
mdoG b1048 P33136 6.26 6.3 55.37 59.45 1.64 0.13 
metE b3829 P25665 5.61 5.7 84.54 119.3 8.79 0.72 
metF b3941 P00394 6 6 33.1 32 0 2.23 
mtn b0159 P24247 5.09 5.2 24.35 28.1 0.19 3.75 
nadE b1740 P18843 5.41 5.6 30.64 36.7 5.73 0.23 
ndk b2518 P24233 5.55 5.6 15.33 14 3 0 
pflB b0903 P09373 5.69 5.70; 
5.75 
85.23 84.00; 
37.75 
4.95 0.31 
pgk b2926 P11665 5.08 5.8 40.99 82.1 0 2.66 
pnp b3164 P05055 5.11 5.2 77.1 50.6 2.03 0 
potD b1123 P23861 4.86 4.5 36.49 36.3 7.61 0 
ppa b4226 P17288 5.03 5 19.57 24.4 0 18.29 
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Table 3.3. Continued 
         
Gene 
Name 
b 
Number 
SwissProt Cal. 
pI
a
 
Obs. pI
b
 Cal. 
MW 
(kD)
c
 
Obs. 
MW 
(kD)
d
 
Total 
Amount 
in Exp. 
e
 
(µg) 
Total 
Amount 
in Stat. 
f
 
(µg) 
proS b0194 P16659 5.12 4.60; 
5.20 
63.69 72.15; 
68.10; 
21.50 
0.59 15.23 
purC b2476 P21155 5.07 5.1 27 29.25; 
28.8 
3.37 0.1 
pykF b1676 P14178 5.77 5.8 50.73 57.5 2.7 0 
ribB b3041 P24199 4.9 4.95 23.35 29.35 0.53 18.8 
rpsA b0911 P02349 4.89 4.40; 
4.60; 
4.70 
61.16 78.15; 
74.10; 
70.10; 
69.50 
85.79 7 
serA b2913 P08328 5.93 5.90; 
5.95 
44.04 46.20; 
42.80 
12.59 0.62 
serC b0907 P23721 5.37 5.5 39.65 40.8 2.62 0 
sucA b0726 P07015 6.04 6 105.06 110.45 0.85 0.05 
tig b0436 P22257 4.83 4.30; 
4.40; 
4.50; 
4.60 
48.19 63.10; 
58.20; 
53.95; 
52.50 
4.1 2.61 
tktA b2935 P27302 5.43 5.55 72.21 77.45 0.19 4.8 
tpx b1324 P37901 4.75 4.9 17.7 19.9 4.79 0 
tsf b0170 P02997 5.22 5.20; 
5.30 
30.29 35.00; 
34.20; 
33.80 
16.41 0.09 
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Table 3.3. Continued 
         
Gene 
Name 
b 
Number 
SwissProt Cal. 
pI
a
 
Obs. pI
b
 Cal. 
MW 
(kD)
c
 
Obs. 
MW 
(kD)
d
 
Total 
Amount 
in Exp. 
e
 
(µg) 
Total 
Amount 
in Stat. 
f
 
(µg) 
tufA b3339 P02990 5.3 4.10; 
5.20; 
5.30; 
5.40; 
5.45 
43.18 49.65; 
47.70; 
45.20; 
43.65; 
43.30; 
43.10; 
36.30 
5.13 58.82 
yhgF b3407 P46837 5.92 5.95 85.12 88.35 2.1 0.06 
ynjA b1753 P76222 8.8 5.40; 
5.70 
20.53 75.35; 
44.60 
3.14 0.26 
yodA b1973 P76344 5.66 5.6 22.34 28.5 0 3.54 
 
a: Cal. pI: calculated pI.  
b: Obs. pI: observed pI.  
c: Cal. MW: calculated molecular weight. 
d: Obs. MW: observed molecular weight.  
e: Exp: exponential growth.  
f: Stat: stationary phase. 
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Spot ID Obs. PI Obs. MW (kD) Log2(E/S) Exp. Total (µg) Stat. Total (µg) 
2792 6.4 33.9 -5 0.02 0.75 
Total 
  
-5 0.02 0.75 
 
A) 
 
 
 
B) 
 
 
 
 
Figure 3.7. Information of the protein spot identified as DnaK on 2D PAGE. A) Elution 
profile of the protein spot (spot ID 2792) identified as DnaK. B) Protein abundance trend 
of spot 2792 between exponential and stationary phase. Protein amount in protein spot 
2792 was found more in stationary phase. 
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Spot ID Obs. PI Obs. MW (kD) Log2(E/S) Exp. Total (µg) 
Stat. Total 
(µg) 
2_1911 4.9 45.6 -4 0.08 1.37 
2_2295 5.1 49.55 +5 3.56 0.12 
Total 
  
+1 3.64 1.49 
 
A) 
 
 
 
 
 
B) 
 
 
 
 
 
Figure 3.8. Information of protein spots identified as AceA on 2D PAGE. A) Elution 
profiles of protein spots (spot ID 2_1911 and 2_2295) identified as AceA. B) Protein 
abundance trends of spot 2_1911 and 2_2295 between exponential and stationary phase. 
Protein amount in protein spot 2_1911 was found more in stationary phase. Protein 
amount in protein spot 2_2295 was found more in stationary phase. 
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Table 3.4. The summary of proteins identified from 2D PAGE.  
 
 
 
 
 
 
 
More amount  
in Exp. 
One spot 
aceE, adhE, atpG, bcp, dapD, efp, eno, ghrB, glyA, guaB, leuA, 
leuD, mdoG, metE, nadE, ndk, pnp, potD, pykF, serC, sucA, 
tpx, uspA, yhgF 
Multiple spots with 
same trend 
atpA, cysK, glnS, pflB, purC, serA, tsf, ynjA 
Multiple spots with 
different trend 
aceA, rpsA 
More amount 
in Stat. 
One spot 
aspC, aspS, cbpA, crr, dps, galM, gdhA, gltD, groL, groS, luxS, 
mdaB, metF, mtn, pgk, ppa, ribB, tktA, yodA 
Multiple spots with 
same trend 
acnB, dnaK, gnd, proS 
Multiple spots with 
different trend 
ahpC, tufA 
Similar amount 
in both 
Multiple spots with 
different trend 
fusA, tig 
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Previously, our laboratories had analyzed the E. coli exponential phase proteome 
using two-dimensional non-denaturing liquid chromatography (2D-NonDeLC) and mass 
spectrometry (Champion et al., 2003). 2D-NonDeLC applied anion exchange (AIX) 
column and hydrophobic interaction column (HIC) to separate protein mixture. Since the 
first dimension of NonDeLC was the same as this study used, some properties of 
identified proteins are expected to be same as those from LC/2D PAGE. 45 of the 61 
proteins identified by this study were also detected in the earlier study (unpublished 
NonDeLC study by Matthew Champion). For these proteins we could compare the 
elution profiles directly. For 12 proteins the elution profiles were very similar (Fig. 3.9).  
To compare proteins in every fraction from NonDeLC and LC/2D PAGE, virtual 2D 
PAGE were generated using the theoretical pI and molecular weight information of 
proteins identified by 2D NonDeLC (http://eep.tamu.edu/nondelc/results/). The real 2D 
gels have more protein spots and more complicated patterns (compare the gels in Fig. 
3.10A and 3.10B). The number of proteins could be identified on 2D PAGE is bigger 
then that by 2D NonDeLC. Furthermore, to make the virtual 2D PAGE for NonDeLC 
and real 2D gel more comparable, every real 2D PAGE was redrawn with spots labeled 
with their identified proteins using the observed pI and observed molecular weight of 
every spot. By comparing the virtual 2D PAGE and redrawn real 2D PAGE (Fig. 3.10C) 
for same fractions, some proteins were identified by both methods, however each 
methods has their own unique protein identification. Number of proteins identified on 
2D PAGE is bigger then that by 2D NonDeLC.   
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Figure 3.9. Comparison of elution profiles between 2D PAGE and 2DLC. Existences of 
protein in certain fraction in exponential growth are boxes filled with blue (by 2D PAGE) 
and light blue (by 2D LC). Stationary phase are boxes filled with red (by 2D PAGE) and 
pink (by 2D LC).   
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A)                                    
 
                    C) 
    
 
 
 
 
 
 
 
B)                                        
 
 
 
 
 
 
Figure 3.10. The virtual 2D PAGE (A), the real 2D PAGE (B) and the redrawn real 2D 
PAGE (C) for 6th elution fraction from AIX column for exponential growth sample of E. coli. 
23 protein spots were visualized on the virtual 2D PAGE. 243 protein spots were visualized 
on the real and redrawn 2D PAGE. Proteins labeled on C were identified by in-gel digestion 
followed with tandem mass spectrometry. Proteins circled were identified by both methods. 
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Discussion 
To study the differences in the soluble proteome from both exponential and 
stationary phase samples, NonDeLC and 2D PAGE were applied. Proteins in 19 
fractions from AIX chromatography were separated on 2D PAGE for sample from each 
growth phase. Using Z3 2D gel analysis system and computational languages, thousands 
of spots on 38 2D PAGE were visualized and analyzed. Of a total of 1949 nonredundant 
spots, 38% of them were more abundant in exponential growth, 47% of them were more 
abundant in stationary. 
For the 179 protein spots cut from gels and identified by MS/MS analysis, 25 
proteins (Table 3.5) were more abundant in stationary phase. The products of 4 genes 
(cbpA, dnaK, groL, and groS) with more amounts in stationary phase are chaperone 
proteins. Chaperone proteins, whose function is to assist proteins to fold properly, are 
often involved in to different stresses such as heat shock (Hightower, 1991). DnaK, GroL 
and GroS proteins are heat shock protein in E. coli (Gragerov et al., 1992; Tilly et al., 
1983). CbpA protein, a DnaJ homolog, is a DnaK co-chaperone responding to heat shock 
(Bird et al., 2006; Chae et al., 2004). Microarray analysis showed that transcription of 
cbpA gene is up-regulated under starvation (Tani et al., 2002) and up-regulated by RpoS 
(Patten et al., 2004). It has been known that E. coli cells increase the level of chaperone 
proteins to decrease protein miss-folding when cell face different stresses entering 
stationary phase (Yoon et al., 2003; Zhang et al., 2006). 
The products of 5 genes (crr, galM, gnd, pgk, tktA) involved in carbohydrate 
metabolism are more abundant in stationary phase. Study showed that crr, which is 
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involved in phosphotransferase system (Roseman and Meadow, 1990), is up regulated by 
sigma S (Lacour and Landini, 2004). Gene tktA is one of the two genes encoding 
transketolase isoenzymes. Study has showed that at transcriptional level, tktA gene was 
suppressed in the stationary growth phase(Jung et al., 2005). In our study, product of 
tktA was more abundant in stationary phase. This could be caused that TktA protein is 
more stable in stationary phase, which could be test by pulse-chase experiments. 
The products of 3 genes (ahpC, dps, and mdaB) involved in starvation or stress 
response are more abundant in stationary phase. dps is known to be unregulated by RpoS 
(Dukan and Touati, 1996; Lacour and Landini, 2004; Patten et al., 2004). Dps protein, as 
a nonspecific DNA binding protein and a bacterial ferritin, known with more abundant in 
stationary phase (Weichart et al., 2003), is involved in resistance to oxidative stress by 
sequestering free ion and protecting DNA from damage. Microarray analysis also 
showed that transcription of dps gene is up-regulated under starvation (Tani et al., 2002) 
and up-regulated by RpoS (Patten et al., 2004). AhpC protein, as an alkyl hydroperoxide 
reductase, is regulated by OxyR. Some study showed that AhpC has similar amount 
between exponential growth and early stationary phase, but degrading in late stationary 
phase in E. coli (Weichart et al., 2003). We found that the amount of AhpC protein was 
increased after 4 hours entering stationary phase. Since AhpC protects cells from damage 
caused by hydroperoxide (Charoenlap et al., 2005; Jung and Kim, 2003) in and reactive 
nitrogen intermediates (Chen et al., 1998), it is possible that E. coli cells increase level 
of AhpC protein in early stationary phase to protect themselves and degraded in late-
stationary phase after other mechanisms adapt to stationary phases. To test this, amount 
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of AhpC protein at different growth phases, such as exponential phase, early-stationary 
phase, and late stationary phase, could be detected by Western or PAGE coupled with 
mass spectrometry. MdaB (modulator of drug activity B) protein is a NADPH quinone 
reductase, which has resistance to the antibiotics DMP 840, adriamycin and etoposide 
(Adams et al., 2005). Recent study shows that structure of MdaB is similar to many 
flavoproteins (Adams and Jia, 2006). Induction of proteins Dps, AhpC, and MadB 
protects E. coli cells from oxidative and drug stress. 
The products of three genes (aspC, gdhA, gltD) involved in amino acid metabolism 
are more abundant in stationary phase. It has been shown that GdhA protein, a glutamate 
dehydrogenase, is significantly up-regulated under nitrogen starvation of E. coli cells 
(Kabir et al., 2004). Gene of gltD, a gene for glutamate synthase, was found induced by 
phosphate starvation in E. coli cells (Metcalf et al., 1990). AspC protein, which is 
involved in amino acid degradation, might be also induced by nitrogen starvation. 
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Gene B_num
a
 Product 
Amino acid metabolism 
 aspC b0928 aspartate aminotransferase, PLP-dependent  
 gdhA b1761 glutamate dehydrogenase, NADP-specific  
 gltD b3213 glutamate synthase, 4Fe-4S protein, small subunit 
Chaperone 
 cbpA b1000 curved DNA-binding protein, DnaJ homologue that functions as a 
co-chaperone of DnaK  
 dnaK b0014 chaperone Hsp70, co-chaperone with DnaJ 
 groL b4143 GroEL, chaperone Hsp60, peptide-dependent ATPase, heat shock 
protein  
 groS b4142 GroES, chaperone binds to Hsp60 in pres. Mg-ATP 
Carbohydrate metabolism 
 crr b2417 phosphotransferase system, glucose-specific enzyme IIA  
 galM b0756 galactose-1-epimerase (mutarotase) 
 gnd b2029 gluconate-6-phosphate dehydrogenase, decarboxylating  
 pgk b2926 phosphoglycerate kinase  
 tktA b2935 glycolysis; gluconeogenesis 
Starvation and stress response 
 ahpC b0605 alkyl hydroperoxide reductase, C22 subunit 
 dps b0812 Fe-binding and storage protein; stationary phase nucleoid protein 
that sequesters iron and protects DNA from damage  
Translation 
 aspS b1866 aspartyl-tRNA synthetase  
 proS b1094 prolyl-tRNA synthetase  
 tufA b3339 protein chain elongation factor EF-Tu (duplicate of tufB) 
Miscellaneous function 
 acnB b0118 bifunctional aconitate hydratase 2 and 2-methylisocitrate dehydratase 
 luxS b2687 autoinducer 2 (AI-2) synthase; acts in quorum sensing 
 metF b3829 5,10-methylenetetrahydrofolate reductase  
 mtn b0159 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase  
 ppa b4226 inorganic pyrophosphatase  
 ribB b3041 3,4-dihydroxy-2-butanone-4-phosphate synthase  
  yodA b1973 cadmium-induced metal binding protein  
 
a: Blattner number 
Table 3.5. Proteins more abundant in stationary phase identified by 2D PAGE. 
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The increased abundance of some proteins was surprising. AspS, ProS, and TufA are 
parts of translation machinery. AspS and ProS are two aminoacyl-tRNA synthetases. 
Usually, whit low growth-rate or nutrient limitation, aminoacyl-tRNA synthetases will 
be degraded or expressed less. One reason might because more AspS and ProS flow 
through the AIX column in exponential phase. To test if more AspS and ProS are in flow 
through from AIX column, PAGE couple with MS could be applied. Gene of tufA 
encodes a protein chain elongation factor, EF-Tu. TufA protein is often found up-
regulated in exponential growth of E. coli cells, while in our study TufA was more 
abundant from AIX column for stationary phase. This could due to more TufA bound to 
AIX column in stationary phase. To test it, proteins in flow through fractions could be 
run on 2D PAGE and TufA could be identified by MS.  
About 90% the observed molecular weights of proteins identified by this study on 
2D PAGE are similar (±20%) to their theoretical molecular weights. The ones with 
observed molecular weight lower than their theoretical one could be due to protein 
degradation. Some proteins, such as AceE, AtpA, Pgk and YnjA, have observed 
molecular weights that are higher than the expected theoretical molecular weight. This 
aberrant migration might be caused by charges of amino acids in proteins (Armstrong 
and Roman, 1992). About 95% the observed pIs of identified proteins are similar (±10%) 
to the theoretical pI. Proteins, such as DnaK, TufA and YnjA, with higher or lower 
observed pI could have post-translational modification or were degraded. Modifications 
could include biologically significant post-translational modifications, but modifications 
during protein handling for 2D gels are common (Herbert et al., 1998; Westermeier et al., 
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1983). In this study, DnaK was found in 3 different protein spots. One of these 3 protein 
spots have higher observed pI, which might be caused by protein degradation since this 
spots had lower observed MW (43.8 kD) compared with the calculated one (68.98 kD). 
Observation of these characters for DnaK was also saw in other literature (Link et al., 
1997).  
Based on the comparison between 2D NonDeLC and AIX/2D PAGE studies, elution 
profiles for same proteins are similar but not exactly same. 2D PAGE has more protein 
spots and more complicated patterns which indicate that more proteins would be 
identified after more efficient separation by 2D PAGE. This also could be post-
translational modification and/or protein degradation. Although 2D PAGE study is labor 
intensive, it can separate complex protein mixture more efficiently. Moreover, more 
properties of protein can be studied by 2D PAGE such as protein amount, post-
translational modifications, etc.  
This is a promising pilot analysis of large number of proteins on a series of 2D gels. 
About 10% of all unique spots were cut and identified. Still spots with amount difference 
lower than 10 fold, and spots have similar amount between these two growth phases 
were not cut and identified by MS. One possible way to predict proteins of uncut spots is 
to compare patterns of protein distributed on 2D gels of this study with other 2D gels 
studies, such as SwissProt, CyberCell Project. This way could be a reference but will not 
be very accurate. One reason is because different 2D gels studies used different E. coli 
strains or different growth phases, which have different proteome. Another reason is the 
pI range of 2D gels used by theses studies are not exactly same, which might cause 
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different patterns of protein distributed. Also E. coli proteome have many proteins with 
similar pI and molecular weight, so it is very hard to differentiate proteins even in a very 
small area. However, if combined with more robotic gel cutting and MS identification, 
more or all proteins can be identified on 2D PAGE.  
There are still problems need to be solved. One problem is that the success of 
protein identification using in-gel digestion coupled with MS/MS is relatively low. 91 
out of 193 cut spots did not have protein identified. One possible reason is that the 
quality of protein identifications for these 91 spots is lower than the threshold (a 
confidence interval ≥ 99.50 %, linear systematic error in the PMF assignments, and a 
lack of redundant PMF identifications). For this reason, success of protein identification 
could be increased by adjusting the threshold. Another possible reason is the efficiency 
of in-gel digestion is low. There are also some other problems. For example, spots at 
same position wouldn‟t be same proteins all the times, because E. coli cells have proteins 
with same observed pI and observed molecular weight. Same proteins showing in distant 
fractions could be recognized as different proteins. Same protein sometime has multiple 
spots on same gel, which is due to post-translational modifications or degradation. 
However CyDye DIGE two-dimensional PAGE could be good methods to solve some of 
problems and more technologies should be explored to improve studies of proteins on 
multiple 2D SDS PAGE. For some proteins, such as AspS, ProS, TufA, abundance ratio 
between exponential growth and stationary phase were found differently from previous 
studies. This could due to different amount of protein bound to AIX column in these two 
growth phases. To test it, proteins in flow through fractions could be run on 2D PAGE 
  
86 
and specific protein could be identified by MS. However, even the amount were verified 
by 2D PAGE for proteins in both elution and flow-through, properties of same protein 
could be different for those bound to AIX column from those in flow-through. These 
properties could be enzyme activity, protein conformation, post-translational 
modification, protein-protein interaction, protein-molecule interaction, etc. Size 
exclusion column and native gel can be applied to study protein conformation. Mass 
spectrometry can be applied to study post-translation modification and protein-protein 
interaction. Different assays can test enzyme activity of specific protein.   
Materials and methods 
Sample preparation 
Cultures of E. coli K-12 strain MG1655 were grown in 2-liter, non-baffled Fernbach 
flasks containing 1 liter of MOPS minimal medium (Neidhardt REF) (0.4% glucose, 19 
mM NH4Cl, 1.32 mM K2HPO4, 2 g/ml thiamine, 10 g/ml uridine, 0.52 mM MgCl2, 
0.25 M CaCl2, 8.37 g/l MOPS, 0.72 g/l tricine, 48 mg/l K2SO4, 2.92 g/l NaCl, 3 mg/l 
FeSO47H2O, and micronutrients). Cultures were inoculated with 5 ml of an overnight 
culture grown in the same medium at 37°C with aeration for 16-18 hr. Cultures were 
grown with aeration (250 RPM) in a 37°C water bath. For the exponential phase sample, 
one culture was harvested when it reached OD600  0.5. For the early stationary-phase 
sample, the other culture was harvested about 3 hr after the onset of stationary phase 
(OD600  1.1). Lysates from about 5 x 108 cells were prepared as described in chapter II, 
materials and methods. 
  
87 
Anion exchange column-HPLC 
Five ml of the clarified cell lysates, containing ~30 mg of protein as estimated by 
Bradford assay, were loaded onto a 1 ml AIX (Q15) 5/50 column (Amersham 
Biosciences) on an AKTA Purifier system (Amersham Biosciences). After washing the 
column, proteins were eluted a 50 mM to 1M NaCl gradient with a flow rate of 3ml/min 
(Champion et al., 2003) and collected in 5 ml fractions. Protein was detected only 
fractions 5 through 23 by Bradford assay. 
Two-dimensional SDS polyacrylamide gel electrophoresis 
Two-dimensional PAGE was performed by the Protein Chemistry Laboratory at 
Texas A & M University. For the exponential phase sample, 1 ml of each protein-
containing fraction was precipitated by TCA. TCA was added to a final concentration of 
14%. To have the same amount of protein from the stationary phase fractions, 740 µl of 
each protein-containing fraction was precipitated by 14% TCA. Before precipitation, 10 
µg of horse myoglobin was added to each fraction as an internal marker of protein 
abundance. Horse myoglobin was chosen as an internal marker because it is not an E. 
coli protein and will not affect the analysis of E. coli proteins, and it has a low molecular 
weight (17.6 kD) and high pI (7.3) so it will migrate at the right lower corner of the 2D 
gels and not overlay any E. coli proteins.  TCA precipitated samples were washed twice 
with cold acetone and air dried. Samples were resuspended and focused on Igphor 
immobilized gradient gels (14 cm pH 3–10 Nonlinear, Pharmacia) for 60–80,000 Volt 
hours. After reduction and exchange in SDS and DTT, 12% polyacrylamide gels (14 x 14 
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cm) were run in the second dimension. The gels were stained with Coomassie blue R-
250 to visualize protein spots. The 2D PAGE were scanned, Gel images are stored in the 
web-based database. Gel images for the exponential growth sample are located at 
http://eep.tamu.edu/nondelc/results/log750.php. Gel images for the stationary phase 
sample are located at http://eep.tamu.edu/nondelc/results/stat750.php.  
Analysis of 2D PAGE 
Gel images of 2D PAGE were analyzed using the Z3 2D gel analysis system. The 
area of each visualized spot is circled. The Z3 software assigns an ID number, locates the 
coordinates, and calculates the intensity of each spot. Proteins with post-translational 
modifications could have multiple spots at different locations on a gel; each of these 
spots would be identified as separate proteins and assigned a unique ID.  
By comparing the intensity of each spot with the intensity of the internal marker 
myoglobin, the amount of each protein was calculated. Spots with amount lower than 
100 ng, the lowest amount detected by coomassie blue, were filtered out. The Z3 
software assigns coordinates using units of pixels. To get the real location of spots on the 
2D gels, the coordinates were changed from pixels to centimeters. With the coordinates 
in cm, an observed pI and observed MW was calculated based on the molecular weight 
markers run in the second dimension and the known pI gradient (Pharmacia) for the first 
dimension 
To compare gels from the two growth phases, the 2D gels from adjacent fractions of 
the same growth phase were compared and linked, and then compared to the 2D gels of 
the corresponding fractions from the other growth phase. For example, 2D gels of 
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exponential phase fractions 5 and 6 were overlaid first. Then the 2D gels of fractions 5 
for both exponential and stationary phase samples were overlaid. Visualized spots were 
assigned ID numbers, coordinates and spot intensities. Spots at the same coordinates on 
all three gels were assigned the same ID. Next, the 2D gels of stationary phase fractions 
5 and 6 were overlaid. As a result, spots on fractions 5 and 6 were linked. Then same 
procedure was done for fractions 6 and 7, 7 and 8, etc. In this way, the proteins detected 
on 2D gels of fractions 5 through 23 from both growth phases were linked together.  
Montage in-gel digestion 
Coomassie-stained spots were excised from the 2D PAGE. In-gel digestions were 
carried out using the Montage In-Gel Digest Kit (Millipore). 
Tandem mass spectrometry 
Tandem mass spectrometry was performed as described in chapter II, materials and 
methods. 
Methods to generate virtual 2D gels and redraw real 2D gels 
To generate virtual 2D gels for every fraction from AIX column for NonDeLC study, 
spot for every protein was plotted on two-dimensional images using the calculated pI 
and calculated MW of every protein. To redraw real 2D gels, every visualized spot on 
the real 2D gels were re-plotted on two-dimensional images using the observed pI and 
observed MW of every spots. The first dimension is for pI and the second dimension is 
for MW. This work was done using Perl script. 
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CHAPTER IV 
EEP 
Background 
Studies of genomics, transcriptomics, metabolomics, proteomics and other „OMICS‟ 
create large amount of data, which are very hard to organize and analyze either manually 
or by using spreadsheets such as Excel. Relational Database Management Systems 
(RDBMS) are more efficient tools to store, organize and analyze data. Moreover, scripts 
can be written to query such databases and to generate a web-based interface to allow 
access to data and analysis by multiple users over the Internet. In this chapter, I describe 
the construction of Experiments in E. coli Proteomics (EEP), a web-based RDBMS I 
wrote to facilitate analysis of proteomics experiments done in our lab, including the non-
denaturing liquid chromatography (NonDeLC) experiments described in dissertation of 
Matthew Champion, the Heparome experiments described in chapter II, the 2D PAGE 
experiments from chapter III. In addition, EEP was designed to allow incorporation of 
data from proteomic studies by other groups for comparative analysis. EEP contains 
information from SwissProt 2D PAGE proteomics (Tonella et al., 2001), the CyberCell 
2D PAGE project (Sundararaj et al., 2004) and Corbin‟s 2D-LC proteomics (Corbin et 
al., 2003). The history of any protein in these proteomic studies can be searched through 
the EEP databases. 
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Results 
Database and website structure 
To construct databases for biological studies, the content of the database should 
contain not only the data of final results but also description of the experiment procedure 
for each experiment, because minor difference of experiments procedure could cause big 
difference to results. Based on the experimental design and procedure, a logical structure 
of database could be constructed by creating multiple tables that describe the details of 
every step of experiments. Relational databases allow representation of logical 
relationships between tables such as one to one, one to many or many to many, which 
are more difficult to represent in spreadsheets.  
Databases in EEP were constructed using MySQL (http://www.mysql.com/) and Perl 
(http://www.perl.com/) to manage the information about proteins identified in different 
experiments. Different databases were constructed for the Heparome, NonDeLC and 2D 
PAGE studies. EEP unifies the querying of these three databases. In the database 
Heparome, tables for experiments, chromatography, fractions, gels, bands, lc_ms, ms 
and msms were created. Different tables store information from different steps of the 
experiments (Fig. 4.1A). A similar database was also constructed for NonDeLC (Fig. 
4.1B). Information from proteomics studies from other groups is also store in the 
NonDeLC database. Right now only 2 tables were constructed for 2D PAGE. 
Information from tables in different databases is sharable, such as information in table 
ecogene and table nc_000913, which store annotations of whole E. coli genome for 
MG1655. 
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To display the databases to other people, a website interface was built using PHP 
(http://www.php.net/), Perl-CGI and HTML (Fig. 4.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1A. Structure of the MySQL database of heparin-binding proteins (Heparome).   
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Figure 4.1B. Structure of the MySQL database of NonDeLC and other proteomic 
studies.   
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Figure 4.2. Connections between the webpage interface and the MySQL databases. Circles 
or boxes with solid lines are elements in database and website. Boxes with dashed lines are 
languages used to create the connection between different elements. 
  
95 
Website content 
In the website for NonDeLC, Heparome or 2D PAGE, there are basically 4 sections: 
introduction, experiment design, results and search (Fig. 4.3). Content in the introduction 
and experiment design sections was generated as static HTML. Queries from results and 
search were dynamically generated using Perl-CGI and PHP. Section „About‟ contains an 
introduction to the project, background, methods and people who worked on the project. 
Section „Experiment design‟ describes the strategies of experiments. Section „Results‟ 
contains details of experiment results, such as proteins identified in each growth phase or 
in every fraction, proteins up-regulated in certain growth phase, etc. Section „Search‟ 
contains frequently used queries, such as elution pattern of every protein, or comparison 
of elution patterns between any two proteins on NonDeLC. 
Fig 4.4 shows an example of the visualization, using DapA and DapB (Fig. 4.4). By 
looking at the visualized elution patterns, DapA had different elution positions between 
exponential growth and stationary phase, while DapB had similar elution positions 
between these two growth phases. Also, DapA and DapB did not elute out together in 
either growth phase. Many displays in EEP also retrieve basic information about 
identified proteins (Fig. 4.5), such as gene name, SwissProt ID, b number, synonym(s), 
isoelectric point (PI), molecular weight (MW) and protein name. Gene name, SwissProt 
ID, b number, synonym(s) and proteins name were obtained from EcoGene (Rudd, 
2000). Isoelectric point (pI) and molecular weight (MW) were obtained from SwissProt 
(Tonella et al., 2001). Also links to other proteomic databases are provided, such as 
NCBI, Expasy Proteomics Server, GenProEC, EcoCyc and Cyber Cell Project. Details 
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of experiments and database construction are posted on the website also. 
Database access 
EEP can be accessed at the website: http://eep.tamu.edu.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. The website content for NonDeLC. The website contains 4 sections: About, 
Experiment design, Results, and Search.  
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Figure 4.4. Comparison of elution patterns between DapA and DapB on NonDeLC. X-
axis is the fraction number from anion exchange chromatography at pH 7.5, and Y-axis 
is the fraction number from hydrophobic interaction chromatography. : Positions of 
DapA on NonDeLC from exponential growth sample. : Positions of DapA on 
NonDeLC from stationary phase sample. : Positions of DapB on NonDeLC from 
exponential growth sample. : Positions of DapB on NonDeLC from stationary phase 
sample. 
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Figure 4.5. Information of DnaK identified by NonDeLC. pI is isoelectric point. MW is 
molecular weight. 
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Discussion 
EEP provides an interface, which facilitates not only the data management for us, 
but also the data mining for the scientific community. Using tools of database and 
computational techniques, the studies from NonDeLC, Heparome and 2D SDS PAGE 
proteomic studies were combined and compared with proteomic studies by other groups.  
Using GD, EEP provide a visualization tool to display the elution position of any 
identified protein. For example, in NonDeLC project, EEP provides a query 
(http://dimer.tamu.edu/cgi-bin/eep/elution_nondelc_Q_phe.pl) which can retrieve and 
visualize the elution positions of any identified protein from samples of both exponential 
growth and stationary phase. By looking at the visualized elution pattern of certain 
protein, one can easily tell if there is any difference of elution position between different 
growth phases. Proteins with difference of elution position could be candidates for study 
of physiology changes in stationary phase.  
EEP can also help us look for protein complex. For example, in NonDeLC project, 
elution positions of any pair of proteins could be visually displayed together to facilitate 
the study of possible protein complex. By looking at the visualized elution positions of 
any two proteins, proteins could be candidates of protein complex if these two proteins 
eluted at same position(s), such as SucC and SucD in exponential phase 
(http://dimer.tamu.edu/cgi-
bin/eep/elution_nondelc_Q_Phe_pair.pl?pH=7.5&item=gene_name&data=SucC&data2
=SucD&submit_query=Search). 
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CHAPTER V 
BIOINFORMATICS 
Background 
This chapter describes bioinformatics tools that were constructed during the course 
of this dissertation research. These were focused in two areas. First, I improved the web-
based database, Doodle (http://dimer.tamu.edu/doodle), which was constructed by 
Leonardo Mariño-Ramírez. This included updating E. coli genome annotation and 
modifying how we display different aspects of the genome annotation of E. coli, using 
the GMOD genome browser, Gbrowse. Second, I developed bioinformatics tools for the 
Practical Genomics for Undergraduates Project (PGU) 
(http://dimer.tamu.edu/young/genomics/) run by Ryland Young and Elizabeth Summer. 
PGU sequences and annotates Burkholderia phage genomes. With more and more phage 
genomes completed, manual annotation of the genome sequence becomes a significant 
burden. Although no genome can be accurately and comprehensively annotated by 
automated methods alone, computational programs can be useful tools for making 
manual genome annotation easier. Phage and bacteria present special challenges for 
bioinformatics analysis of genomes. To facilitate the PGU, I wrote several programs that 
are now used by the project. Some of these, such as “GetORF”, “LipoRy”, “Primary 
structure with charges”, and “Amino acid content”, were written because similar existing 
programs were not easily obtainable or needed to be modified for specific requirements, 
including web access. Other programs, such as “GetRzRz1”, “SAREndolysin”, and 
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“Phage lysis genes”, were written to search and predict specific phage genes. The 
program “GroupProtein” was written to group phage genes into families.  
Results 
Programs for E. coli genome annotation 
Workflow for updating Doodle 
Doodle is an acronym for the Database of Oligomerization Domains from Lambda 
Experiments.  Doodle was built primarily to serve as a laboratory information 
management system to track the clones, sequences, and analysis of self-assembling 
domains from repressor fusion cloning projects (Marino-Ramirez and Hu, 2002; Marino-
Ramirez et al., 2003). However, Doodle also serves as a source of information about E. 
coli proteins based on information compiled from other resources and from analysis 
done locally. The structure and pipeline of Doodle database were described in the 
dissertation of Leonardo Mariño-Ramírez and also in the web-accessible documentation 
(http://dimer.tamu.edu/doodle/docs/intro.html). In this section I describe how I improved 
the updating of information in Doodle.  
Updating the data in Doodle involves three kinds of operations: 1) adding new 
interacting sequence tag (IST) annotations (this did not occur in my work), 2) updating 
information from other sources, such as identifying proteins with Protein Data Bank 
(PDB) homologs, proteins with InterPro hits, and 3) correcting the coordinates of 
features in the database, based on changes in the reference sequence.  
To update information in the Doodle database, several tables needed to change to 
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stay synchronized with their external data sources. Basically, most of the tables, such as 
“gi2gene_name”, “ist”, “pdb_feature”, “coils”, and “spinterpro”, need to be updated 
every time the genome sequence or annotation changes for E. coli K-12 MG1655. Due 
to changes in the genome sequence and annotation, basic information, such as 
coordinates and sequence for DNA and protein, gi number, b number and products, in 
relevant tables need to be updated.  
Because new X-ray structures are being deposited in the PDB at a rapid rate, we 
periodically rescan the PDB for E. coli proteins and homologs. To do this, the pdbaa file 
is obtained from PBD (http://www.pdb.org/). To update the table “pdb_feature” in the 
database, which is used to generate lists of PDB homologs (http://dimer.tamu.edu/cgi-
bin/doodle/homo.pl?org=E), the script “genome2blast” performs a BLAST of all E. coli 
proteins against all proteins in the PDB, the script “parse_pdb” parses the BLAST result, 
and the script “pdb2feature” uploads parsed BLAST results into the database. 
To update proteins with InterPro hits, which are protein families, domains and 
functional sites, the protein2interpro.dat.gz file is obtained from InterPro database 
(ftp://ftp.ebi.ac.uk/pub/databases/interpro/). To update the table “spinterpro”, which is 
for proteins with InterPro hits, the script “swiss2ip” is run to generate an interpro file for 
E. coli, and the script “interpro2doodle” is run to upload data into database. 
To correct the coordinates of features in the database based on changes in the 
reference sequence, the tables “gi2gene_name”, “ist”, “pdb_feature”, “coils”, and 
“spinterpro” need to be updated. Processing and updating tables “pdb_feature” and 
“spinterpro” have been mentioned above. Table “gi2gene_name” stores the genome 
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annotation of the E. coli strain MG1655. To update information in table “gi2gene_name”, 
the NC_000913.ptt file, which contains the annotation of E. coli K-12 MG1655, was 
obtained from NCBI 
(ftp://ftp.ncbi.nih.gov/genomes/Bacteria/Escherichia_coli_K12/NC_000913.ptt). The 
ECOLI.dat file was obtained from Expasy 
(ftp://ca.expasy.org/databases/complete_proteomes/entries/bacteria/ECOLI.dat). The 
script “NC_SP2gi2genename” regenerates the table “gi2gene_name” using the files 
NC_000913.ppt and ECOLI.dat. The script “gi2gene_name_loader” uploads the new 
“gi2gene_name” table into the database. 
To update coordinates for features in the table “ist”, sequences of ISTs are compared 
to the new whole genome DNA sequence of E. coli MG1655 using BLAST by the script 
“dir2blast”. The script “parse_report” parses the blast result to a form that is uploaded 
into the database using the script “txt2feature”.  
To update coordinates feature in table “coils”, which store the coiled coil predictions 
for the whole genome, the script “fasta2ccp” is run to re-predict all the coiled coils 
encoded in the annotated proteins in the genome using the COILS2 program of Lupas 
(Lupas, 1997). Results are parsed by the script “coils2pos.pl” and uploaded into database 
by the script “coils2doodle”. 
Gbrowse for E. coli genome annotation 
Graphical genome browsers are used to display annotations in their genome context. 
Gbrowse (Stein et al., 2002) is a powerful, open source genome browser and is part of 
the Generic Model Organism Database project (http://www.gmod.org). Gbrowse is a 
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web-based tool developed by the group of L. Stein. It has been utilized by different 
studies such as the Saccharomyces Genome Database (Nash et al., 2007), Wormbase 
(Harris et al., 2003), SwissRegulon (Pachkov et al., 2007), PseudoCAP (Winsor et al., 
2005) and soybean genome database (Shultz et al., 2006), and many others. 
To facilitate the display of genome annotations for E. coli and its plasmids and 
phages, we installed and customized a local installation of Gbrowse version 1.64 at 
http://dimer.tamu.edu/cgi-bin/gb/gbrowse. Fig.5.1 shows a screenshot for display of E. 
coli annotations for strain K-12 MG1655. The display of annotations in Gbrowse is 
based on annotation tracks, which can be toggled to display or hide a particular set of 
annotations. Table 5.1 shows annotation tracks for our E. coli Gbrowse. There are also 
separate Gbrowse database for strain K-12 W3110 (Fig. 5.2) and for 28 bacteriophages. 
To generate different tracks into Gbrowse, a Gene Finding Format (GFF) 
(http://www.sanger.ac.uk/Software/formats/GFF/) file for every track was created and 
loaded into the Gbrowse database. GFF is a format for describing genes and other 
features associated with DNA, RNA and Protein sequences. In Gbrowse version 1.64, 
GFF2 was used. Also the information of different tracks need to be added into the 
configure file for each specific strain or phage.  
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Figure 5.1. The genome view of E. coli K-12 MG1655 in Gbrowse. Information for two 
versions of annotation (U00096.1 and U00096.2), DNA/GC content, noncoding RNAs, 
operons from RegulonDB (operon, promoter, TF binding site), and information for 
oligos from company Operon were included.
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Table 5.1. Annotation tracks for E. coli Gbrowse 
 
 
 
  
Annotation tracks Strain (s) applied 
Named Genes (Version: Pre 2006) K-12 MG1655 and K-12 W3110 
Named Genes (Riley et al., 2006) K-12 MG1655 and K-12 W3110 
Genes K-12 MG1655 
GenesDetail K-12 MG1655 
ORF (Version: Pre 2006) K-12 MG1655 
IST K-12 MG1655 
SwissProt (Version: Pre 2006) K-12 MG1655 
COG (Version: Pre 2006) K-12 MG1655 
3-frame translation (forward) K-12 MG1655 and K-12 W3110 
3-frame translation (reverse) K-12 MG1655 and K-12 W3110 
DNA/GC Content K-12 MG1655 and K-12 W3110 
Noncoding RNAs (Version: Pre 2006) K-12 MG1655 
Operon_RegulonDB (Version: Pre 2006) K-12 MG1655 
Operon Oligos (version: by June, 2006) K-12 MG1655 
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Figure 5.2. The genome view of E. coli K-12 W3110 in Gbrowse. Information for two 
versions of annotation (Genobase 2006 and Riley, Abe et. al. 2006) and DNA/GC 
content were included. In version of Riley M. 2006, ychG_1 is a new gene and adhE has 
different coordinates from the previous annotation. 
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To generate the GFF file for every track, the existing annotation, I wrote Perl scripts 
to parse several E. coli annotation types into GFF format suitable for Gbrowse. 
Annotations of E. coli genome and RNA coding genes were obtained from NCBI 
(http://www.ncbi.nlm.nih.gov/). Annotation of operons was obtained from RegulonDB 
(http://regulondb.ccg.unam.mx/index.html). The position of oligonucleotide probes was 
obtained from Operon Company (http://www.operon.com). Since the  genome sequences 
of both E. coli K12 MG1655 and W3110 were updated (Hayashi et al., 2006), 
coordinates of genes from the previous annotation needed to be updated. First, gene 
sequences from previous annotation were retrieved from the old genome sequence using 
the script “fastacmd”, which is part of the NCBI C toolkit 
(http://www.ncbi.nlm.nih.gov/IEB/ToolBox/SDKDOCS/INDEX.HTML). New 
coordinates for every gene were obtained by BLASTing the old gene sequences against 
the new genome sequence. As a result, gene coordinates obtained to populate a GFF file 
are corresponding to the gene models for the new genome sequence. For some 
annotations, a Perl script (ldas_bulk_load.pl) from the Gbrowse distribution was also 
used to load GFF files into an underlying MySQL database. 
By clicking links of figures, details can be displayed in a Gbrowse details page. The 
Gbrowse details page contains information about the gene name, source, coordinates, 
gene length, COG number and link, JW ID, products name, SwissProt ID, synonyms and 
DNA sequence (Fig. 5.3). I configured our Gbrowse to allow searching genes not only 
with standard names, but also with ambiguous names, which information was obtained 
from EcoCyc (http://ecocyc.org/). For example both dnaJ and dnaB have groP as a 
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synonym. By searching groP, these two genes are listed and a summary of each one is 
displayed, including all synonyms and gene coordinates (Fig. 5.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. The Gbrowse details page for dnaK in version of Genobase 2005 of E. coli 
K-12 W3110. This page contains information of gene name, source, coordinates, gene 
length, COG number and link, JW ID, products name, SwissProt ID, synonyms and 
DNA sequence.  
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Figure 5.4. Genes with groP as synonyms in E. coli K-12 MG1655. Both dnaJ and dnaB 
have groP as a synonym.
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Programs for the PGU project 
 With more and more Burkholderia phage genomes sequenced by the PGU project, 
annotation has become a major issue. To improve the process of annotation, 
computational programs were developed and applied. 
GetORF 
Many of the programs I wrote for the PGU involve identifying which polypeptide 
sequences encoded in a genome could be a member of a particular protein family.  For 
example, “GetRzRz1” predicts genes encoding Rz and Rz1 genes.  These programs 
apply rule-based filtering to a list of candidate proteins.  Open reading frames (ORF) are 
sequences of DNA, which are located from a start codon to a stop codon that could be 
translated into proteins or polypeptides with no internal stop codons. The ORFs that 
correspond to actual genes are a subset of possible open reading frames in a genome. 
Part of the annotations of prokaryotic proteins are based on predictions of which ORFs 
in the DNA sequences correspond to the actual genes. 
Many programs have been written for this purpose. One commonly used program is 
GeneMark.hmm (Lukashin and Borodovsky, 1998) 
(http://opal.biology.gatech.edu/GeneMark/heuristic_hmm2.cgi), which predicts genes 
from ORFs using hidden Markov models based on the properties of well-characterized 
genes. Although GeneMark gives the most confident gene candidates, which are often 
correlated to validated genes, for my purposes this filtering might lose too many 
potential gene candidates. For some predictions of specific genes, such as lipoproteins, 
the start positions of proteins are very important for prediction. It is better to have the 
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unfiltered information about all the possible ORFs.  To predict all possible ORFs and 
translate them into proteins, GetORF (http://dimer.tamu.edu/cgi-
bin/phage_genomics/get_orf.pl) was written. GetORF is used as a first step in many of 
the other programs described below. 
By uploading the DNA sequence, choosing the start codon (ATG, TTG, CTG, or 
GTG), minimal gene length and strand, GetORF predicts all possible ORFs (Fig. 5.5). In 
the output, protein length, coordinates of genes and strand are displayed, under which 
protein sequences were also generated for every possible ORF, based on the codon usage 
of bacteria (Fig. 5.6). 
Note that GetORF is not a program to predict genes. In other words, GetORF 
processes raw predictions that search all possible ORFs to facilitate further prediction of 
specific genes. Some programs in this chapter, such as LipoRy, utilize GetORF to get 
amino acid sequences of all possible ORFs and search proteins with unique features.  
  
  
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. The form to submit ORF searching in GetORF.  
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Figure 5.6. Results of ORF searching for the complete genome of Burkholderia 
cenocepacia phage Bcep1 by GetORF. 1091 ORF(s) were found for the forward (F) 
strands. Protein sequence, protein length, coordinates of genes and strand information 
were displayed.  
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LipoRy 
Lipoproteins, containing both protein and lipid, play different roles, such as 
enzymes, transporters, structural proteins, antigens, adhesions and toxins. LipoP 
(Juncker et al., 2003) has been widely used to predict lipoproteins of Gram-negative 
bacteria and their phages. However, LipoP is not well suited for the PGU project. LipoP 
is only available as a website; the source code is not downloadable. LipoP can process 
single protein sequences or multiple proteins as FASTA files, but it cannot predict 
lipoproteins using a DNA sequence. For new sequenced genomes, such as the phage 
genomes from the PGU project, without finished annotation, DNA sequence is a more 
accurate source for prediction. Also LipoP has difficulty performing bulk searches, larger 
than four thousand protein sequences over the web. Moreover, sometimes different 
formats for the output of the prediction are required for further annotation. Driven by the 
limitations of LipoP, LipoRy was written. LipoRy is based on rules generated by R. 
Young to predict lipoproteins from Gram-negative bacteria and their phages. All 
bacterial lipoproteins have a signal sequence in the N-terminal end followed by a 
cysteine (Hayashi and Wu, 1990). The signal sequence of lipoproteins is cleavable by 
lipoprotein signal peptidase (Lsp), which is also called signal peptidase II (SPaseII). The 
cysteine following a signal sequence is in the first 40 amino acids from N-terminal end, 
and the signal sequence contains at least 10 consecutive residues without charged amino 
acid. LipoRy is a web-based program (http://dimer.tamu.edu/cgi-
bin/phage_genomics/Lipo_Ry.pl). Since the characters of lipoproteins are located at N-
terminal end of proteins, the start positions of proteins are very important. Instead of 
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missing any possible candidates, GetORF is applied to predict all possible ORFs, from 
which candidates for lipoprotein are predicted. By uploading the DNA sequence or DNA 
FASTA file, choosing the start codon (ATG, GTG, CTG, and TTG), minimal gene length 
and strand (Fig. 5.7), candidates for lipoproteins will be predicted based on all possible 
ORFs (Fig. 5.8). Besides the basic information of ORFs, cysteines following the signal 
sequence are highlighted in yellow. Since the start source is DNA sequence and the ORF 
prediction search gives all possible ORFs without filtration, there will be higher 
percentage of false positives among the candidates from LipoRy than from LipoP. For 
example, LipoRy predicts 187 lipoprotein candidates for bacteriophage lambda. Out of 
these 187 candidates, 26 of them are also predicted by LipoP. However for some studies, 
such as the beginning of genome annotation for phages in PGU project, it is better to 
have false positives than false negatives. More restrictions could be added for more 
specific properties of certain genes to filter out more false positives. For example 
LipoRy was integrated into the program “GetRzRz1” to predict Rz and Rz1 gene pairs in 
phage genomes.  
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Figure 5.7. The form to submit lipoproteins searching in LipoRy. 
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Figure 5.8. Results of lipoprotein searching for the complete genome of bacteriophage 
lambda. 187 candidates for lipoproteins were found. Cysteines following the signal 
sequence are highlighted in yellow.  
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GetRzRz1 
Rz and Rz1 genes are found in most dsDNA and dsRNA bacteriophages. The Rz 
protein is widely annotated as an endopeptidase, which might cleave the cell wall and 
the Lpp lipoproteins in the outer membrane of Gram-negative bacteria. Rz1 gene is 
located in or closely after Rz gene sequence. The Rz1 protein is out membrane 
lipoprotein. Proteins encoded by both Rz and Rz1 are required for lysis since both Rz and 
Rz1 mutations block lysis of bacteriophage lambda (Zhang and Young, 1999),. 
Rz and Rz1 have been characterized in only a few bacteriophages genomes(Markov 
et al., 2004). To predict Rz/Rz1 genes, there was no existing program. A project in the R. 
Young‟s laboratory is to find Rz/Rz1 genes in all sequenced phage genomes. Based on 
the specific character of Rz and Rz1 genes, GetRzRz1 (http://dimer.tamu.edu/cgi-
bin/phage_genomics/Rz_Rz1.pl) was written to predict pairs of Rz and Rz1 genes. 
Prediction of Rz1 genes is the same as LipoRy, which predicts lipoproteins of Gram-
negative bacteria and their phages. To predict Rz genes, the following rules were 
generated by R. Young and E. Summer:  1) there must be a transmembrane domain 
(TMD) with at least 16 contiguous non-charged amino acid except positions +4 and -4, 
which could be lysine; 2) there must be only one TMD; 3) the TMD must be within the 
first 40 amino acids from the N-terminal end; 4) there must be at least one positively 
charged residue proceeding the TMD; 5) a lysine (K) at the N-terminus of the TMD 
counts for the positively charged amino acid. The process begins by finding all possible 
ORFs based on the input DNA sequence. Next, lipoproteins and transmembrane proteins 
were predicted. Then the Rz and Rz1 gene pairs of were predicted. The maximum 
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distance between Rz and Rz1 genes is set at 200nt.  The input of GetRzRz1 is similar to 
LipoRy (Fig. 5.7). In the output of GetRzRz1, the gene pairs of Rz and Rz1 are listed 
with information of gene coordinates, length of protein and protein sequence (Fig. 5.9). 
To test it, the genome sequence enterobacteria phage lambda was searched using this 
program and 25 Rz/Rz1 gene pair candidates were found. Out of the 25 pairs, many Rz 
or Rz1 candidates are proteins with same sequences but different N-terminus, so some of 
the pairs actually contain the same candidate gene pair. As a result, 13 Rz/Rz1 gene pair 
candidates were found, among which was the known R z/Rz1 gene pair was found in 
these candidates (Fig. 5.9). This program can be applied to any sequenced genome or 
DNA sequence to search candidate for Rz/Rz1 gene pair. 
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Figure 5.9. Results of Rz/Rz1 pair searching from enterobacteria phage lambda using 
GetRzRz1. 25 candidates of Rz/Rz1 pairs were found. Arrow points the real Rz/Rz1 gene 
pair of enterobacteria phage lambda.  
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SAREndolysin 
Recently, the signal arrest-release (SAR) domain was characterized in lysozyme Lyz 
protein of P1 phage (Xu et al., 2005), which is an ortholog of T4 lysozyme (Bonovich 
and Young, 1991; Schmidt et al., 1996). Lysozymes of many phages, such as, lambdoid 
coliphage 21 (R21),  coliphages Mu (Xu et al., 2004) and T1 (Roberts et al., 2004), have 
similar motifs as SAR. Sequences of SAR lysozymes have big diversity in different 
phages (Xu et al., 2005).  It was of interest to determine how wide spread SAR domains 
are in the lysozemes of other phages. In a SAR domain, there is a transmembrane 
domain (TMD) in the first 40 amino acids of N-terminal domain. Following the TMD, 
within 25 residues, there is a lysozyme domain. In the T4 type lysozyme family, there is 
a glutamic acid (E) followed by an aspartic acid or a cysteine at position +10, and a 
threonine at position +15 or +16. Based on these characteristic of SAR domain, a 
program (SAREndolysin) (http://dimer.tamu.edu/cgi-
bin/phage_genomics/SarEndolysin.pl) was written to predict candidates of SAR 
endolysin protein from all possible ORFs of a given DNA sequence (Fig. 5.10). To test 
this program, the genome sequence of enterobacteria phage P1 was searched. Only one 
hit, lyz gene obtained. As a negative control, the complete genome sequence of 
Bacteriophage lambda was searched and no SAR endolysin was found. This program 
can be applied to search for SAR endolysins in any DNA sequence. 
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Figure 5.10. The result of SAR endolysin searching from genome of enterobacteria 
phage P1. One candidate was found which located at 20328 to 20882 in reverse strand.  
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Primary structure with charges 
Current algorithms for predictions of signal sequences and TMD still have a high 
error rate, so it is imperative to be able to inspect the predicted amino acid sequence 
manually. Especially important is the ability to see the amino acid sequence and 
distribution of charged residues. To display the primary structure of amino acid with 
charges, current existing programs have defined length of output for each line and can 
only display one protein each time. For comparison of a set of similar proteins, it is more 
convenient to have a program that could display multiple proteins each time. Moreover 
to display the output more flexible, which could facilitate comparison between proteins, 
it is better to have the length of output for each line changeable by users. To satisfy these 
requirements, the program “primary structure with charges” (http://dimer.tamu.edu/cgi-
bin/phage_genomics/charged_aa.pl) was written. After uploading the FASTA protein 
sequence, the user can choose the number of amino acids per line, and select whether or 
not to show amino acid position numbers (Fig. 5. 11). The output consists of the primary 
structure of any ORF, with charge distribution conveniently displayed (Fig. 5. 12). 
Amino acid content 
Amino acid content is a unique characteristic for proteins, potentially differentiating 
a specific protein from a group of protein, shared by a set of similar proteins. To 
calculate amino acid content for both single protein and a set of proteins, a program 
(http://dimer.tamu.edu/cgi-bin/phage_genomics/AA_content.pl) was written. Charged (in 
red color), polar (in blue color) and hydrophobic (in yellow color) amino acids are also 
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grouped (Fig. 5. 13). Moreover, this program can calculate the amino acid content not 
only for every single protein but also for a set of protein. For example, after calculating 
and comparing the amino acid content of Rz1 proteins of lambdoid phages and the total 
proteins of E. coli, one could easily find out that Rz1 proteins have higher percentage of 
cysteine and proline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11. The form to display primary structure of protein sequence.  
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Figure 5.12. Display of primary structure with charges for serine sensor receptor of E. 
coli K-12.  
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Figure 5.13. Calculation of amino acid content of Rz1 proteins of lambdoid phages 
versus the total proteins of E. coli. Charged, polar and hydrophobic amino acids are 
grouped. Arrows point amino acids, cysteine and proline, with high percentage in Rz1 
proteins compared with the total proteins of E. coli. 
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GroupProtein 
There are many programs which process multiple protein sequence alignment, such 
as ClustalW, MULTALIAN (Batzoglou, 2005). To be accurate most of these programs 
require the sequences are closely related (Higgins et al., 1996). However for phage 
proteins with similar function, their protein sequences are widely diverse and hard to 
align accurately with available software. One way to solve this problem is to group these 
proteins into sub-families that have related sequences, and then apply ClustalW or other 
program to align each sub-family and draw a family evolution “tree”.  
To group proteins into sub-families a program (http://dimer.tamu.edu/cgi-
bin/phage_genomics/blast_group_aa.pl) was written using BLAST as a tool. BLAST 
(Basic Local Alignment Search Tool) (Altschul et al., 1990; Pertsemlidis and Fondon, 
2001), is a tool to search similarity between nucleotide and/or protein sequences using 
an algorithm to detect local as well as global alignments. There are many applications of 
BLAST for genome annotations and functional and structural annotation of proteins 
(Muller et al., 1999). Functions and even structures (Muller et al., 1999; Song et al., 
2006) of unknown proteins could be predicted by BLASTing with nucleotide and/or 
protein sequences databases.  
BLAST can be applied to assess similarity between proteins (Corpet et al., 1998, 
1999; Remm and Sonnhammer, 2000). Using the BLAST score of sequence similarities, 
proteins could be grouped into families.  If protein A is similar to protein B, protein B is 
similar to protein C, then protein A, B and C will be grouped into the same family. To do 
this work, a program “GroupProtein” was written. The input of this program contains 
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protein FASTA sequences, name of the query, and E-value for BLAST (Fig. 5.14). 
Proteins will be compared by BLAST and grouped into families (Fig. 5.15). BLAST 
result is also retrievable (Fig. 5.15). This program was tested using a mixture of 92 Rz 
proteins and 108 Rz1 proteins. As a result, Rz proteins were grouped with Rz proteins 
and Rz1 proteins were group with Rz1 proteins. No Rz protein was grouped with Rz1 
proteins.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14. The form for “GroupProtein”. Protein FASTA sequences of APSE-1 Rz1, 
ShigellaV Rz1, and Mu Rz 1 were input. E-value was set as 0.0001.  
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Figure 5.15. Results of BLASTing and grouping APSE-1 Rz1, ShigellaV Rz1, and Mu 
Rz 1 using “GroupProtein”. These three proteins were grouped as one family and the 
BLAST result is retrievable in this result. 
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Phage lysis genes 
Lysis genes have identified in many phage genomes. The common types of lysis 
genes are holin, antiholine, endolysin, and Rz/Rz1. To build a web-based database of all 
the annotated phage lysis genes (http://www.ncbi.nlm.nih.gov/genomes/static/phg.html), 
programs were written for different steps. First, annotation page for every annotated 
phage genome was searched. For example, for Acholeplasma phage L2, the annotation 
page is located at 
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi??db=nucleotide&val=NC_001447. Any 
annotated gene in which the text contains the following word, “lysis”, “lysozyme”, 
“lysin”, “holin”, “antiholine”, “endolysin”, “Rz”, “Rz1”, or “endopeptidase”,  are 
selected as candidates for phage lysis genes. Second, the results were stored in a MySQL 
database and displayed on a web page (http://dimer.tamu.edu/cgi-
bin/phage_genomics/phage_lysis_genes.pl). In the first part, phage genomes with 
candidates of phage lysis gene(s) were displayed (Fig. 5.16). By August, 2006, out of 
405 annotated phage genomes, 214 of them have one to ten lysis gene candidates, while 
191 phage genomes have no annotated lysis gene candidates. In the second part, details 
of every candidate, such as phage genome name, Genbank Accession ID, version, gene, 
CDS, locus, product, protein ID, protein GI, note and date, is shown (Fig. 5.17). By 
August, 2006, 458 candidates for lysis genes were found from 214 annotated phage 
genomes. 
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Figure 5.16. Phage genomes with candidates of lysis gene(s). By Aug. 2006, 214 
annotated phage genomes were found having candidates of lysis genes. 
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Figure 5.17. Details of candidate phage lysis genes from annotated phage genomes. 
Candidates highlighted are the three lysis genes, S, R and Rz, found for enterobacteria 
phage lambda,  
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Discussion 
For specific requirements in the annotation of the genome of E. coli and a number of 
bacteriophages, I generated broad array of programs. Using Gbrowse, the genome of E. 
coli MG1655, E. coli W3110, and 28 bacteriophages were displayed. Programs were 
also generated for prediction of lipoproteins, Rz and Rz1 genes, and SAR endolysins.  
LipoRy and GetRzRz1 have relative high false positive rates. One reason is the first 
step of these programs searches all possible ORFs, instead of genes. However, some 
phage genomes are just recently sequenced and have crude or no-existed annotation. 
Without knowing the properties of genes, it is hard to add restrictions to filter non-gene 
ORFs. For the first step of searching specific genes, false positive is better than false 
negative. Before GetORF was generated, programs have been written to search for 
Shine-Dalgarno (S-D) motif sequences in several phage genomes. There are some 
common S-D motifs such as AGGAG, but the S-D motifs of large proportion genes are 
very diverse. With more and more knowledge of properties of phage genes and specific 
genes, programs such as LipoRy and GetRzRz1 can be improved with less false positive 
with better filters. 
GroupProtein is a program to group proteins into families using the results from 
BLAST. The motivation to write this program is from the large diversity of phage 
protein sequences even for those within protein families sharing the same function. To be 
useful, programs like ClustalW require sequences to be closely related. To align proteins 
with lower sequence similarity, such as phage proteins, GroupProtein can be applied to 
group proteins into sub-families first. For each sub-family, which has relative high 
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similarity in sequence, other alignment programs can be applied. 
Rz/Rz1, and SAR endolysin gene are all phage lysis genes. Besides programs written 
to predict these genes, it is also critical to see how many lysis genes are already 
annotated in the current phage genomes. Programs were written to search all the 
candidates for phage lysis genes in current annotated phage genomes. Out of 405 
annotated phage genomes, 301 of them have only one or no annotated lysis gene at all. 
Based on this result, there are many lysis genes need to be annotated even in annotated 
phage genomes. Summary of the current lysis genes in all annotated phage genomes can 
help scientist focus on genomes that need more effort to improve the annotation.   
Although genome annotation of bacteria and phages cannot be done automatically 
by any current computer program, with more knowledge of specific protein properties, 
more programs could be generated to make this process easier and faster. With proper 
combination of different programs, the process of genome annotation could be mad 
semi-automatic or, eventually, automatic.  
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
Summary 
To study changes happen when E. coli cells enter stationary phase, two different 
subproteome of E. coli cells were analyzed using heparin and AIX columns. Also 
bioinformatics tools were utilized to facilitate our proteomic studies. In total 318 
heparin-binding proteins and 61 AIX-binding proteins were identified. 116 heparin-
binding proteins and 2 AIX-binding proteins were newly identified compared with other 
proteomics studies (Champion et al., 2003; Corbin et al., 2003; Sundararaj et al., 2004; 
Tonella et al., 2001). Heparin enriched and identified low abundance proteins. The 
AIX/2D PAGE study provided a novel way to study protein abundance and 
chromatography behavior. Thousands of proteins spots on 38 2D PAGE of continuous 
AIX fractions were visualized for both exponential and stationary phase samples. 
Elution profile and abundance for same spot on different 2D PAGE were obtained using 
Z3 gel image software and Perl script.  
Using heparin columns and AIX columns, differences were found in protein 
presence, protein abundance and chromatography behavior between exponential and 
stationary phase of E. coli cells. Changes also happened to proteins in different 
functional groups. For protein presence, more proteins were found in functional groups 
of carbohydrate transport and metabolism, post-translational modification, protein 
turnover, chaperones, and inorganic ion transport and metabolism for stationary phase 
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Heparome. Five heparin-binding proteins and twenty-five AIX-binding proteins were 
found more abundant in stationary phase. These proteins with more abundance in 
stationary phase are mainly in functional groups of chaperones, starvation stresses, 
amino acid transport and metabolism, carbohydrate transport and metabolism and 
translation. Also seven proteins were found with different elution profiles on heparin 
columns between exponential and stationary phase.  
Web-based databases, EEP, were generated to manage and mine our data more 
accurately and efficiently. Using the website, our data is possible to be shared with 
others. EEP is the first E. coli proteomic database, which include data from different E. 
coli proteomic studies. By including data from other groups into our databases, 
comparisons of different proteomic studies were made.  
Discussion and future prospects 
Heparome and AIX/2D PAGE identified protein with different amount and different 
elution positions on columns for samples from exponential growth and stationary phase. 
More work should be done to study the reasons that cause the difference, which is 
related to the physiology of E. coli cells in stationary phase. For example, FtnA were 
found at different elution positions from heparin column between these two growth 
phases. Elution positions of FtnA were also verified by western blot. Reason causing the 
elution shift might be protein conformation, post-translational modification or protein-
protein interactions.  
Heparome and AIX/2D PAGE increased the coverage of whole E. coli proteome by 
118 newly identified proteins. However the predicted proteome of E. coli has more than 
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4000 gene products. Although not all of them expressed under all conditions, global 
proteomics are biased to high abundant proteins. To increase the coverage of E. coli 
proteome, more growth conditions and subproteomics should be applied.  
2D PAGE has advantages to study amount, physical properties (Obs. pI and Obs. 
MW) and post-translational modifications of proteins. 18 proteins were found in 
multiple protein spots on gel by AIX/2D PAGE.  6 of these proteins, AceA, AhpC, FusA, 
RpsA, Tig, TufA, have multiple proteins spots with different abundant trend between 
exponential and stationary phase. Isoform of protein on 2D PAGE could be caused by 
protein degradation or post-translational modifications.   
 Linkage between multiple 2D PAGE using Z2 2D gel analysis system and 
computational language is efficient. Although there are still technique difficulties to 
study proteins in multiple fractions and 2D PAGE, new technologies, such as CyDye 
DIGE 2D PAGE and robotic gel visualization and spot cutting could be applied to 
improve this study. 
The web-based database is a modern way to manage large amount of data generated 
by “OMICS” studies. As more and more proteomics studies will be accomplished, 
proteomic databases, such as EEP, which will handle data merging, would be important 
to trace the current status of proteomics study. This will also help scientists to find out 
what is lack in proteomics study.  
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APPENDIX A 
Table A.1. Heparin-binding proteins identified in every fraction from heparin column.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Exponential 1 accC P24182 49.32 6.65 54 4 
Exponential 1 aceE P06958 99.54 5.46 110  
Exponential 1 adhE P17547 96 6.33 110  
Exponential 1 crl P24251 15.52 5.67 18 2 
Exponential 1 dnaK P04475 68.98 4.83 80  
Exponential 1 fabB P14926 42.61 5.35 54;51 3 
Exponential 1 fabF P39435 42.91 5.71 51  
Exponential 1 fabI P29132 27.73 5.58 37 6 
Exponential 1 ftnA P23887 19.42 4.77 18  
Exponential 1 fur P06975 16.79 5.68 18  
Exponential 1 glnS P00962 63.35 5.89 69  
Exponential 1 gltX P04805 53.82 5.59 60 4 
Exponential 1 gnd P00350 51.48 5.05 48  
Exponential 1 hisG P10366 33.37 5.47  3 
Exponential 1 lpd P00391 50.56 5.79 60 4 
Exponential 1 metE P25665 84.54 5.61 96;80;69  
Exponential 1 metF P00394 33.1 6 48  
Exponential 1 mprA P24201 20.56 5.82 21 2 
Exponential 1 ompC P06996 38.31 4.48 40  
Exponential 1 ompT P09169 33.48 5.38 40  
Exponential 1 oppA P23843 58.36 5.85 60  
Exponential 1 pgk P11665 40.99 5.08  5 
Exponential 1 ppc P00864 99.06 5.52 96  
Exponential 1 ppk P28688 80.3 8.96 43;40  
Exponential 1 purU P37051 31.93 6.5 48  
Exponential 1 rlpB P10101 19.46 8.05 60  
Exponential 1 rplL P02392 12.16 4.6  1 
Exponential 1 rplP P02414 15.28 11.22  1 
Exponential 1 rplY P02426 10.69 9.6  3 
Exponential 1 rpsA P02349 61.16 4.89 80  
Exponential 1 rpsT P02378 9.55 11.18  1 
Exponential 1 sucA P07015 105.06 6.04 110  
Exponential 1 tufA P02990 43.18 5.3  4 
Exponential 1 yfjH P52123 37.14 7.04 40  
Exponential 1 yggS P52054 25.79 6.09 30  
Exponential 1 ykgM P71302 9.92 9.3  1 
 
  
167 
Table A.1. Continued 
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Exponential 2 accC P24182 49.32 6.65  3 
Exponential 2 adhE P17547 96 6.33 116  
Exponential 2 crl P24251 15.52 5.67 18  
Exponential 2 fabB P14926 42.61 5.35 150;50;40 5 
Exponential 2 fabG P25716 25.56 6.76 29  
Exponential 2 fabH P24249 33.52 5.08 36 2 
Exponential 2 fabI P29132 27.73 5.58 36  
Exponential 2 fur P06975 16.79 5.68 18  
Exponential 2 gapA P06977 35.4 6.58 40  
Exponential 2 glnS P00962 63.35 5.89 69  
Exponential 2 gltB P09831 161.93 6.19 190  
Exponential 2 gltX P04805 53.82 5.59 57  
Exponential 2 hisG P10366 33.37 5.47 36 2 
Exponential 2 lpd P00391 50.56 5.79 57 2 
Exponential 2 metE P25665 84.54 5.61 150;80;69 2 
Exponential 2 metG P00959 76.12 5.56 80  
Exponential 2 mfd P30958 129.98 5.79 150  
Exponential 2 mprA P24201 20.56 5.82  3 
Exponential 2 ompA P02934 35.17 5.6 36  
Exponential 2 ompC P06996 38.31 4.48 40  
Exponential 2 ompF P02931 37.08 4.64 40  
Exponential 2 ompR P03025 27.35 6.04 29  
Exponential 2 ompT P09169 33.48 5.38 40  
Exponential 2 oppA P23843 58.36 5.85 190;96;62;57 7 
Exponential 2 pbpC P76577 85.07 9.52 96  
Exponential 2 pdxH P28225 25.41 9.18 29  
Exponential 2 pgk P11665 40.99 5.08 190;150;44;29 15 
Exponential 2 pnp P05055 77.1 5.11 93  
Exponential 2 rplC P02386 22.24 9.9  4 
Exponential 2 rplJ P02408 17.58 9.04  2 
Exponential 2 rplL P02392 12.16 4.6  3 
Exponential 2 rplU P02422 11.56 9.85  2 
Exponential 2 rplY P02426 10.69 9.6  5 
Exponential 2 sucA P07015 105.06 6.04 116  
Exponential 2 thrS P00955 74.01 5.8 80  
Exponential 2 trpS P00954 37.44 6.27 40  
Exponential 2 ung P12295 25.56 6.71 29  
Exponential 2 yggS P52054 25.79 6.09 29  
Exponential 2 ykgM P71302 9.92 9.3  2 
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel Obs.MW (kD) LC 
Peptides# 
Exponential 3 accC P24182 49.32 6.65  5 
Exponential 3 aceE P06958 99.54 5.46 140  
Exponential 3 adhE P17547 96 6.33 140  
Exponential 3 crl P24251 15.52 5.67  4 
Exponential 3 fabB P14926 42.61 5.35 50;40 9 
Exponential 3 fabF P39435 42.91 5.71 50  
Exponential 3 fabH P24249 33.52 5.08  5 
Exponential 3 fabI P29132 27.73 5.58  5 
Exponential 3 glgB P07762 84.34 5.91 90  
Exponential 3 glnS P00962 63.35 5.89 80;70 5 
Exponential 3 gltB P09831 161.93 6.19 190  
Exponential 3 gltX P04805 53.82 5.59 55 10 
Exponential 3 gnd P00350 51.48 5.05 50  
Exponential 3 hisG P10366 33.37 5.47  4 
Exponential 3 lpd P00391 50.56 5.79 55 6 
Exponential 3 metE P25665 84.54 5.61 110;96;90;80 1 
Exponential 3 metG P00959 76.12 5.56 80  
Exponential 3 minE P18198 10.23 5.15  3 
Exponential 3 mprA P24201 20.56 5.82 22 3 
Exponential 3 nusB P04381 15.69 6.6  2 
Exponential 3 ompR P03025 27.35 6.04  3 
Exponential 3 oppA P23843 58.36 5.85 190;80;70;60;55;50 8 
Exponential 3 pgk P11665 40.99 5.08 190;90;44;40;36;29;22 22 
Exponential 3 pnp P05055 77.1 5.11 90  
Exponential 3 rplC P02386 22.24 9.9  4 
Exponential 3 rplD P02388 22.09 9.72  3 
Exponential 3 rplJ P02408 17.58 9.04  4 
Exponential 3 rplL P02392 12.16 4.6  5 
Exponential 3 rplS P02420 13 10.62  2 
Exponential 3 rplU P02422 11.56 9.85  2 
Exponential 3 rplY P02426 10.69 9.6  4 
Exponential 3 rpoA P00574 36.51 4.98  7 
Exponential 3 rpsH P02361 14 9.44  5 
Exponential 3 rpsJ P02364 11.74 9.68  1 
Exponential 3 sucA P07015 105.06 6.04 140 4 
Exponential 3 trpS P00954 37.44 6.27  1 
Exponential 3 tufA P02990 43.18 5.3 50 6 
Exponential 3 ykgM P71302 9.92 9.3  4 
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW (kD) 
LC 
Peptides# 
Exponential 4 accC P24182 49.32 6.65  5 
Exponential 4 aceE P06958 99.54 5.46  4 
Exponential 4 adhE P17547 96 6.33 110 16 
Exponential 4 crl P24251 15.52 5.67  2 
Exponential 4 era P06616 33.81 6.73 43  
Exponential 4 fabB P14926 42.61 5.35 43;37 9 
Exponential 4 fabG P25716 25.56 6.76  3 
Exponential 4 fabH P24249 33.52 5.08  5 
Exponential 4 fabI P29132 27.73 5.58 33  
Exponential 4 fur P06975 16.79 5.68  2 
Exponential 4 glgB P07762 84.34 5.91  2 
Exponential 4 glnS P00962 63.35 5.89 75;70 7 
Exponential 4 gltB P09831 161.93 6.19  11 
Exponential 4 gltX P04805 53.82 5.59  6 
Exponential 4 gnd P00350 51.48 5.05  12 
Exponential 4 hisG P10366 33.37 5.47  6 
Exponential 4 iscS P39171 45.09 5.94  7 
Exponential 4 lpd P00391 50.56 5.79  13 
Exponential 4 metE P25665 84.54 5.61 180;140 5 
Exponential 4 mfd P30958 129.98 5.79  4 
Exponential 4 minE P18198 10.23 5.15  2 
Exponential 4 mprA P24201 20.56 5.82 30 2 
Exponential 4 ompC P06996 38.31 4.48 40  
Exponential 4 ompR P03025 27.35 6.04 43;40;37;33 5 
Exponential 4 oppA P23843 58.36 5.85 43;37 9 
Exponential 4 panC P31663 31.6 5.92 43  
Exponential 4 pgk P11665 40.99 5.08 43;40;37;33;30 24 
Exponential 4 rbfA P09170 15.02 5.96  4 
Exponential 4 rplA P02384 24.6 9.64  2 
Exponential 4 rplC P02386 22.24 9.9  3 
Exponential 4 rplJ P02408 17.58 9.04  3 
Exponential 4 rplL P02392 12.16 4.6  4 
Exponential 4 rplS P02420 13 10.62  2 
Exponential 4 rplU P02422 11.56 9.85  2 
Exponential 4 rplY P02426 10.69 9.6  6 
Exponential 4 rpoA P00574 36.51 4.98 60 6 
Exponential 4 rpsH P02361 14 9.44  3 
Exponential 4 rpsJ P02364 11.74 9.68  2 
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Table A.1. Continued 
 
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Exponential 4 rpsS P02375 10.3 10.52  1 
Exponential 4 slyA P55740 16.35 6.6  2 
Exponential 4 sucA P07015 105.06 6.04 110 23 
Exponential 4 sucB P07016 43.88 5.58 52 11 
Exponential 4 thrS P00955 74.01 5.8  7 
Exponential 4 trpS P00954 37.44 6.27 40 6 
Exponential 4 tufA P02990 43.18 5.3  6 
Exponential 4 ung P12295 25.56 6.71 37  
Exponential 4 yciK P31808 27.93 7.67  2 
Exponential 4 yggS P52054 25.79 6.09 37  
Exponential 4 yhaJ P42623 33.26 6.05  4 
Exponential 4 yibQ P37691 32.87 9.45 30  
Exponential 4 yjeQ P39286 36.83 5.09  3 
Exponential 4 ykgM P71302 9.92 9.3  2 
Exponential 5 aceE P06958 99.54 5.46  4 
Exponential 5 adhE P17547 96 6.33 115 9 
Exponential 5 def P27251 19.2 5.23  2 
Exponential 5 dksA P18274 17.53 5.06  2 
Exponential 5 fabB P14926 42.61 5.35  3 
Exponential 5 fabG P25716 25.56 6.76 32;25 2 
Exponential 5 fabH P24249 33.52 5.08  3 
Exponential 5 fur P06975 16.79 5.68  1 
Exponential 5 ghrA P75913 36.84 6.76 29 3 
Exponential 5 gidB P17113 23.43 6.06 32  
Exponential 5 glnS P00962 63.35 5.89 66 7 
Exponential 5 gltB P09831 161.93 6.19 180 22 
Exponential 5 gnd P00350 51.48 5.05 55;46 19 
Exponential 5 guaB P06981 52.02 6.02  11 
Exponential 5 hisG P10366 33.37 5.47  5 
Exponential 5 hscC P77319 61.99 5.05  2 
Exponential 5 iscS P39171 45.09 5.94  7 
Exponential 5 lpd P00391 50.56 5.79  5 
Exponential 5 lpxB P10441 42.38 6.57 38  
Exponential 5 metE P25665 84.54 5.61 96 5 
Exponential 5 metF P00394 33.1 6 35 1 
Exponential 5 mprA P24201 20.56 5.82  2 
Exponential 5 ompA P02934 35.17 5.6 29  
 
  
171 
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Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel Obs.MW 
(kD) 
LC 
Peptides# 
Exponential 5 oppA P23843 58.36 5.85 180;70;66;55;46;36;
35;32;29;28 
5 
Exponential 5 parE P20083 70.24 5.44 26  
Exponential 5 pgk P11665 40.99 5.08 43;36;35;32 12 
Exponential 5 rbfA P09170 15.02 5.96 17 5 
Exponential 5 rplJ P02408 17.58 9.04 17 3 
Exponential 5 rplL P02392 12.16 4.6 17 4 
Exponential 5 rplS P02420 13 10.62 17 4 
Exponential 5 rplY P02426 10.69 9.6  3 
Exponential 5 rpoA P00574 36.51 4.98  5 
Exponential 5 rpsH P02361 14 9.44  1 
Exponential 5 skp P11457 15.69 9.52 21  
Exponential 5 sucA P07015 105.06 6.04 115 9 
Exponential 5 sucB P07016 43.88 5.58 55 7 
Exponential 5 thrS P00955 74.01 5.8 70 13 
Exponential 5 trpS P00954 37.44 6.27 38 8 
Exponential 5 tufA P02990 43.18 5.3  6 
Exponential 5 ycgK P76002 12.52 9.01 17 2 
Exponential 5 yegQ P76403 51.19 5.8  4 
Exponential 5 yggS P52054 25.79 6.09 32  
Exponential 5 ykgM P71302 9.92 9.3  2 
Exponential 5 ynhG P76193 33.67 9.21  2 
Exponential 5 zwf P22992 55.7 5.56  3 
Exponential 6 accA P30867 35.11 5.76 37;35 17 
Exponential 6 accD P08193 33.32 7.58  8 
Exponential 6 aceE P06958 99.54 5.46  22 
Exponential 6 adhE P17547 96 6.33 68 9 
Exponential 6 alaS P00957 96.03 5.53  8 
Exponential 6 argA P08205 49.2 6.09  5 
Exponential 6 aroH P00887 38.74 6.42  9 
Exponential 6 atpA P00822 55.22 5.8  7 
Exponential 6 atpD P00824 50.19 4.9  11 
Exponential 6 bglX P33363 81.41 5.77 52  
Exponential 6 dapE P24176 41.27 5.31 52  
Exponential 6 def P27251 19.2 5.23  4 
Exponential 6 dinG P27296 81.44 7.62  5 
Exponential 6 dksA P18274 17.53 5.06  4 
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Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel Obs.MW 
(kD) 
LC 
Peptides# 
Exponential 6 erfK P39176 32.08 7.97  7 
Exponential 6 fabA P18391 18.84 6.16  2 
Exponential 6 fabG P25716 25.56 6.76  11 
Exponential 6 fadR P09371 26.84 6.54  3 
Exponential 6 fur P06975 16.79 5.68  3 
Exponential 6 ghrA P75913 36.84 6.76 37;35 15 
Exponential 6 glgB P07762 84.34 5.91  3 
Exponential 6 glmU P17114 49.19 6.09  7 
Exponential 6 glnE P30870 108.42 5.08  6 
Exponential 6 glnS P00962 63.35 5.89  23 
Exponential 6 gltB P09831 161.93 6.19  49 
Exponential 6 glyA P00477 45.32 6.03  6 
Exponential 6 gnd P00350 51.48 5.05 52;46;40;35;28;25 35 
Exponential 6 guaB P06981 52.02 6.02 60 21 
Exponential 6 gyrA P09097 96.96 5.09  7 
Exponential 6 gyrB P06982 89.82 5.72  9 
Exponential 6 hns P08936 15.41 5.44  4 
Exponential 6 infB P02995 97.35 5.8 68;52 41 
Exponential 6 iscS P39171 45.09 5.94 43 20 
Exponential 6 ligA P15042 73.61 5.39  5 
Exponential 6 lpd P00391 50.56 5.79  5 
Exponential 6 map P07906 29.33 5.64  3 
Exponential 6 metE P25665 84.54 5.61 68;60;57;52 43 
Exponential 6 metF P00394 33.1 6 35 15 
Exponential 6 mfd P30958 129.98 5.79  14 
Exponential 6 miaA P16384 35.07 5.68  7 
Exponential 6 mnmG P17112 69.52 6.2  14 
Exponential 6 nuoG P33602 100.17 5.85  7 
Exponential 6 ompA P02934 35.17 5.6  4 
Exponential 6 oppA P23843 58.36 5.85 60;57 8 
Exponential 6 pdxH P28225 25.41 9.18  4 
Exponential 6 pgk P11665 40.99 5.08 43;33 13 
Exponential 6 pheS P08312 36.83 5.79  3 
Exponential 6 pntA P07001 54.62 5.65  5 
Exponential 6 prc P23865 74.32 6.04  7 
Exponential 6 proC P00373 28.14 5.64  3 
Exponential 6 purU P37051 31.93 6.5 38 10 
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Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Exponential 6 rbfA P09170 15.02 5.96 16 7 
Exponential 6 relA P11585 83.88 6.29  15 
Exponential 6 rho P03002 47 6.75  9 
Exponential 6 rne P21513 118.2 5.48  7 
Exponential 6 rplA P02384 24.6 9.64  8 
Exponential 6 rplB P02387 29.73 10.93  5 
Exponential 6 rplC P02386 22.24 9.9  6 
Exponential 6 rplF P02390 18.77 9.71  6 
Exponential 6 rplI P02418 15.77 6.17  4 
Exponential 6 rplJ P02408 17.58 9.04  3 
Exponential 6 rplK P02409 14.74 9.64  2 
Exponential 6 rplL P02392 12.16 4.6  3 
Exponential 6 rplM P02410 16.02 9.91  3 
Exponential 6 rplN P02411 13.54 10.43  2 
Exponential 6 rplO P02413 14.98 11.18  6 
Exponential 6 rplS P02420 13 10.62  6 
Exponential 6 rplU P02422 11.56 9.85  3 
Exponential 6 rplY P02426 10.69 9.6  6 
Exponential 6 rpmA P02427 8.99 10.58  3 
Exponential 6 rpoA P00574 36.51 4.98  7 
Exponential 6 rpoB P00575 150.63 5.15  13 
Exponential 6 rpoD P00579 70.26 4.69  9 
Exponential 6 rpsH P02361 14 9.44  3 
Exponential 6 rpsJ P02364 11.74 9.68  6 
Exponential 6 rpsN P02370 11.45 11.16  2 
Exponential 6 rpsO P02371 10.14 10.4  2 
Exponential 6 rpsQ P02373 9.57 9.64  2 
Exponential 6 rpsU P02379 8.37 11.15  4 
Exponential 6 rsd P31690 18.24 5.65  4 
Exponential 6 skp P11457 15.69 9.52 20 8 
Exponential 6 sucA P07015 105.06 6.04 68 7 
Exponential 6 sucB P07016 43.88 5.58  9 
Exponential 6 talB P30148 35.09 5.11 37  
Exponential 6 thrS P00955 74.01 5.8  29 
Exponential 6 tktA P27302 72.21 5.43  4 
Exponential 6 trpR P03032 12.22 5.42  2 
Exponential 6 trpS P00954 37.44 6.27  7 
Exponential 6 tufA P02990 43.18 5.3  13 
Exponential 6 tyrR P07604 57.66 5.54  11 
Exponential 6 tyrS P00951 47.4 5.59  13 
Exponential 6 ugpQ P10908 27.41 6.09  5 
Exponential 6 uidR Q59431 21.8 5.69 28  
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW (kD) 
LC 
Peptides# 
Exponential 6 uvrB P07025 76.09 5.14  4 
Exponential 6 uvrY P07027 23.89 6.53  4 
Exponential 6 xthA P09030 30.97 5.8  6 
Exponential 6 yafC P30864 33.78 6.93  5 
Exponential 6 yafJ Q47147 28.64 8.14  5 
Exponential 6 ybaK P37175 17.09 9.02  3 
Exponential 6 ybeZ P77349 40.65 6.24  14 
Exponential 6 ybgK P75745 34.39 8.59  3 
Exponential 6 ycgK P76002 12.52 9.01 33;16 10 
Exponential 6 ycjX P76046 52.61 8.25  3 
Exponential 6 ydgH P76177 31.91 9.1 37 14 
Exponential 6 yegQ P76403 51.19 5.8  11 
Exponential 6 yfaA P17994 62.67 5.32  3 
Exponential 6 ykgM P71302 9.92 9.3  8 
Exponential 6 ynhG P76193 33.67 9.21  11 
Exponential 6 zwf P22992 55.7 5.56  18 
Exponential 7 accA P30867 35.11 5.76 34 6 
Exponential 7 fabA P18391 18.84 6.16 20  
Exponential 7 fabG P25716 25.56 6.76 29;27  
Exponential 7 fadR P09371 26.84 6.54 30  
Exponential 7 gnd P00350 51.48 5.05 50  
Exponential 7 infB P02995 97.35 5.8  5 
Exponential 7 iscS P39171 45.09 5.94 50;42 8 
Exponential 7 map P07906 29.33 5.64  1 
Exponential 7 metE P25665 84.54 5.61 90;80;70;66;60
;56;53;50;45;4
2;39;37;34;30;
29;27;25 
30 
Exponential 7 metJ P08338 12.01 5.4  2 
Exponential 7 purU P37051 31.93 6.5 34;30  
Exponential 7 rcsB P14374 23.67 6.85 29  
Exponential 7 rplK P02409 14.74 9.64  2 
Exponential 7 rplO P02413 14.98 11.18  4 
Exponential 7 rplS P02420 13 10.62  3 
Exponential 7 rpoA P00574 36.51 4.98  3 
Exponential 7 rpsN P02370 11.45 11.16  1 
Exponential 7 skp P11457 15.69 9.52 20  
Exponential 7 xthA P09030 30.97 5.8 34  
Exponential 7 ycgK P76002 12.52 9.01  3 
Exponential 7 ydgH P76177 31.91 9.1  6 
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel Obs.MW 
(kD) 
LC 
Peptides# 
Exponential 8 arcA P03026 27.29 5.21 32;29 5 
Exponential 8 aroC P12008 39.01 5.82 40  
Exponential 8 fabG P25716 25.56 6.76 29 4 
Exponential 8 gyrA P09097 96.96 5.09 230 7 
Exponential 8 hisS P04804 46.9 5.65 46 6 
Exponential 8 hns P08936 15.41 5.44  2 
Exponential 8 infA P02998 8.12 9.23  3 
Exponential 8 iscS P39171 45.09 5.94 44 4 
Exponential 8 map P07906 29.33 5.64  2 
Exponential 8 mdoG P33136 55.37 6.26 48  
Exponential 8 metE P25665 84.54 5.61 230;170;80;55;48
;46;40;29;18 
24 
Exponential 8 metJ P08338 12.01 5.4  4 
Exponential 8 mug P43342 18.67 9.17 21  
Exponential 8 rho P03002 47 6.75 46  
Exponential 8 rplA P02384 24.6 9.64 32;29 4 
Exponential 8 rplF P02390 18.77 9.71 21 7 
Exponential 8 rplI P02418 15.77 6.17 18 3 
Exponential 8 rplJ P02408 17.58 9.04 18  
Exponential 8 rplO P02413 14.98 11.18  4 
Exponential 8 rplS P02420 13 10.62  2 
Exponential 8 rplX P02425 11.19 10.21  3 
Exponential 8 rpoA P00574 36.51 4.98 40 3 
Exponential 8 rpoB P00575 150.63 5.15 170  
Exponential 8 rpsB P02351 26.61 6.69 32  
Exponential 8 rpsJ P02364 11.74 9.68  3 
Exponential 8 rpsN P02370 11.45 11.16  2 
Exponential 8 rpsQ P02373 9.57 9.64  2 
Exponential 8 rpsS P02375 10.3 10.52  2 
Exponential 8 stpA P30017 15.35 7.95 18  
Exponential 8 suhB P22783 29.17 6.45 32 5 
Exponential 8 tgt P19675 42.59 5.97 18  
Exponential 8 ycbB P22525 67.81 8.63 55  
Exponential 8 ydcC P28917 43.08 6.97 29  
Exponential 8 yibK P33899 17.73 6.2 21  
Exponential 8 yjgA P26650 21.36 5.3 21  
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Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Exponential 9 arcA P03026 27.29 5.21  3 
Exponential 9 aroC P12008 39.01 5.82 43  
Exponential 9 atpD P00824 50.19 4.9 46  
Exponential 9 creA P08367 17.11 9.04  3 
Exponential 9 crp P03020 23.64 8.38 29 4 
Exponential 9 glgC P00584 48.57 5.78 25  
Exponential 9 gltB P09831 161.93 6.19 25  
Exponential 9 gltX P04805 53.82 5.59 25  
Exponential 9 gyrA P09097 96.96 5.09  7 
Exponential 9 hflX P25519 48.33 5.68 47  
Exponential 9 hisS P04804 46.9 5.65 47;46 10 
Exponential 9 hns P08936 15.41 5.44  3 
Exponential 9 lexA P03033 22.36 6.23 29  
Exponential 9 lrp P19494 18.76 8.91  5 
Exponential 9 mdoG P33136 55.37 6.26 66  
Exponential 9 metE P25665 84.54 5.61 90;66 7 
Exponential 9 moaB P30746 18.53 5.73  5 
Exponential 9 oppA P23843 58.36 5.85 25;23  
Exponential 9 oxyR P11721 34.28 5.96 43  
Exponential 9 pepA P11648 54.88 6.82 47 3 
Exponential 9 pgk P11665 40.99 5.08 23  
Exponential 9 rho P03002 47 6.75 47;46 12 
Exponential 9 rluE P75966 24.88 10.03 29  
Exponential 9 rne P21513 118.2 5.48 66  
Exponential 9 rplA P02384 24.6 9.64 31;30 6 
Exponential 9 rplB P02387 29.73 10.93  4 
Exponential 9 rplC P02386 22.24 9.9  7 
Exponential 9 rplE P02389 20.17 9.49 26 8 
Exponential 9 rplF P02390 18.77 9.71 26;25;21 11 
Exponential 9 rplI P02418 15.77 6.17 18 11 
Exponential 9 rplJ P02408 17.58 9.04 18 5 
Exponential 9 rplL P02392 12.16 4.6  3 
Exponential 9 rplM P02410 16.02 9.91  3 
Exponential 9 rplO P02413 14.98 11.18  4 
Exponential 9 rplS P02420 13 10.62  3 
Exponential 9 rplX P02425 11.19 10.21  5 
Exponential 9 rpoA P00574 36.51 4.98  4 
Exponential 9 rpoB P00575 150.63 5.15  6 
Exponential 9 rpsB P02351 26.61 6.69 31;30;29 9 
Exponential 9 rpsJ P02364 11.74 9.68  4 
Exponential 9 rpsQ P02373 9.57 9.64  3 
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Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Exponential 9 secA P10408 102.02 5.43 116;90;66 11 
Exponential 9 stpA P30017 15.35 7.95  4 
Exponential 9 suhB P22783 29.17 6.45  4 
Exponential 9 ttk P06969 22.84 8.78 31  
Exponential 9 ydfH P77577 26.57 5.91 30  
Exponential 9 ydjA P24250 20.06 6.31  3 
Exponential 9 yfiF P33635 37.78 8.94 43  
Exponential 9 ykgM P71302 9.92 9.3  3 
Exponential 10 ccmH P33925 37.18 6.22 40  
Exponential 10 crp P03020 23.64 8.38 26 6 
Exponential 10 cysH P17854 27.84 5.51 28 4 
Exponential 10 gyrA P09097 96.96 5.09  4 
Exponential 10 hflX P25519 48.33 5.68  4 
Exponential 10 lon P08177 87.44 6.01 17  
Exponential 10 metE P25665 84.54 5.61  1 
Exponential 10 moaB P30746 18.53 5.73 36 2 
Exponential 10 moaC P30747 17.34 6.58 28  
Exponential 10 oxyR P11721 34.28 5.96 40  
Exponential 10 rplB P02387 29.73 10.93  4 
Exponential 10 rplC P02386 22.24 9.9  5 
Exponential 10 rplD P02388 22.09 9.72 17 1 
Exponential 10 rplE P02389 20.17 9.49 22 11 
Exponential 10 rplF P02390 18.77 9.71 36;23 7 
Exponential 10 rplI P02418 15.77 6.17 40;17 10 
Exponential 10 rplJ P02408 17.58 9.04 17 5 
Exponential 10 rplL P02392 12.16 4.6  4 
Exponential 10 rplM P02410 16.02 9.91  1 
Exponential 10 rplO P02413 14.98 11.18  5 
Exponential 10 rplS P02420 13 10.62  2 
Exponential 10 rplX P02425 11.19 10.21  3 
Exponential 10 rpmB P02428 8.88 11.42  2 
Exponential 10 rpmC P02429 7.27 9.98  2 
Exponential 10 rpoA P00574 36.51 4.98 47 7 
Exponential 10 rpoB P00575 150.63 5.15 28 14 
Exponential 10 rpoC P00577 155.16 6.67 28 11 
Exponential 10 rpsB P02351 26.61 6.69 36;30;28 14 
Exponential 10 rpsO P02371 10.14 10.4  2 
Exponential 10 rpsQ P02373 9.57 9.64  2 
Exponential 10 spoT P17580 79.34 8.89 40  
Exponential 10 tgt P19675 42.59 5.97 17  
Exponential 10 ttk P06969 22.84 8.78 22  
Exponential 10 tufA P02990 43.18 5.3 47  
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Exponential 10 yaaA P11288 29.59 6.86 30  
Exponential 10 yaeH P37048 15.1 6.61  2 
Exponential 10 ydjA P24250 20.06 6.31  6 
Exponential 10 yfiF P33635 37.78 8.94 40  
Exponential 10 yihA P24253 23.56 6.86 26  
Exponential 10 ykgM P71302 9.92 9.3  3 
Exponential 11 atpD P00824 50.19 4.9 45  
Exponential 11 crp P03020 23.64 8.38 26  
Exponential 11 fabR P27307 24.4 9.33 26  
Exponential 11 glf P37747 42.97 6.62 30  
Exponential 11 lon P08177 87.44 6.01 80 9 
Exponential 11 malP P00490 90.39 6.93 66 5 
Exponential 11 metE P25665 84.54 5.61 80;30  
Exponential 11 oppA P23843 58.36 5.85 40  
Exponential 11 parC P20082 83.83 6.24 66  
Exponential 11 pheT P07395 87.38 5.17 66  
Exponential 11 rhlB P24229 46.99 7.28 45  
Exponential 11 rne P21513 118.2 5.48 80  
Exponential 11 rob P27292 33.14 6.66 35  
Exponential 11 rplB P02387 29.73 10.93 28 14 
Exponential 11 rplD P02388 22.09 9.72 16 5 
Exponential 11 rplE P02389 20.17 9.49 22 9 
Exponential 11 rplI P02418 15.77 6.17 17 7 
Exponential 11 rplM P02410 16.02 9.91 20 6 
Exponential 11 rplN P02411 13.54 10.43  4 
Exponential 11 rplO P02413 14.98 11.18  6 
Exponential 11 rplR P02419 12.77 10.42  3 
Exponential 11 rplS P02420 13 10.62 17;16 4 
Exponential 11 rplX P02425 11.19 10.21  5 
Exponential 11 rpmB P02428 8.88 11.42  6 
Exponential 11 rpmC P02429 7.27 9.98  3 
Exponential 11 rpoA P00574 36.51 4.98 35 6 
Exponential 11 rpoB P00575 150.63 5.15 140 15 
Exponential 11 rpoC P00577 155.16 6.67 140 17 
Exponential 11 rpsB P02351 26.61 6.69 30 7 
Exponential 11 rpsE P02356 17.47 10.11 20 4 
Exponential 11 rpsO P02371 10.14 10.4  4 
Exponential 11 rpsP P02372 9.19 10.54  5 
Exponential 11 rpsQ P02373 9.57 9.64  2 
Exponential 11 rpsS P02375 10.3 10.52  5 
Exponential 11 rsmC P39406 37.49 6 35  
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Exponential 11 ydjA P24250 20.06 6.31  7 
Exponential 11 yejK P33920 37.69 4.88 35  
Exponential 11 yfhD P30135 53.16 5.03  2 
Exponential 11 yfiF P33635 37.78 8.94 35  
Exponential 11 yggH P32049 27.31 6.42  3 
Exponential 11 ykgM P71302 9.92 9.3  1 
Exponential 12 atpD P00824 50.19 4.9 44  
Exponential 12 hupA P02342 9.53 9.57  4 
Exponential 12 infC P02999 20.56 9.54  5 
Exponential 12 metE P25665 84.54 5.61 75  
Exponential 12 mraW P18595 34.88 6.07  4 
Exponential 12 rhlB P24229 46.99 7.28 44  
Exponential 12 rne P21513 118.2 5.48 130;75  
Exponential 12 rnr P21499 92.11 8.78 75  
Exponential 12 rplB P02387 29.73 10.93 30;27 10 
Exponential 12 rplD P02388 22.09 9.72 25 4 
Exponential 12 rplM P02410 16.02 9.91 25;19 8 
Exponential 12 rplO P02413 14.98 11.18  4 
Exponential 12 rplR P02419 12.77 10.42  3 
Exponential 12 rplS P02420 13 10.62  2 
Exponential 12 rplX P02425 11.19 10.21  4 
Exponential 12 rpmB P02428 8.88 11.42  4 
Exponential 12 rpmC P02429 7.27 9.98  2 
Exponential 12 rpoA P00574 36.51 4.98 40  
Exponential 12 rpoB P00575 150.63 5.15 130  
Exponential 12 rpoC P00577 155.16 6.67 130  
Exponential 12 rpsC P02352 25.85 10.27 27 10 
Exponential 12 rpsD P02354 23.34 10.05  3 
Exponential 12 rpsE P02356 17.47 10.11 19 6 
Exponential 12 rpsG P02359 19.89 10.37  2 
Exponential 12 rpsI P02363 14.73 10.94  3 
Exponential 12 rpsM P02369 12.97 10.78  4 
Exponential 12 rpsP P02372 9.19 10.54  3 
Exponential 12 rpsS P02375 10.3 10.52  4 
Exponential 12 rsmC P39406 37.49 6 40 2 
Exponential 12 rsuA P33918 25.87 5.75 30  
Exponential 12 selB P14081 68.87 6.11 48  
Exponential 12 yhhX P46853 38.77 6.07 46  
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Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW (kD) 
LC 
Peptides# 
Exponential 13 deaD P23304 70.41 8.76 55;47 8 
Exponential 13 hupA P02342 9.53 9.57  3 
Exponential 13 infC P02999 20.56 9.54 21 6 
Exponential 13 kdgR P76268 30.03 5.43 30  
Exponential 13 metE P25665 84.54 5.61 70  
Exponential 13 panC P31663 31.6 5.92 70  
Exponential 13 rhlE P25888 49.99 10.06 45  
Exponential 13 rnr P21499 92.11 8.78 70  
Exponential 13 rplB P02387 29.73 10.93 30;27 9 
Exponential 13 rplD P02388 22.09 9.72 125;26 6 
Exponential 13 rplE P02389 20.17 9.49 47  
Exponential 13 rplM P02410 16.02 9.91  8 
Exponential 13 rplO P02413 14.98 11.18  5 
Exponential 13 rplP P02414 15.28 11.22  3 
Exponential 13 rplQ P02416 14.36 11.05  2 
Exponential 13 rplR P02419 12.77 10.42  3 
Exponential 13 rplU P02422 11.56 9.85  2 
Exponential 13 rplW P02424 11.2 9.94  4 
Exponential 13 rpmB P02428 8.88 11.42  5 
Exponential 13 rpoA P00574 36.51 4.98 40  
Exponential 13 rpsC P02352 25.85 10.27 125;70;55;27 11 
Exponential 13 rpsD P02354 23.34 10.05 125;70;55;26;25 8 
Exponential 13 rpsE P02356 17.47 10.11 18 9 
Exponential 13 rpsG P02359 19.89 10.37 40;21 6 
Exponential 13 rpsI P02363 14.73 10.94  3 
Exponential 13 rpsM P02369 12.97 10.78  6 
Exponential 13 rpsS P02375 10.3 10.52 15 6 
Exponential 13 rpsT P02378 9.55 11.18  3 
Exponential 13 yafL Q47151 27.02 9.59  2 
Exponential 14 hupA P02342 9.53 9.57  5 
Exponential 14 hupB P02341 9.23 9.69  5 
Exponential 14 rplB P02387 29.73 10.93 30 11 
Exponential 14 rplM P02410 16.02 9.91  2 
Exponential 14 rplO P02413 14.98 11.18 40 7 
Exponential 14 rplP P02414 15.28 11.22 16 4 
Exponential 14 rplQ P02416 14.36 11.05 40;16 4 
Exponential 14 rplR P02419 12.77 10.42  5 
Exponential 14 rplU P02422 11.56 9.85  2 
Exponential 14 rpmB P02428 8.88 11.42  4 
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Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Exponential 14 rpoA P00574 36.51 4.98 40  
Exponential 14 rpsC P02352 25.85 10.27 125;47;40 13 
Exponential 14 rpsD P02354 23.34 10.05 125;40;24 15 
Exponential 14 rpsE P02356 17.47 10.11 40;16 9 
Exponential 14 rpsF P02358 15.32 5.16  4 
Exponential 14 rpsG P02359 19.89 10.37 40;20;16 8 
Exponential 14 rpsI P02363 14.73 10.94  3 
Exponential 14 rpsM P02369 12.97 10.78  7 
Exponential 14 rpsR P02374 8.86 10.6  2 
Exponential 14 rpsS P02375 10.3 10.52  3 
Exponential 14 rpsT P02378 9.55 11.18  2 
Exponential 15 hupA P02342 9.53 9.57  4 
Exponential 15 hupB P02341 9.23 9.69  3 
Exponential 15 metE P25665 84.54 5.61 47  
Exponential 15 pcnB P13685 54.66 9.68  6 
Exponential 15 rluC P23851 36.03 9.85  5 
Exponential 15 rplB P02387 29.73 10.93 30 5 
Exponential 15 rplE P02389 20.17 9.49  3 
Exponential 15 rplM P02410 16.02 9.91  3 
Exponential 15 rplO P02413 14.98 11.18 55 6 
Exponential 15 rplP P02414 15.28 11.22  5 
Exponential 15 rplQ P02416 14.36 11.05  5 
Exponential 15 rplS P02420 13 10.62  3 
Exponential 15 rplT P02421 13.37 11.47  2 
Exponential 15 rplU P02422 11.56 9.85  3 
Exponential 15 rplV P02423 12.23 10.23  5 
Exponential 15 rpmB P02428 8.88 11.42  3 
Exponential 15 rpoC P00577 155.16 6.67 55  
Exponential 15 rpsC P02352 25.85 10.27 55;47 10 
Exponential 15 rpsD P02354 23.34 10.05 55;24 14 
Exponential 15 rpsE P02356 17.47 10.11 17 6 
Exponential 15 rpsF P02358 15.32 5.16  8 
Exponential 15 rpsG P02359 19.89 10.37 34;19;17 10 
Exponential 15 rpsI P02363 14.73 10.94  5 
Exponential 15 rpsK P02366 13.71 11.33  6 
Exponential 15 rpsM P02369 12.97 10.78  7 
Exponential 15 rpsR P02374 8.86 10.6  2 
Exponential 15 rpsS P02375 10.3 10.52  1 
Exponential 15 rpsT P02378 9.55 11.18  4 
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Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW (kD) 
LC 
Peptides# 
Exponential 16 hupA P02342 9.53 9.57  3 
Exponential 16 hupB P02341 9.23 9.69  2 
Exponential 16 hycE P16431 61.15 5.66 33  
Exponential 16 ihfA P06984 11.35 9.34  2 
Exponential 16 ihfB P08756 10.65 9.34  2 
Exponential 16 metE P25665 84.54 5.61 70  
Exponential 16 pcnB P13685 54.66 9.68 40 5 
Exponential 16 pgk P11665 40.99 5.08 125  
Exponential 16 rplB P02387 29.73 10.93 29 5 
Exponential 16 rplE P02389 20.17 9.49  2 
Exponential 16 rplM P02410 16.02 9.91  1 
Exponential 16 rplO P02413 14.98 11.18  4 
Exponential 16 rplP P02414 15.28 11.22  6 
Exponential 16 rplQ P02416 14.36 11.05 70;19 4 
Exponential 16 rplT P02421 13.37 11.47  2 
Exponential 16 rplU P02422 11.56 9.85  2 
Exponential 16 rplV P02423 12.23 10.23  8 
Exponential 16 rpmB P02428 8.88 11.42  2 
Exponential 16 rpsB P02351 26.61 6.69 40  
Exponential 16 rpsC P02352 25.85 10.27 70;25 9 
Exponential 16 rpsD P02354 23.34 10.05 25 6 
Exponential 16 rpsE P02356 17.47 10.11  2 
Exponential 16 rpsF P02358 15.32 5.16 19 8 
Exponential 16 rpsG P02359 19.89 10.37 55;29;24;19;17 9 
Exponential 16 rpsI P02363 14.73 10.94 125;70;55;19 7 
Exponential 16 rpsJ P02364 11.74 9.68  2 
Exponential 16 rpsK P02366 13.71 11.33  2 
Exponential 16 rpsM P02369 12.97 10.78  7 
Exponential 16 rpsR P02374 8.86 10.6 70;19 2 
Exponential 16 rpsT P02378 9.55 11.18  4 
Exponential 16 ybiB P30177 35.05 6.38 29 2 
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel Obs.MW 
(kD) 
LC 
Peptides# 
Stationary 1 accC P24182 49.32 6.65  7 
Stationary 1 adhE P17547 96 6.33 120;65  
Stationary 1 atpF P00859 17.26 5.99 25  
Stationary 1 dksA P18274 17.53 5.06 25  
Stationary 1 fabB P14926 42.61 5.35  6 
Stationary 1 fabH P24249 33.52 5.08  5 
Stationary 1 fabI P29132 27.73 5.58  5 
Stationary 1 ghrA P75913 36.84 6.76 40  
Stationary 1 glnS P00962 63.35 5.89  3 
Stationary 1 gltB P09831 161.93 6.19 175;150;120;100;65  
Stationary 1 gltX P04805 53.82 5.59  6 
Stationary 1 gnd P00350 51.48 5.05 53;44;33;31;28;25 11 
Stationary 1 guaB P06981 52.02 6.02 65;62  
Stationary 1 hns P08936 15.41 5.44  2 
Stationary 1 infB P02995 97.35 5.8 78  
Stationary 1 oppA P23843 58.36 5.85 65  
Stationary 1 pdxH P28225 25.41 9.18 31  
Stationary 1 pgk P11665 40.99 5.08 48;45;37;31 22 
Stationary 1 rplC P02386 22.24 9.9  4 
Stationary 1 rplJ P02408 17.58 9.04  2 
Stationary 1 rplL P02392 12.16 4.6  4 
Stationary 1 rplS P02420 13 10.62  3 
Stationary 1 skp P11457 15.69 9.52 28;25  
Stationary 1 sucB P07016 43.88 5.58 58  
Stationary 1 thrS P00955 74.01 5.8 78  
Stationary 1 trpS P00954 37.44 6.27 44 2 
Stationary 1 yggS P52054 25.79 6.09 31  
Stationary 1 yicC P23839 33.17 5.1 40  
Stationary 1 ykgM P71302 9.92 9.3  3 
Stationary 1 ynhG P76193 33.67 9.21 28  
Stationary 1 zwf P22992 55.7 5.56 58  
Stationary 2 accC P24182 49.32 6.65  13 
Stationary 2 aceE P06958 99.54 5.46  9 
Stationary 2 adhE P17547 96 6.33 155;125;63 13 
Stationary 2 arcA P03026 27.29 5.21  1 
Stationary 2 def P27251 19.2 5.23  5 
Stationary 2 dksA P18274 17.53 5.06  2 
Stationary 2 fabB P14926 42.61 5.35 54 11 
Stationary 2 fabG P25716 25.56 6.76  5 
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Stationary 2 fabH P24249 33.52 5.08 40 9 
Stationary 2 fabI P29132 27.73 5.58  7 
Stationary 2 glgB P07762 84.34 5.91 107 3 
Stationary 2 glnS P00962 63.35 5.89 75;30 12 
Stationary 2 gltB P09831 161.93 6.19 180;155;125 22 
Stationary 2 gltX P04805 53.82 5.59  14 
Stationary 2 gnd P00350 51.48 5.05 54 16 
Stationary 2 guaB P06981 52.02 6.02 63 6 
Stationary 2 hns P08936 15.41 5.44  3 
Stationary 2 infB P02995 97.35 5.8 85 6 
Stationary 2 infC P02999 20.56 9.54  1 
Stationary 2 lpd P00391 50.56 5.79  8 
Stationary 2 map P07906 29.33 5.64  1 
Stationary 2 mfd P30958 129.98 5.79 125 20 
Stationary 2 mprA P24201 20.56 5.82 28;23 3 
Stationary 2 mukB P22523 170.23 5.24  5 
Stationary 2 nusG P16921 20.4 6.33  2 
Stationary 2 ompR P03025 27.35 6.04  8 
Stationary 2 oppA P23843 58.36 5.85  6 
Stationary 2 pdxH P28225 25.41 9.18  4 
Stationary 2 pgk P11665 40.99 5.08 125;47;23 29 
Stationary 2 purR P15039 38.04 6.3  4 
Stationary 2 rbfA P09170 15.02 5.96  3 
Stationary 2 rplA P02384 24.6 9.64  2 
Stationary 2 rplB P02387 29.73 10.93  2 
Stationary 2 rplC P02386 22.24 9.9  4 
Stationary 2 rplD P02388 22.09 9.72  4 
Stationary 2 rplE P02389 20.17 9.49  7 
Stationary 2 rplI P02418 15.77 6.17  3 
Stationary 2 rplJ P02408 17.58 9.04  3 
Stationary 2 rplK P02409 14.74 9.64  1 
Stationary 2 rplL P02392 12.16 4.6  5 
Stationary 2 rplM P02410 16.02 9.91  2 
Stationary 2 rplS P02420 13 10.62  4 
Stationary 2 rplU P02422 11.56 9.85  2 
Stationary 2 rplX P02425 11.19 10.21  1 
Stationary 2 rplY P02426 10.69 9.6  5 
Stationary 2 rpmA P02427 8.99 10.58  2 
Stationary 2 rpmB P02428 8.88 11.42  1 
Stationary 2 rpmC P02429 7.27 9.98  1 
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Stationary 2 rpmD P02430 6.41 10.96  2 
Stationary 2 rpoA P00574 36.51 4.98  6 
Stationary 2 rpsA P02349 61.16 4.89 85 8 
Stationary 2 rpsH P02361 14 9.44  3 
Stationary 2 rpsJ P02364 11.74 9.68  1 
Stationary 2 rpsM P02369 12.97 10.78  3 
Stationary 2 rpsP P02372 9.19 10.54  2 
Stationary 2 rpsR P02374 8.86 10.6  2 
Stationary 2 rpsT P02378 9.55 11.18  3 
Stationary 2 skp P11457 15.69 9.52 23 1 
Stationary 2 slyA P55740 16.35 6.6  3 
Stationary 2 sucA P07015 105.06 6.04 107 9 
Stationary 2 sucB P07016 43.88 5.58 58 8 
Stationary 2 thrS P00955 74.01 5.8 85 7 
Stationary 2 tig P22257 48.19 4.83  6 
Stationary 2 trpS P00954 37.44 6.27 44 8 
Stationary 2 tufA P02990 43.18 5.3  8 
Stationary 2 ycgK P76002 12.52 9.01  5 
Stationary 2 yciK P31808 27.93 7.67  4 
Stationary 2 yggS P52054 25.79 6.09 30  
Stationary 2 yhaJ P42623 33.26 6.05  4 
Stationary 2 yicC P23839 33.17 5.1  3 
Stationary 2 ykgM P71302 9.92 9.3  6 
Stationary 2 ynhG P76193 33.67 9.21  4 
Stationary 2 zwf P22992 55.7 5.56 58 4 
Stationary 3 accC P24182 49.32 6.65 58 6 
Stationary 3 adhE P17547 96 6.33 125 12 
Stationary 3 fabB P14926 42.61 5.35  4 
Stationary 3 fabH P24249 33.52 5.08  6 
Stationary 3 fabI P29132 27.73 5.58  3 
Stationary 3 glgB P07762 84.34 5.91  2 
Stationary 3 glnS P00962 63.35 5.89 75 3 
Stationary 3 gltB P09831 161.93 6.19 180 7 
Stationary 3 gltX P04805 53.82 5.59 63 4 
Stationary 3 gnd P00350 51.48 5.05 58;54 12 
Stationary 3 guaB P06981 52.02 6.02  5 
Stationary 3 infB P02995 97.35 5.8  3 
Stationary 3 lpd P00391 50.56 5.79  7 
Stationary 3 mprA P24201 20.56 5.82 24 1 
Stationary 3 ompR P03025 27.35 6.04 35 4 
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Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel Obs.MW (kD) LC 
Peptides# 
Stationary 3 pgk P11665 40.99 5.08 150;80;47;44;40;35;31;27 14 
Stationary 3 phoB P08402 26.43 5.46  2 
Stationary 3 rbfA P09170 15.02 5.96  4 
Stationary 3 rnr P21499 92.11 8.78 80  
Stationary 3 rplA P02384 24.6 9.64  1 
Stationary 3 rplB P02387 29.73 10.93  2 
Stationary 3 rplI P02418 15.77 6.17  2 
Stationary 3 rplJ P02408 17.58 9.04  2 
Stationary 3 rplL P02392 12.16 4.6  4 
Stationary 3 rplS P02420 13 10.62  2 
Stationary 3 rplU P02422 11.56 9.85  2 
Stationary 3 rplY P02426 10.69 9.6  4 
Stationary 3 rpoA P00574 36.51 4.98  3 
Stationary 3 rpsA P02349 61.16 4.89  3 
Stationary 3 skp P11457 15.69 9.52  1 
Stationary 3 slyA P55740 16.35 6.6  2 
Stationary 3 sucA P07015 105.06 6.04  11 
Stationary 3 sucB P07016 43.88 5.58  7 
Stationary 3 thrS P00955 74.01 5.8  6 
Stationary 3 trpS P00954 37.44 6.27  2 
Stationary 3 ycgK P76002 12.52 9.01  4 
Stationary 3 yciK P31808 27.93 7.67  1 
Stationary 3 yicC P23839 33.17 5.1  4 
Stationary 3 ykgM P71302 9.92 9.3  1 
Stationary 3 ynhG P76193 33.67 9.21  3 
Stationary 3 zwf P22992 55.7 5.56  2 
Stationary 4 accA P30867 35.11 5.76  6 
Stationary 4 accC P24182 49.32 6.65 57  
Stationary 4 accD P08193 33.32 7.58  2 
Stationary 4 aceE P06958 99.54 5.46  4 
Stationary 4 adhE P17547 96 6.33 120;100 11 
Stationary 4 dksA P18274 17.53 5.06  1 
Stationary 4 fabB P14926 42.61 5.35 54 2 
Stationary 4 fabG P25716 25.56 6.76  3 
Stationary 4 fabH P24249 33.52 5.08  3 
Stationary 4 ghrA P75913 36.84 6.76  4 
Stationary 4 glnS P00962 63.35 5.89 80 5 
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Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW (kD) 
LC 
Peptides# 
Stationary 4 gltB P09831 161.93 6.19 170;145;100;6
8 
32 
Stationary 4 gltX P04805 53.82 5.59 63  
Stationary 4 gnd P00350 51.48 5.05 54 21 
Stationary 4 guaB P06981 52.02 6.02  16 
Stationary 4 hns P08936 15.41 5.44  3 
Stationary 4 infB P02995 97.35 5.8  8 
Stationary 4 lpd P00391 50.56 5.79  4 
Stationary 4 mfd P30958 129.98 5.79 145 15 
Stationary 4 nikE P33594 29.72 10.11 47  
Stationary 4 oppA P23843 58.36 5.85 68  
Stationary 4 pgk P11665 40.99 5.08 145;47;44;40;3
5;31;28;25;22 
15 
Stationary 4 rbfA P09170 15.02 5.96  6 
Stationary 4 rplB P02387 29.73 10.93  4 
Stationary 4 rplC P02386 22.24 9.9  3 
Stationary 4 rplI P02418 15.77 6.17  1 
Stationary 4 rplJ P02408 17.58 9.04  1 
Stationary 4 rplL P02392 12.16 4.6  4 
Stationary 4 rplS P02420 13 10.62  5 
Stationary 4 rplY P02426 10.69 9.6  3 
Stationary 4 skp P11457 15.69 9.52  4 
Stationary 4 sucA P07015 105.06 6.04  3 
Stationary 4 sucB P07016 43.88 5.58  6 
Stationary 4 thrS P00955 74.01 5.8  15 
Stationary 4 trpS P00954 37.44 6.27  9 
Stationary 4 ycgK P76002 12.52 9.01  8 
Stationary 4 yegQ P76403 51.19 5.8  4 
Stationary 4 ykgM P71302 9.92 9.3  1 
Stationary 4 ynhG P76193 33.67 9.21  5 
Stationary 4 zwf P22992 55.7 5.56  9 
Stationary 5 accA P30867 35.11 5.76  8 
Stationary 5 accD P08193 33.32 7.58  6 
Stationary 5 aceA P05313 47.52 5.16 47  
Stationary 5 adhE P17547 96 6.33  2 
Stationary 5 atpF P00859 17.26 5.99 26  
Stationary 5 bfr P11056 18.5 4.69 23  
Stationary 5 dksA P18274 17.53 5.06  3 
Stationary 5 erfK P39176 32.08 7.97  2 
Stationary 5 ghrA P75913 36.84 6.76  3 
Stationary 5 gltB P09831 161.93 6.19  28 
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 Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Stationary 5 gnd P00350 51.48 5.05  21 
Stationary 5 guaB P06981 52.02 6.02  7 
Stationary 5 hns P08936 15.41 5.44  5 
Stationary 5 infB P02995 97.35 5.8  6 
Stationary 5 manX P08186 34.92 5.74  4 
Stationary 5 pgk P11665 40.99 5.08  7 
Stationary 5 purU P37051 31.93 6.5  5 
Stationary 5 rbfA P09170 15.02 5.96  2 
Stationary 5 rplK P02409 14.74 9.64  1 
Stationary 5 rplS P02420 13 10.62  6 
Stationary 5 rplY P02426 10.69 9.6  1 
Stationary 5 skp P11457 15.69 9.52  4 
Stationary 5 thrS P00955 74.01 5.8  9 
Stationary 5 trpS P00954 37.44 6.27  4 
Stationary 5 tyrS P00951 47.4 5.59  7 
Stationary 5 ybaK P37175 17.09 9.02  3 
Stationary 5 ycgK P76002 12.52 9.01  7 
Stationary 5 ydgH P76177 31.91 9.1  8 
Stationary 5 ykgM P71302 9.92 9.3  2 
Stationary 5 ynhG P76193 33.67 9.21  2 
Stationary 5 zwf P22992 55.7 5.56  2 
Stationary 6 accA P30867 35.11 5.76  7 
Stationary 6 accD P08193 33.32 7.58  5 
Stationary 6 aceA P05313 47.52 5.16 55  
Stationary 6 aceE P06958 99.54 5.46 107 9 
Stationary 6 aceF P06959 65.96 5.09 95 6 
Stationary 6 adhE P17547 96 6.33 170;107  
Stationary 6 ahpC P26427 20.63 5.03 29  
Stationary 6 arcA P03026 27.29 5.21  8 
Stationary 6 aroC P12008 39.01 5.82  2 
Stationary 6 atpD P00824 50.19 4.9  2 
Stationary 6 carB P00968 117.71 5.22 170  
Stationary 6 cbpA P36659 34.46 6.33  4 
Stationary 6 cpsB P24174 53.02 5.2  4 
Stationary 6 crp P03020 23.64 8.38 30  
Stationary 6 dacB P24228 49.57 8.73  4 
Stationary 6 dinB Q47155 39.52 9.28  3 
Stationary 6 dksA P18274 17.53 5.06  4 
Stationary 6 dnaK P04475 68.98 4.83 75  
Stationary 6 dps P27430 18.56 5.72  5 
Stationary 6 eda P10177 22.28 5.57 30  
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Table A.1. Continued 
 Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Stationary 6 fabA P18391 18.84 6.16  8 
Stationary 6 fabG P25716 25.56 6.76  6 
Stationary 6 fmt P23882 34.04 5.56  8 
Stationary 6 ftnA P23887 19.42 4.77 23  
Stationary 6 glgB P07762 84.34 5.91  9 
Stationary 6 glnK P38504 12.26 5.84  3 
Stationary 6 gltB P09831 161.93 6.19 170 18 
Stationary 6 gnd P00350 51.48 5.05  12 
Stationary 6 gpmA P31217 28.43 5.86 34  
Stationary 6 groL P06139 57.2 4.85 65;60  
Stationary 6 grxB P39811 24.35 7.72 32  
Stationary 6 guaB P06981 52.02 6.02  4 
Stationary 6 gyrA P09097 96.96 5.09  20 
Stationary 6 hisS P04804 46.9 5.65  6 
Stationary 6 hns P08936 15.41 5.44  8 
Stationary 6 htpG P10413 71.42 5.09 75  
Stationary 6 icd P08200 45.76 5.15 55  
Stationary 6 ilvE P00510 33.96 5.54  2 
Stationary 6 infB P02995 97.35 5.8  12 
Stationary 6 iscS P39171 45.09 5.94  9 
Stationary 6 ivy P45502 14.1 5.51  5 
Stationary 6 ligA P15042 73.61 5.39  12 
Stationary 6 lrp P19494 18.76 8.91  5 
Stationary 6 manX P08186 34.92 5.74  10 
Stationary 6 map P07906 29.33 5.64  10 
Stationary 6 mdh P06994 32.34 5.61 39  
Stationary 6 mdoG P33136 55.37 6.26  20 
Stationary 6 metE P25665 84.54 5.61  4 
Stationary 6 metJ P08338 12.01 5.4  5 
Stationary 6 metQ P28635 27.24 4.93 34  
Stationary 6 nadR P27278 47.35 5.42  8 
Stationary 6 nagA P15300 40.95 5.65  2 
Stationary 6 ompC P06996 38.31 4.48 45  
Stationary 6 pdxH P28225 25.41 9.18  6 
Stationary 6 pepA P11648 54.88 6.82  5 
Stationary 6 pgk P11665 40.99 5.08  8 
Stationary 6 polA P00582 103.12 5.4  8 
Stationary 6 ppc P00864 99.06 5.52 95  
Stationary 6 prc P23865 74.32 6.04  11 
Stationary 6 purC P21155 27 5.07 34  
Stationary 6 purU P37051 31.93 6.5  6 
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Stationary 6 rbsA P04983 55.04 5.84 36  
Stationary 6 relE P07008 11.23 9.67  2 
Stationary 6 rho P03002 47 6.75  7 
Stationary 6 rnc P05797 25.55 6.4  6 
Stationary 6 rplA P02384 24.6 9.64 36 5 
Stationary 6 rplB P02387 29.73 10.93  4 
Stationary 6 rplC P02386 22.24 9.9  5 
Stationary 6 rplD P02388 22.09 9.72 30  
Stationary 6 rplE P02389 20.17 9.49 27 6 
Stationary 6 rplF P02390 18.77 9.71 75 5 
Stationary 6 rplI P02418 15.77 6.17 23 7 
Stationary 6 rplJ P02408 17.58 9.04  3 
Stationary 6 rplK P02409 14.74 9.64  6 
Stationary 6 rplL P02392 12.16 4.6  2 
Stationary 6 rplO P02413 14.98 11.18  5 
Stationary 6 rplQ P02416 14.36 11.05 25;23  
Stationary 6 rplS P02420 13 10.62  5 
Stationary 6 rplX P02425 11.19 10.21  3 
Stationary 6 rplY P02426 10.69 9.6  3 
Stationary 6 rpmA P02427 8.99 10.58  2 
Stationary 6 rpmD P02430 6.41 10.96  3 
Stationary 6 rpoA P00574 36.51 4.98  7 
Stationary 6 rpoB P00575 150.63 5.15  6 
Stationary 6 rpsA P02349 61.16 4.89 75  
Stationary 6 rpsB P02351 26.61 6.69  6 
Stationary 6 rpsD P02354 23.34 10.05 32  
Stationary 6 rpsE P02356 17.47 10.11 25  
Stationary 6 rpsI P02363 14.73 10.94 25  
Stationary 6 rpsJ P02364 11.74 9.68  3 
Stationary 6 rpsM P02369 12.97 10.78  2 
Stationary 6 rpsS P02375 10.3 10.52  2 
Stationary 6 rpsT P02378 9.55 11.18  2 
Stationary 6 rpsU P02379 8.37 11.15  4 
Stationary 6 selA P23328 50.61 6.05  6 
Stationary 6 serA P08328 44.04 5.93 55  
Stationary 6 skp P11457 15.69 9.52 25 5 
Stationary 6 sodB P09157 21.13 5.58 30;29  
Stationary 6 sthA P27306 51.43 6.09  2 
Stationary 6 stpA P30017 15.35 7.95  6 
Stationary 6 talB P30148 35.09 5.11 43  
Stationary 6 trpS P00954 37.44 6.27  2 
Stationary 6 truA P07649 30.4 8.68  4 
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Stationary 6 tufA P02990 43.18 5.3 51  
Stationary 6 tyrS P00951 47.4 5.59  7 
Stationary 6 uvrB P07025 76.09 5.14  4 
Stationary 6 wrbA P30849 20.71 5.6 30  
Stationary 6 xthA P09030 30.97 5.8  6 
Stationary 6 yaeB P28634 26.36 7.86  3 
Stationary 6 yaeH P37048 15.1 6.61  2 
Stationary 6 yaiN P55756 10.32 5.84  2 
Stationary 6 ybeX P77392 33.3 4.55  3 
Stationary 6 ybeZ P77349 40.65 6.24  7 
Stationary 6 ycgK P76002 12.52 9.01  5 
Stationary 6 yciH P08245 11.4 9.38  3 
Stationary 6 ydcP P76104 70.58 6.69 39  
Stationary 6 ydgH P76177 31.91 9.1  14 
Stationary 6 yeaO P76243 13.39 6.29  7 
Stationary 6 yffB P24178 13.6 6.09  2 
Stationary 6 yggS P52054 25.79 6.09  3 
Stationary 6 yhbJ P33995 32.49 6.72  2 
Stationary 6 yhhK P37613 14.51 6.59  2 
Stationary 6 ykgM P71302 9.92 9.3  5 
Stationary 6 zwf P22992 55.7 5.56  3 
Stationary 7 aceA P05313 47.52 5.16 58  
Stationary 7 adhE P17547 96 6.33 115  
Stationary 7 ahpC P26427 20.63 5.03 30  
Stationary 7 arcA P03026 27.29 5.21  7 
Stationary 7 aroC P12008 39.01 5.82  2 
Stationary 7 atpA P00822 55.22 5.8 65  
Stationary 7 carB P00968 117.71 5.22 155  
Stationary 7 dnaK P04475 68.98 4.83 78  
Stationary 7 dnaX P06710 71.14 6.39  2 
Stationary 7 eda P10177 22.28 5.57 32  
Stationary 7 fabG P25716 25.56 6.76  7 
Stationary 7 fmt P23882 34.04 5.56  4 
Stationary 7 gltB P09831 161.93 6.19 180  
Stationary 7 groL P06139 57.2 4.85 65  
Stationary 7 grxB P39811 24.35 7.72 32  
Stationary 7 gyrA P09097 96.96 5.09  10 
Stationary 7 hisS P04804 46.9 5.65  16 
Stationary 7 hns P08936 15.41 5.44  4 
Stationary 7 infA P02998 8.12 9.23  4 
Stationary 7 kdgR P76268 30.03 5.43 30  
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Stationary 7 lacZ P00722 116.35 5.28 145;65  
Stationary 7 map P07906 29.33 5.64  2 
Stationary 7 metJ P08338 12.01 5.4  6 
Stationary 7 moaB P30746 18.53 5.73  4 
Stationary 7 rho P03002 47 6.75  4 
Stationary 7 rlmB P39290 26.56 6.17  2 
Stationary 7 rplA P02384 24.6 9.64 40 1 
Stationary 7 rplB P02387 29.73 10.93  3 
Stationary 7 rplC P02386 22.24 9.9  4 
Stationary 7 rplE P02389 20.17 9.49 27 6 
Stationary 7 rplF P02390 18.77 9.71  7 
Stationary 7 rplI P02418 15.77 6.17  9 
Stationary 7 rplJ P02408 17.58 9.04  5 
Stationary 7 rplL P02392 12.16 4.6  2 
Stationary 7 rplM P02410 16.02 9.91  1 
Stationary 7 rplO P02413 14.98 11.18  3 
Stationary 7 rplS P02420 13 10.62  5 
Stationary 7 rplX P02425 11.19 10.21  6 
Stationary 7 rpmD P02430 6.41 10.96  3 
Stationary 7 rpsA P02349 61.16 4.89 78  
Stationary 7 rpsB P02351 26.61 6.69 40 9 
Stationary 7 rpsD P02354 23.34 10.05 32  
Stationary 7 rpsJ P02364 11.74 9.68  3 
Stationary 7 rpsQ P02373 9.57 9.64  2 
Stationary 7 rpsT P02378 9.55 11.18  2 
Stationary 7 serA P08328 44.04 5.93 53  
Stationary 7 sodB P09157 21.13 5.58 30  
Stationary 7 stpA P30017 15.35 7.95  5 
Stationary 7 suhB P22783 29.17 6.45  6 
Stationary 7 tpx P37901 17.7 4.75 27  
Stationary 7 tsf P02997 30.29 5.22 40  
Stationary 7 tufA P02990 43.18 5.3 53;43;40  
Stationary 7 yjgA P26650 21.36 5.3  5 
Stationary 7 ykgM P71302 9.92 9.3  4 
Stationary 8 aceF P06959 65.96 5.09 75  
Stationary 8 arcA P03026 27.29 5.21  1 
Stationary 8 crp P03020 23.64 8.38  3 
Stationary 8 fabG P25716 25.56 6.76  2 
Stationary 8 hflX P25519 48.33 5.68 54  
Stationary 8 hisS P04804 46.9 5.65 54;52 10 
Stationary 8 hns P08936 15.41 5.44  1 
Stationary 8 infA P02998 8.12 9.23  2 
 
  
193 
Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW (kD) 
LC 
Peptides# 
Stationary 9 manX P08186 34.92 5.74 37  
Stationary 9 moaB P30746 18.53 5.73 21 3 
Stationary 9 oxyR P11721 34.28 5.96 38  
Stationary 9 parC P20082 83.83 6.24  5 
Stationary 9 pepA P11648 54.88 6.82 58 2 
Stationary 9 ppx P29014 58 6.69 58  
Stationary 9 rho P03002 47 6.75 54 6 
Stationary 9 rplB P02387 29.73 10.93 30 12 
Stationary 9 rplC P02386 22.24 9.9 29 6 
Stationary 9 rplD P02388 22.09 9.72  6 
Stationary 9 rplE P02389 20.17 9.49 23 10 
Stationary 9 rplF P02390 18.77 9.71 24 9 
Stationary 9 rplI P02418 15.77 6.17  8 
Stationary 9 rplJ P02408 17.58 9.04  6 
Stationary 9 rplL P02392 12.16 4.6  4 
Stationary 9 rplM P02410 16.02 9.91  4 
Stationary 9 rplO P02413 14.98 11.18  5 
Stationary 9 rplR P02419 12.77 10.42  3 
Stationary 9 rplS P02420 13 10.62  6 
Stationary 9 rplX P02425 11.19 10.21  4 
Stationary 9 rplY P02426 10.69 9.6  2 
Stationary 9 rpmB P02428 8.88 11.42  3 
Stationary 9 rpmC P02429 7.27 9.98  2 
Stationary 9 rpoA P00574 36.51 4.98 45 10 
Stationary 9 rpoB P00575 150.63 5.15 175;140;110 19 
Stationary 9 rpoC P00577 155.16 6.67 175;140;110;63 15 
Stationary 9 rpsB P02351 26.61 6.69 37;33;32 13 
Stationary 9 rpsC P02352 25.85 10.27 30 5 
Stationary 9 rpsD P02354 23.34 10.05 29  
Stationary 9 rpsE P02356 17.47 10.11 21 1 
Stationary 9 rpsJ P02364 11.74 9.68  2 
Stationary 9 rpsO P02371 10.14 10.4  3 
Stationary 9 rpsP P02372 9.19 10.54  5 
Stationary 9 rpsQ P02373 9.57 9.64  3 
Stationary 9 rpsR P02374 8.86 10.6  1 
Stationary 9 rpsS P02375 10.3 10.52  3 
Stationary 9 rpsT P02378 9.55 11.18  2 
Stationary 9 rsmC P39406 37.49 6 43  
Stationary 9 secA P10408 102.02 5.43 110;105 5 
Stationary 9 stpA P30017 15.35 7.95  5 
Stationary 9 truD Q57261 39.09 6.15 43  
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Table A.1. Continued  
 Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel Obs.MW 
(kD) 
LC 
Peptides
# 
Stationary 9 tsf P02997 30.29 5.22  3 
Stationary 9 wcaI P32057 44.91 8.8  4 
Stationary 9 yaaA P11288 29.59 6.86  5 
Stationary 9 ydjA P24250 20.06 6.31 23 5 
Stationary 9 ygeA P03813 25.25 5.09 30  
Stationary 9 yihA P24253 23.56 6.86 29 7 
Stationary 9 yihI P32130 19.06 6.37  2 
Stationary 9 ykgM P71302 9.92 9.3  3 
Stationary 9 yraL P45528 31.35 5.83  5 
Stationary 10 cbpA P36659 34.46 6.33 36;35;27  
Stationary 10 clpA P15716 84.21 5.91  2 
Stationary 10 crp P03020 23.64 8.38 26 1 
Stationary 10 envC P37690 46.59 9.91 26  
Stationary 10 hupA P02342 9.53 9.57  3 
Stationary 10 infC P02999 20.56 9.54 23  
Stationary 10 lon P08177 87.44 6.01 110 9 
Stationary 10 malP P00490 90.39 6.93 100;66 9 
Stationary 10 malQ P15977 78.5 6.14 100  
Stationary 10 mraW P18595 34.88 6.07  2 
Stationary 10 pgk P11665 40.99 5.08 36  
Stationary 10 ppk P28688 80.3 8.96 110;100;66 3 
Stationary 10 ppx P29014 58 6.69 58  
Stationary 10 rnr P21499 92.11 8.78  4 
Stationary 10 rob P27292 33.14 6.66 38 4 
Stationary 10 rplB P02387 29.73 10.93 35;33;29;27 12 
Stationary 10 rplD P02388 22.09 9.72 26;24 6 
Stationary 10 rplE P02389 20.17 9.49 24 8 
Stationary 10 rplI P02418 15.77 6.17  6 
Stationary 10 rplM P02410 16.02 9.91 21 7 
Stationary 10 rplO P02413 14.98 11.18  6 
Stationary 10 rplR P02419 12.77 10.42  3 
Stationary 10 rplS P02420 13 10.62  2 
Stationary 10 rplX P02425 11.19 10.21  6 
Stationary 10 rpmA P02427 8.99 10.58  2 
Stationary 10 rpmB P02428 8.88 11.42  6 
Stationary 10 rpmC P02429 7.27 9.98  3 
Stationary 10 rpoA P00574 36.51 4.98 49;35 12 
Stationary 10 rpoB P00575 150.63 5.15 140;110 24 
Stationary 10 rpoC P00577 155.16 6.67 175;140;110;100;66;
58;54 
29 
Stationary 10 rpsB P02351 26.61 6.69 33 7 
Stationary 10 rpsC P02352 25.85 10.27 27 9 
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Stationary 10 rpsD P02354 23.34 10.05 27 4 
Stationary 10 rpsE P02356 17.47 10.11 21 4 
Stationary 10 rpsM P02369 12.97 10.78  3 
Stationary 10 rpsO P02371 10.14 10.4  3 
Stationary 10 rpsP P02372 9.19 10.54  5 
Stationary 10 rpsS P02375 10.3 10.52  4 
Stationary 10 rpsT P02378 9.55 11.18  4 
Stationary 10 rsmC P39406 37.49 6 45  
Stationary 10 secA P10408 102.02 5.43 140  
Stationary 10 speG P37354 21.76 6.22 25 2 
Stationary 10 spy P77754 15.88 9.45  6 
Stationary 10 ydjA P24250 20.06 6.31 24;21 8 
Stationary 10 yggH P32049 27.31 6.42  5 
Stationary 11 allR P77734 29.27 5.77  2 
Stationary 11 gadB P28302 52.67 5.29  2 
Stationary 11 hupA P02342 9.53 9.57  5 
Stationary 11 infC P02999 20.56 9.54 24 6 
Stationary 11 kdgR P76268 30.03 5.43 35 5 
Stationary 11 rnr P21499 92.11 8.78  8 
Stationary 11 rplB P02387 29.73 10.93 35;30 14 
Stationary 11 rplD P02388 22.09 9.72 27 6 
Stationary 11 rplE P02389 20.17 9.49  5 
Stationary 11 rplM P02410 16.02 9.91  10 
Stationary 11 rplN P02411 13.54 10.43  3 
Stationary 11 rplO P02413 14.98 11.18  7 
Stationary 11 rplP P02414 15.28 11.22  3 
Stationary 11 rplQ P02416 14.36 11.05  4 
Stationary 11 rplR P02419 12.77 10.42  6 
Stationary 11 rplS P02420 13 10.62  2 
Stationary 11 rplU P02422 11.56 9.85  2 
Stationary 11 rplV P02423 12.23 10.23  2 
Stationary 11 rplW P02424 11.2 9.94  3 
Stationary 11 rplX P02425 11.19 10.21  4 
Stationary 11 rpmA P02427 8.99 10.58  4 
Stationary 11 rpmB P02428 8.88 11.42  6 
Stationary 11 rpmC P02429 7.27 9.98  2 
Stationary 11 rpoA P00574 36.51 4.98  4 
Stationary 11 rpsC P02352 25.85 10.27 30;29 11 
Stationary 11 rpsD P02354 23.34 10.05  11 
Stationary 11 rpsE P02356 17.47 10.11  7 
Stationary 11 rpsF P02358 15.32 5.16  3 
Stationary 11 rpsG P02359 19.89 10.37  8 
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptide
s# 
Stationary 11 rpsI P02363 14.73 10.94  4 
Stationary 11 rpsK P02366 13.71 11.33  6 
Stationary 11 rpsM P02369 12.97 10.78  6 
Stationary 11 rpsN P02370 11.45 11.16  3 
Stationary 11 rpsP P02372 9.19 10.54  5 
Stationary 11 rpsR P02374 8.86 10.6  2 
Stationary 11 rpsS P02375 10.3 10.52  4 
Stationary 11 rpsT P02378 9.55 11.18  5 
Stationary 11 yggH P32049 27.31 6.42  2 
Stationary 11 yhhX P46853 38.77 6.07  9 
Stationary 12 hupA P02342 9.53 9.57  4 
Stationary 12 hupB P02341 9.23 9.69  2 
Stationary 12 infC P02999 20.56 9.54 25;23 6 
Stationary 12 kdgR P76268 30.03 5.43 35;34  
Stationary 12 relA P11585 83.88 6.29  2 
Stationary 12 rhlE P25888 49.99 10.06 54  
Stationary 12 rplB P02387 29.73 10.93 35;34 10 
Stationary 12 rplD P02388 22.09 9.72 27;22 4 
Stationary 12 rplM P02410 16.02 9.91  5 
Stationary 12 rplO P02413 14.98 11.18  6 
Stationary 12 rplP P02414 15.28 11.22  4 
Stationary 12 rplQ P02416 14.36 11.05  3 
Stationary 12 rplR P02419 12.77 10.42  4 
Stationary 12 rplU P02422 11.56 9.85  2 
Stationary 12 rplV P02423 12.23 10.23  2 
Stationary 12 rpmB P02428 8.88 11.42  5 
Stationary 12 rpoC P00577 155.16 6.67 175  
Stationary 12 rpsC P02352 25.85 10.27 175;105;65;5
4;46;40;35;34 
10 
Stationary 12 rpsD P02354 23.34 10.05 27;25 10 
Stationary 12 rpsE P02356 17.47 10.11 54;20 8 
Stationary 12 rpsG P02359 19.89 10.37 23 5 
Stationary 12 rpsI P02363 14.73 10.94  3 
Stationary 12 rpsM P02369 12.97 10.78  4 
Stationary 12 rpsR P02374 8.86 10.6  2 
Stationary 12 rpsS P02375 10.3 10.52  6 
Stationary 12 rpsT P02378 9.55 11.18  3 
Stationary 12 yhhX P46853 38.77 6.07 46  
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides
# 
Stationary 13 hupA P02342 9.53 9.57  8 
Stationary 13 hupB P02341 9.23 9.69  6 
Stationary 13 infC P02999 20.56 9.54  3 
Stationary 13 rluC P23851 36.03 9.85  4 
Stationary 13 rplB P02387 29.73 10.93  9 
Stationary 13 rplD P02388 22.09 9.72  5 
Stationary 13 rplM P02410 16.02 9.91  3 
Stationary 13 rplO P02413 14.98 11.18  11 
Stationary 13 rplP P02414 15.28 11.22  6 
Stationary 13 rplQ P02416 14.36 11.05  4 
Stationary 13 rplR P02419 12.77 10.42  3 
Stationary 13 rplS P02420 13 10.62  1 
Stationary 13 rplU P02422 11.56 9.85  2 
Stationary 13 rplV P02423 12.23 10.23  6 
Stationary 13 rplW P02424 11.2 9.94  3 
Stationary 13 rpmB P02428 8.88 11.42  4 
Stationary 13 rpsC P02352 25.85 10.27 100;63;54;
35;29 
15 
Stationary 13 rpsD P02354 23.34 10.05 28;18 16 
Stationary 13 rpsE P02356 17.47 10.11 20 11 
Stationary 13 rpsF P02358 15.32 5.16  7 
Stationary 13 rpsG P02359 19.89 10.37  10 
Stationary 13 rpsI P02363 14.73 10.94  4 
Stationary 13 rpsM P02369 12.97 10.78  8 
Stationary 13 rpsR P02374 8.86 10.6  2 
Stationary 13 rpsS P02375 10.3 10.52  4 
Stationary 13 rpsT P02378 9.55 11.18  3 
Stationary 14 hupA P02342 9.53 9.57  4 
Stationary 14 hupB P02341 9.23 9.69  5 
Stationary 14 relA P11585 83.88 6.29  2 
Stationary 14 rmf P22986 6.51 10.86  1 
Stationary 14 rplB P02387 29.73 10.93  3 
Stationary 14 rplO P02413 14.98 11.18  5 
Stationary 14 rplP P02414 15.28 11.22  5 
Stationary 14 rplQ P02416 14.36 11.05 21 3 
Stationary 14 rplT P02421 13.37 11.47  2 
Stationary 14 rplU P02422 11.56 9.85  3 
Stationary 14 rplV P02423 12.23 10.23  4 
Stationary 14 rpmB P02428 8.88 11.42  2 
Stationary 14 rpsC P02352 25.85 10.27 28 10 
Stationary 14 rpsD P02354 23.34 10.05 28 11 
Stationary 14 rpsE P02356 17.47 10.11 18 5 
Stationary 14 rpsF P02358 15.32 5.16  7 
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Stationary 14 rpsG P02359 19.89 10.37 18 8 
Stationary 14 rpsI P02363 14.73 10.94  4 
Stationary 14 rpsK P02366 13.71 11.33  1 
Stationary 14 rpsM P02369 12.97 10.78  5 
Stationary 14 rpsR P02374 8.86 10.6  2 
Stationary 14 rpsT P02378 9.55 11.18  3 
Stationary 14 ybiB P30177 35.05 6.38  5 
Stationary 15 aidB P33224 60.59 7.98 54;47 7 
Stationary 15 hupA P02342 9.53 9.57  3 
Stationary 15 ihfA P06984 11.35 9.34  3 
Stationary 15 ihfB P08756 10.65 9.34  2 
Stationary 15 pcnB P13685 54.66 9.68 47  
Stationary 15 rmf P22986 6.51 10.86  2 
Stationary 15 rplB P02387 29.73 10.93  8 
Stationary 15 rplD P02388 22.09 9.72  3 
Stationary 15 rplE P02389 20.17 9.49  4 
Stationary 15 rplM P02410 16.02 9.91  2 
Stationary 15 rplN P02411 13.54 10.43  4 
Stationary 15 rplO P02413 14.98 11.18  5 
Stationary 15 rplP P02414 15.28 11.22 18 5 
Stationary 15 rplQ P02416 14.36 11.05 18 5 
Stationary 15 rplS P02420 13 10.62  3 
Stationary 15 rplT P02421 13.37 11.47  3 
Stationary 15 rplU P02422 11.56 9.85  2 
Stationary 15 rplV P02423 12.23 10.23  7 
Stationary 15 rpmB P02428 8.88 11.42  2 
Stationary 15 rpsC P02352 25.85 10.27 29 11 
Stationary 15 rpsD P02354 23.34 10.05 28 10 
Stationary 15 rpsE P02356 17.47 10.11 21 5 
Stationary 15 rpsF P02358 15.32 5.16  7 
Stationary 15 rpsG P02359 19.89 10.37 23;21 9 
Stationary 15 rpsI P02363 14.73 10.94  5 
Stationary 15 rpsK P02366 13.71 11.33  4 
Stationary 15 rpsM P02369 12.97 10.78  7 
Stationary 15 rpsR P02374 8.86 10.6  2 
Stationary 15 rpsT P02378 9.55 11.18  5 
Stationary 15 ybiB P30177 35.05 6.38 36 11 
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Table A.1. Continued  
Cell Fraction# Gene 
Name 
SwissProt 
ID 
MW 
(kD) 
pI In-Gel 
Obs.MW 
(kD) 
LC 
Peptides# 
Stationary 16 aidB P33224 60.59 7.98 120;54 6 
Stationary 16 hisB P06987 40.28 5.76 42 3 
Stationary 16 hupA P02342 9.53 9.57  2 
Stationary 16 ihfA P06984 11.35 9.34  4 
Stationary 16 ihfB P08756 10.65 9.34  3 
Stationary 16 infC P02999 20.56 9.54  2 
Stationary 16 rplB P02387 29.73 10.93  4 
Stationary 16 rplD P02388 22.09 9.72  3 
Stationary 16 rplM P02410 16.02 9.91  1 
Stationary 16 rplN P02411 13.54 10.43  1 
Stationary 16 rplO P02413 14.98 11.18  5 
Stationary 16 rplP P02414 15.28 11.22  3 
Stationary 16 rplS P02420 13 10.62  2 
Stationary 16 rplT P02421 13.37 11.47  3 
Stationary 16 rplU P02422 11.56 9.85  2 
Stationary 16 rplV P02423 12.23 10.23  4 
Stationary 16 rpmB P02428 8.88 11.42  3 
Stationary 16 rpsC P02352 25.85 10.27 42;35;29;27 6 
Stationary 16 rpsD P02354 23.34 10.05 27 5 
Stationary 16 rpsE P02356 17.47 10.11 20 4 
Stationary 16 rpsF P02358 15.32 5.16  3 
Stationary 16 rpsG P02359 19.89 10.37 22;20 5 
Stationary 16 rpsI P02363 14.73 10.94  4 
Stationary 16 rpsK P02366 13.71 11.33  3 
Stationary 16 rpsM P02369 12.97 10.78  5 
Stationary 16 rpsR P02374 8.86 10.6  2 
Stationary 16 rpsT P02378 9.55 11.18  4 
Stationary 16 ybiB P30177 35.05 6.38   5 
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